Anti-PD-L1 antibodies

Antibodies targeting PD-L1 modulate IL-2 activity in immunocytokines to enhance anti-tumor immune responses, addressing toxicity issues in current immunocytokines and improving cancer treatment efficacy.

JP7595618B2Active Publication Date: 2024-12-06KYMBA LIMITED
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022129085
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-04-06
Filing Date
2022-08-12
Publication Date
2024-12-06
Estimated Expiration
2037-06-20

AI Technical Summary

Technical Problem

Current immunocytokines targeting IL-2 receptors for cancer treatment face challenges with significant side effects and toxicity, necessitating a need for reduced IL-2Rβγ binding to enhance efficacy and safety.

Method used

Development of antibodies and antigen-binding fragments that specifically target PD-L1, modulating IL-2 activity and reducing IL-2Rβγ binding, combined with IL-2 cytokines to create immunocytokines that enhance anti-tumor immune responses while minimizing toxicity.

Benefits of technology

The antibodies effectively enhance T-cell activation and immune response against tumors, reducing side effects and improving treatment outcomes in cancer patients by targeting PD-L1, thereby increasing therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595618000115
    Figure 0007595618000115
  • Figure 0007595618000116
    Figure 0007595618000116
  • Figure 0007595618000117
    Figure 0007595618000117
Patent Text Reader

Abstract

Anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity for PD-L1, and immunocytokines, including anti-PD-L1 antibodies fused to a cytokine such as IL-2, are provided. The present invention provides a V antibody that specifically binds to hPD-L1 defined by a specific sequence, competes with antibody 1D05 for binding to said hPD-L1, and comprises a CDRH3 containing the motif X1GSGX2YGX3X4FD, where X1, X2, and X3 are independently any amino acid, and X4 is either present or absent, and, if present, can be any amino acid. H The present invention provides an antibody or fragment thereof comprising the domain.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Antibodies and methods of using the antibodies are described. In particular, antibodies that specifically bind to the human PD-L1 antigen and their use in treating various diseases are described. [Background technology]

[0002] Immunocytokines (antibody-cytokine fusion proteins) were first reported in the literature in the early 1990s and consisted of whole-antibody fusions with cytokines such as lymphotoxin (TNF-α) or interleukin 2 (IL-2). Subsequent studies of GD2-expressing tumor models in mice showed that both the ch14.18 antibody and the ch14.18-IL2 immunocytokine had antitumor activity, but the immunocytokine was much more potent than the antibody, even when combined with free IL-2 (see Sabzevari H et al., Proc. Natl. Acad. Sci. USA, 1994, 91:9626-30; Pancook JD, et al., Cancer Immunol. Immunother., 1996, 42:88-92; Becker JC, et al., Proc. Natl. Acad. Sci. USA, 1996, 93:2702-7). Furthermore, immunocompetent mice treated with immune cytokines but not antibodies and IL-2 showed increased CD8 +They developed a T-cell-dependent adaptive immune response that prevented subsequent tumor burden (Becker JC, et al., J. Exp. Med., 1996, 183:2361-6; Becker JC, et al., Proc. Natl. Acad. Sci. USA, 1996, 93:7826-31). Thus, targeting IL-2 to the tumor microenvironment, alone or in combination with free cytokines, induces an antitumor vaccine effect that antibodies cannot. The related humanized immunocytokine hu 14.18-IL2 has demonstrated clinical proof-of-concept as monotherapy in recurrent non-giant neuroblastoma, inducing a significant number of complete responses in patients with no other treatment options (Shusterman et al., Journal of Clinical Oncology, 2010, 28(33), 4969-4975). Several publications have demonstrated that this molecule activates several components of the immune system to target tumor cells (particularly NK cells and CD8 + T cells) and develop T cell memory to resist subsequent tumor challenge (Yamane et al. 2009; Expert Opi, Investig. Drugs, 18(7):991-1000; Neal et al., 2004, Clin. Cancer Res., 1010, 4839-4847).

[0003] Because IL-2-based immunocytokines can have significant side effects, efforts in recent years have focused on reducing toxicity while maintaining efficacy. One example is selectin (EMD 521873), which has an aspartic acid substitution for threonine at position 20 of IL-2, a key residue in IL-2Rβ binding (Gillies et al., Clinical Cancer Research, 2011, 17(11), 3673-3685). Selectin, which binds to necrotic tissue, has been shown to have good antitumor activity despite its selectivity for high-affinity IL-2R over intermediate IL-2R in phase I trials and good tolerability (Laurent et al., Journal of Translational Medicine, 2013, 11(1), 5. http: / / doi.org / 10.1186 / 1479-5876-11-5).

[0004] WO2012 / 178137 (Gillies) and a related journal article (Gilles, Protein Engineering, Design and Selection, 2013, 26(10), 561-569) describe light chain immunocytokine fusions with tumor-targeting antibodies and modulation of IL-2 activity by introducing truncations in the N-terminal portion of the cytokine that reduce signaling through IL-2Rβγ. IL-2 fusion proteins specifically targeting IL-2Rβγ have been shown to have increased toxicity compared to the wild type (Vasquez-Lombardi et al. Nat Comm, 2017, DOI: 10.1038 / ncomms15373), supporting the notion that reducing IL-2Rβγ binding may be beneficial in terms of side effects.

[0005] The adaptive immune response involves the activation, selection, and clonal expansion of two major classes of lymphocytes, called T cells and B cells. After encountering an antigen, T cells proliferate and differentiate into antigen-specific effector cells, while B cells proliferate and differentiate into antibody-secreting cells. T cell activation is a multistep process that requires several signaling events between T cells and antigen-presenting cells (APCs). For T cell activation to occur, two types of signals must be delivered to resting T cells. The first type is mediated by antigen-specific T cell receptors (TcRs) and confers specificity to the immune response. The second signal, a costimulatory signal, controls the magnitude of the response and is delivered via accessory receptors on T cells.

[0006] The primary costimulatory signal is delivered via the activating CD28 receptor upon engagement of its ligands, B7-1 or B7-2. In contrast, engagement of the inhibitory CTLA-4 receptor by the same B7-1 or B7-2 ligand results in attenuation of T cell responses. Thus, CTLA-4 signals antagonize CD28-mediated costimulation. At high antigen concentrations, CD28 costimulation negates the inhibitory effects of CTLA-4. Primary control of CD28 and CTLA-4 expression maintains a balance between activating and inhibitory signals, ensuring the development of an effective immune response while protecting against the development of autoimmunity.

[0007] Programmed death 1 (PD-1) is a 50-55 kDa type I transmembrane receptor that is a member of the CD28 family. PD-1 is involved in the regulation of T cell activation and is expressed on T cells, B cells, and myeloid cells. Two ligands for PD-1, PD-ligand 1 (PD-L1) and PD-L2, have been identified, which have costimulatory properties.

[0008] Programmed cell death 1 ligand 1 (PD-L1), also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the B7 family that regulates activation or inhibition of the PD-1 receptor. The PD-L1 open reading frame encodes a putative type 1 transmembrane protein of 290 amino acids, containing two extracellular Ig domains (an N-terminal V-like domain and an Ig C-like domain), a hydrophobic transmembrane domain, and a 30-amino acid cytoplasmic tail. The 30-amino acid intracellular (cytoplasmic) domain does not contain obvious signaling motifs but does have potential sites for protein kinase C phosphorylation.

[0009] The complete amino acid sequence of PD-L1 can be found in NCBI Reference Sequence NP_054862.1 (SEQ ID NO: 1), which references numerous journal articles, including, for example, Dong, H., et al. (1999), "PD-L1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion," Nat. Med. 5(12), 1365-1369. The PD-L1 gene is conserved in chimpanzees, rhesus monkeys, dogs, cows, mice, rats, chickens, and zebrafish. The mouse form of PD-L1 shares 69% amino acid identity with the human form of PD-L1 and also shares a conserved structure.

[0010] In humans, PD-L1 is expressed on several immune cell types, including activated and anergic / exhausted T cells, naive and activated B cells, and myeloid dendritic cells (DCs), monocytes, and mast cells. PD-L1 is also expressed on non-immune cells, including pancreatic islets, Kupffer cells in the liver, vascular endothelium, and selected epithelia, such as airway epithelium and renal tubular epithelium, and its expression is enhanced during inflammatory episodes. PD-L1 expression has also been found at elevated levels on several tumors, including breast cancer (including but not limited to triple-negative breast cancer and inflammatory breast cancer), ovarian cancer, cervical cancer, colon cancer, colorectal cancer, lung cancer, including non-small cell lung cancer, kidney cancer, including renal cell carcinoma, gastric cancer, esophageal cancer, bladder cancer, hepatocellular carcinoma, squamous cell carcinoma of the head and neck (SCCHN), and pancreatic cancer, melanoma, and uveal melanoma.

[0011] PD-1 / PD-L1 signaling is thought to play a critical, nonredundant role within the immune system by negatively regulating T cell responses. This regulation is involved in T cell development in the thymus, controlling chronic inflammatory responses, and maintaining both peripheral tolerance and immune privilege. Upregulation of PD-L1 may enable cancers to evade the host immune system, and in many cancers, PD-L1 expression is associated with reduced survival and poor prognosis. Therapeutic monoclonal antibodies capable of blocking the PD-1 / PD-L1 pathway may enhance antitumor immune responses in cancer patients. Published clinical data show a correlation between clinical response and tumor membrane expression of PD-L1 (Brahmer et al., Journal of Clinical Oncology, 2010; Topalian et al., NEJM, 2012), and an even stronger correlation between lack of clinical response and lack of membrane-localized PD-L1 protein (Brahmer et al., Journal of Clinical Oncology, 2010; Topalian et al., NEJM, 2012). Therefore, PD-L1 expression on tumors or tumor-infiltrating leukocytes (Herbst RS, et al., "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients", Nature, 2014, Nov 27, 515(7528):563-7, doi:10.1038 / nature14011) is a candidate molecular marker for use in patient selection for immunotherapy, e.g., immunotherapy using anti-PD-L1 antibodies. Enrichment of patients based on surface expression of PD-L1 can significantly increase the clinical success of treatment with drugs targeting the PD-1 / PD-L1 pathway. Tumor-infiltrating CD8 + There is also evidence of the presence of an ongoing immune response such as T cells or signs of cytokine activation such as IFNγ.

[0012] Further evidence of PD-L1 expression and its correlation with disease will emerge from numerous ongoing clinical trials. Atezolizumab is the most advanced, and recent data from phase II trials have demonstrated the role of PD-L1 in metastatic urothelial carcinoma and NSCLC, particularly in the tumor microenvironment. + It demonstrates immune cell-mediated therapeutic efficacy (see Fehrenbacher et al., 2016, The Lancet, http: / / doi.org / 10.1016 / S0140-6736(16)00587-0; Rosenberg et al., 2016, The Lancet, http: / / doi.org / 10.1016 / S0140-6736(16)00561-4). Recent results from a phase III trial of 1,225 NSCLC patients showed improved survival in patients receiving azelizumab compared with chemotherapy, regardless of tumor expression of PD-L1 (Rittmeyer et al., 2017, The Lancet, 389(10066), 255-265). Summary of the Invention

[0013] antibody Disclosed herein are antibodies and antigen-binding fragments thereof that specifically bind to PD-L1. In one embodiment, the antibody or antigen-binding fragment thereof specifically binds to surface-expressed PD-L1.

[0014] In a first configuration, an antibody or fragment thereof that specifically binds to hPD-L1 as defined by SEQ ID NO: 1 and competes with antibody 1D05 for binding to hPD-L1, wherein the antibody or fragment comprises a V H

[0023] An antibody or fragment thereof is provided that comprises the domain, wherein X1, X2, and X3 are independently any amino acid, and X4 is either present or absent, and if present, can be any amino acid.

[0015] In a second configuration, an antibody or fragment thereof that specifically binds to hPD-L1 and competes with antibody 1D05 for binding to hPD-L1, wherein the antibody or fragment comprises a V H Antibodies or fragments thereof containing the domain are provided.

[0016] In a third configuration, an antibody or fragment thereof is provided that specifically binds to the same epitope as that specifically bound by antibody 1D05.

[0017] In a fourth configuration, an antibody or fragment thereof is provided that competes with antibody 1D05 for binding to hPD-L1.

[0018] In a fifth configuration, there is provided a bispecific antibody or fusion protein comprising an antibody or fragment thereof according to any other configuration, embodiment, or concept.

[0019] In a sixth configuration, there is provided an antibody or fragment according to any other configuration, embodiment or concept for use in the treatment or prevention of an hPD-L1 mediated disease or pathological condition.

[0020] In a seventh configuration, there is provided an antibody or fragment according to any other configuration, embodiment or concept in the manufacture of a medicament for administration to a human to treat or prevent an hPD-L1 mediated disease or pathological condition in the human.

[0021] In an eighth configuration, there is provided a method of treating or preventing an hPD-L1 mediated disease or pathological condition in a human, the method comprising administering to the human a therapeutically effective amount of an antibody or fragment according to any other configuration, embodiment, or concept, whereby the hPD-L1 mediated disease or pathological condition is treated or prevented.

[0022] In a ninth aspect, there is provided a pharmaceutical composition comprising an antibody fragment according to any other aspect, embodiment, or concept, and a pharmaceutically acceptable excipient, diluent, or carrier.

[0023] In a tenth aspect, a kit is provided that includes a pharmaceutical composition comprising an antibody fragment according to any other aspect, embodiment, or concept, and a pharmaceutically acceptable excipient, diluent, or carrier.

[0024] In an eleventh aspect, there is provided a method of modulating PD-1 / PD-L1 interaction in a patient, the method comprising administering to the patient an effective amount of an antibody or fragment described in any other aspect, embodiment, or concept.

[0025] In a twelfth aspect, there is provided a method of inhibiting PD-L1 activity in a patient, the method comprising administering to the patient an effective amount of an antibody or fragment described in any other aspect, embodiment, or concept.

[0026] In a thirteenth aspect, there is provided a method for treating a proliferative disease in an animal (e.g., a human), comprising administering to said patient an effective amount of an antibody or fragment described in any other aspect, embodiment, or concept.

[0027] In a fourteenth aspect, there is provided a method for detecting PD-L1 expression in a sample, the method comprising contacting the sample with an antibody or fragment described in any other aspect, embodiment, or concept.

[0028] In a fifteenth configuration, a method is provided that includes contacting a biological sample with an antibody or fragment according to any other configuration, embodiment, or concept to form a complex with PD-L1 present in the sample, and determining the presence, absence, or level of the complex in the biological sample.

[0029] In a sixteenth configuration, there is provided a method of detecting PD-L1 expression in a sample, comprising contacting the sample with an antibody or fragment described in any other configuration, embodiment, or concept.

[0030] In a seventeenth configuration, there is provided a method comprising contacting a biological sample with an antibody or fragment according to any other configuration, embodiment, or concept to form a complex with PD-L1 present in the sample, and determining the presence, absence, or level of the complex in the biological sample.

[0031] In an eighteenth configuration, there is provided a method for identifying a binding partner for PD-L1, the method comprising immunoprecipitating an intact protein complex comprising PD-L1 using an antibody or fragment described in any other configuration, embodiment, or concept.

[0032] In a nineteenth configuration, there is provided a method of diagnosing a disease in a human subject associated with altered PD-L1 expression, the method comprising contacting a biological sample from the human subject with an antibody described in any other configuration, embodiment, or concept to form a complex between the antibody and PD-L1 present in the sample, and detecting the amount of complex.

[0033] In a twentieth configuration, there is provided a nucleic acid encoding the CDRH3 of an antibody or fragment according to any other configuration, embodiment, or concept.

[0034] In a twenty-first configuration, there is provided a nucleic acid encoding the VH domain and / or VL domain of an antibody or fragment according to any other configuration, embodiment, or concept.

[0035] In a twenty-second aspect, there is provided a vector comprising a nucleic acid according to any other aspect, embodiment, or concept, optionally wherein the vector may be a CHO or HEK293 vector.

[0036] In a twenty-third aspect, there is provided a host comprising a nucleic acid according to any other aspect, embodiment, or concept, or a vector according to any other aspect, embodiment, or concept.

[0037] immune cytokines In a first configuration, an immunocytokine comprises an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain is arranged, from N-terminus to C-terminus, as follows: a) V containing CDRH1, CDRH2, and CDRH3 H The domain and b) a heavy chain constant region; The light chain is arranged in the N-terminal to C-terminal direction as follows: c) a V comprising CDRL1, CDRL2, and CDRL3 L The domain and d) Light chain constant region (C L )and, e) optionally a linker (L); f) IL-2 cytokine, V H Domains and V L a domain comprised of an antigen-binding site that specifically binds to hPD-L1 as defined by SEQ ID NO: 1, and competes with antibody 1D05 for binding to hPD-L1; The immunocytokine contains a CDRH3 containing the motif X1GSGX2YGX3X4FD. H domain, wherein X1, X2, and X3 are independently any amino acid, and X4 is either present or absent, and if present, can be any amino acid.

[0038] In a second configuration, an immunocytokine comprises an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain is arranged, from N-terminus to C-terminus, as follows: a) V containing CDRH1, CDRH2, and CDRH3 H The domain and b) a heavy chain constant region; The light chain is arranged in the N-terminal to C-terminal direction as follows: c) a V comprising CDRL1, CDRL2, and CDRL3 L The domain and d) Light chain constant region (C L )and, e) optionally a linker (L); f) IL-2 cytokine, V H Domains and V L a V domain comprising an antigen-binding site that specifically binds to hPD-L1 and competes with antibody 1D05 for binding to hPD-L1, and the antibody or fragment comprises a V domain comprising the CDRH3 sequence of SEQ ID NO: 29 or 32, or the CDRH3 sequence of SEQ ID NO: 29 or 32 containing no more than 6 amino acid substitutions. H Antibodies or fragments thereof containing the domain are provided.

[0039] In a third configuration, an immunocytokine comprises an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises, from N-terminus to C-terminus: a) V containing CDRH1, CDRH2, and CDRH3 H The domain and b) a heavy chain constant region; The light chain is arranged in the N-terminal to C-terminal direction as follows: c) a V comprising CDRL1, CDRL2, and CDRL3 L The domain and d) Light chain constant region (C L )and, e) optionally a linker (L); f) IL-2 cytokine, V H Domains and V L a domain comprising an antigen-binding site that specifically binds to hPD-L1; V H The domain contains a CDRH3 of 12 to 20 amino acids, and is H gene segment, a human D gene segment, and a human J H derived from the recombination of gene segments, HAn immunocytokine is provided, wherein the gene segment is IGHJ5 (eg, IGHJ5*02).

[0040] In a fourth configuration, an immunocytokine comprises an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises, from N-terminus to C-terminus: a) V containing CDRH1, CDRH2, and CDRH3 H The domain and b) a heavy chain constant region; The light chain is arranged in the N-terminal to C-terminal direction as follows: c) a V comprising CDRL1, CDRL2, and CDRL3 L The domain and d) Light chain constant region (C L )and, e) optionally a linker (L); f) IL-2 cytokine, V H Domains and V L An immunocytokine is provided, the domain of which is constituted by an antigen binding site that specifically binds to an epitope that is identical to the epitope specifically bound by antibody 1D05.

[0041] In a fifth configuration, an immunocytokine comprises an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain is arranged, from N-terminus to C-terminus, as follows: a) V containing CDRH1, CDRH2, and CDRH3 H The domain and b) a heavy chain constant region; The light chain is arranged in the N-terminal to C-terminal direction as follows: c) a V comprising CDRL1, CDRL2, and CDRL3 L The domain and d) Light chain constant region (C L )and, e) optionally a linker (L); f) IL-2 cytokine, V H Domains and V LAn immunocytokine is provided, wherein the domain is comprised of an antigen-binding site that competes with antibody 1D05 for binding to hPD-L1.

[0042] In a sixth configuration, there is provided an immunocytokine according to any other configuration, embodiment or aspect for use in treating or preventing an hPD-L1 mediated disease or pathological condition.

[0043] In a seventh configuration, there is provided an immunocytokine according to any other configuration, embodiment or aspect in the manufacture of a medicament for administration to a human to treat or prevent an hPD-L1 mediated disease or pathological condition in the human.

[0044] In an eighth configuration, there is provided a method of treating or preventing an hPD-L1 mediated disease or pathological condition in a human, the method comprising administering to the human a therapeutically effective amount of an immunocytokine as described in any other configuration, embodiment, or aspect, whereby the hPD-L1 mediated disease or pathological condition is treated or prevented.

[0045] In a ninth configuration, there is provided a pharmaceutical composition comprising an immunocytokine according to any other configuration, embodiment, or aspect, and a pharmaceutically acceptable excipient, diluent, or carrier.

[0046] In a tenth configuration, there is provided a kit comprising a pharmaceutical composition comprising an immunocytokine according to any other configuration, embodiment, or aspect, and a pharmaceutically acceptable excipient, diluent, or carrier.

[0047] In an eleventh configuration, there is provided a nucleic acid encoding the heavy and / or light chain of an immunocytokine according to any other configuration, embodiment or aspect.

[0048] In a twelfth configuration, there is provided a vector comprising a nucleic acid encoding the heavy and / or light chain of an immunocytokine according to any other configuration, embodiment or aspect.

[0049] In a thirteenth aspect, there is provided a host comprising a nucleic acid according to any other aspect, embodiment, or aspect, or a vector according to any other aspect, embodiment, or aspect.

[0050] Anti-ICOS bispecific antibody In the first configuration, a multispecific antibody (e.g., a bispecific or biconjugated antibody) is provided that binds ICOS (e.g., human ICOS) and additional target antigens (optionally having specificity for them).

[0051] In a second configuration, there is provided a composition comprising a multispecific, bispecific, or biconjugate antibody described herein and a pharmaceutically acceptable excipient, diluent, or carrier.

[0052] In a third configuration, there is provided a multispecific, bispecific, or biconjugate antibody as described herein for use in the treatment or prevention of a disease or pathological condition selected from neurological diseases, neoplastic or non-neoplastic diseases, chronic viral infections, and malignant tumors such as melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell carcinoma, bladder cancer, head and neck squamous cell carcinoma, mesothelioma, virus-induced cancers (e.g., cervical cancer and nasopharyngeal carcinoma), soft tissue sarcoma, hematological tumors such as Hodgkin's and non-Hodgkin's disease, and diffuse large B-cell lymphoma (e.g., melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell carcinoma, bladder cancer, head and neck squamous cell carcinoma, and mesothelioma, or e.g., virus-induced cancers (e.g., cervical cancer and nasopharyngeal carcinoma) and soft tissue sarcoma).

[0053] In a fourth configuration, there is provided use of a multispecific, bispecific, or biconjugate antibody as described herein in the manufacture of a medicament for administration to a human for the treatment or prevention of a disease or pathological condition in said human selected from neurological diseases, neoplastic or non-neoplastic diseases, chronic viral infections, and malignant tumors, such as melanoma, Merkel cell carcinoma, non-small cell lung carcinoma (squamous and non-squamous), renal cell carcinoma, bladder cancer, head and neck squamous cell carcinoma, mesothelioma, virus-induced cancers (e.g., cervical carcinoma and nasopharyngeal carcinoma), soft tissue sarcoma, hematological tumors, such as Hodgkin's and non-Hodgkin's disease, and diffuse large B-cell lymphoma (e.g., melanoma, Merkel cell carcinoma, non-small cell lung carcinoma (squamous and non-squamous), renal cell carcinoma, bladder cancer, head and neck squamous cell carcinoma, and mesothelioma, or e.g., virus-induced cancers (e.g., cervical carcinoma and nasopharyngeal carcinoma) and soft tissue sarcoma).

[0054] In a fifth configuration, the present invention relates to neurological disorders, neoplastic or non-neoplastic diseases, chronic viral infections, and malignant tumors, such as melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell carcinoma, bladder cancer, head and neck squamous cell carcinoma, mesothelioma, virus-induced cancers (e.g., cervical cancer and nasopharyngeal carcinoma), soft tissue sarcoma, hematological tumors, such as Hodgkin's and non-Hodgkin's disease, and diffuse large B-cell lymphoma (e.g., ... and non-squamous carcinoma, renal cell carcinoma, bladder cancer, head and neck squamous cell carcinoma, and mesothelioma, or, for example, virally induced cancers (e.g., cervical and nasopharyngeal carcinoma) and soft tissue sarcoma), comprising administering to said human a therapeutically effective amount of a multispecific, bispecific, or biconjugate antibody as described herein, whereby said disease or pathological condition is treated or prevented.

[0055] In a sixth configuration, nucleic acids encoding the heavy and / or light chains of the multispecific antibodies described herein are provided.

[0056] In a seventh configuration, there is provided a vector comprising nucleic acid encoding the heavy and / or light chains of the multispecific antibodies described herein. [Brief explanation of the drawings]

[0057] [Figure 1] Analysis of selected antibodies in dendritic cell-T cell mixed lymphocyte reactions. Monocytes were cultured with GM-CSF and IL-4 for 7 days before the addition of allogeneic purified CD3+ T cells and titration of antibodies. Supernatants were collected on day 5 for analysis of IFNγ production. Data from one experiment are shown. Note that for 84G09, one replicate failed, so there is a single point per concentration. [Figure 2] Direct neutralization ELISA of PD-L1 using the PD-1 receptor. Neutralization profiles of 1D05 and 84G09 compared to benchmark anti-PD-L1 antibodies and isotype controls. Data are representative of three independent experiments. [Figure 3] Neutralization of human PD-L1 CHO-S FACS by the PD-1 receptor. Neutralization profiles of 1D05 and 84G09 compared to benchmark anti-PD-L1 antibodies and isotype controls. Data are representative of three independent experiments. [Figure 4] Neutralization of human PD-L1 CHO FACS by the CD80 receptor. Neutralization profiles of 1D05 and 84G09 compared to benchmark anti-PD-L1 antibodies and isotype controls. Data are representative of three independent experiments. [Figure 5] Lead antibody binds to PD-L1 but not PD-L2. The lead antibody binds to plate-bound PD-L1 (Figure 5a) but not to PD-L2 (Figure 5b). An anti-PD-L2 antibody was used as a control. Data are expressed as time-resolved fluorescence units at 615 nm. Data are representative of two independent experiments. [Figure 6]Lead antibodies induce IFNγ production in dendritic cell-T cell mixed lymphocyte reactions. Immature dendritic cells were co-cultured with allogeneic CD4+ T cells for 5 days in the presence of antibodies. IFNγ was measured in the supernatant by ELISA. Data are representative of three independent experiments. B1 refers to the benchmark antibody. [Figure 7] The lead antibody binds to naturally expressed PD-L1 on dendritic cells. Dendritic cells were generated from monocyte precursors with GM-CSF and IL-4 and stained with lead antibodies (a) 1D05 and (b) 84G09; the isotype control was directly labeled with AlexaFluor 647. Data shown is from one donor representative of four. [Figure 8a] Direct neutralization ELISA of PD-L1 using the PD-1 receptor. Neutralization profile of KM121 hits compared to benchmark anti-PD-L1 antibodies and isotype controls. Data are representative of three independent experiments. [Figure 8b] Direct neutralization ELISA of PD-L1 using the PD-1 receptor. Neutralization profile of KM122 lead candidate molecule compared to benchmark anti-PD-L1 antibodies. Data are from a single experiment. [Figure 8c] Direct neutralization ELISA of PD-L1 using the PD-1 receptor. Neutralization profile of KM122 lead candidate molecule 416E01 compared to benchmark anti-PD-L1 antibodies. Data are from a single experiment. [Figure 9a] Direct neutralization ELISA of PD-L1 using the CD80 receptor. Neutralization profile of KM121 hits compared to benchmark anti-PD-L1 antibodies and isotype controls. Data are representative of three independent experiments. [Figure 9b] Direct neutralization ELISA of PD-L1 using the CD80 receptor. Neutralization profile of the KM122 lead candidate compared to a benchmark anti-PD-L1 antibody. Data are from a single experiment. [Figure 9c]Direct neutralization ELISA of PD-L1 using the CD80 receptor. Neutralization profile of KM122 lead candidate molecule 416E01 compared to benchmark anti-PD-L1 antibodies. Data are from a single experiment. [Figure 10] Bispecific binding by SPR using PD-L1 as the first antigen and TIGIT as the second antigen. A) Bispecific 1, B) Bispecific 2, C) Bispecific 3, D) Bispecific 4. See Table 6 for detailed construction information for each bispecific construct. [Figure 11] Bispecific binding by SPR using TIGIT as the first antigen and PD-L1 as the second antigen. A) Bispecific 1, B) Bispecific 2, C) Bispecific 3, D) Bispecific 4. See Table 6 for detailed construction information for each bispecific construct. [Figure 12(a)] Ability of immunocytokine constructs to induce proliferation of IL-2Rαβγ-expressing TF-1 cells compared to equimolar concentrations of free IL-2. Data shown are from a single experiment representative of three. [Figure 12(b)] Ability of immunocytokine constructs to induce proliferation of IL-2Rβγ-expressing TF-1 cells compared to equimolar concentrations of free IL-2. Data shown are from a single experiment representative of four. [Figure 13(a)] The ability of the 1D05 antibody to neutralize the interaction between PD-1 and PD-L1, as measured by neutralization ELISA, is not affected by fusion of IL-2 to the antibody. Data shown is from a single experiment representative of three. [Figure 13(b)] The ability of the 1D05 antibody to neutralize the interaction between CD80 and PD-L1, as measured by neutralization ELISA, is not affected by fusion of IL-2 to the antibody. Data shown is from a single experiment representative of three. [Figure 14] Mean group and individual animal growth curves for NOD / SCID:Xenograft in vivo efficacy studies [Figure 14(a)]Group mean (n=8 / 9) tumor growth curves are shown. In this graph, if an animal is removed from the study due to tumor size, the last reading is used for the remainder of the study. The shaded area indicates the area where the last reading is used. [Figure 14(b)-(e)] Shown are tumor growth curves for individual animals in each group. (b) A375 tumor alone; (c) A375 tumor co-injected with CD4+ / 8+ T cells at a 6:1 ratio. For panels (d) and (e), A375 tumor cells were co-injected with CD4+ / 8+ T cells at a 6:1 ratio. (d) Isotype control antibody at 10 mg / kg; and (e) anti-PD-L1 antibody 1D05 at 10 mg / kg. Dosing occurred 1 hour after tumor / T cell implantation and on days 3, 6, 8, and 10, as indicated by the dotted lines on the graphs. [Figure 15] Kaplan-Meier plot of the NOD / SCID:Xenograft in vivo efficacy study, showing the number of animals still on study. The plot shows a slight increase in study time when CD4+ / CD8+ T cells were co-injected with tumor cells (T cells / A375) (n=9) compared to the tumor cell-only A375 group (n=9). Treatment with the isotype control (T cells / A375-isotype (n=8)) did not affect survival time compared to T cells co-injected with tumor cells without antibody. Treatment with 10 mg / kg of the anti-PD-L1 antibody 1D05 (T cells / A375-anti-PD-L1) (n=8) significantly increased study time compared to the isotype control group. Dosing occurred 1 hour after T cell / tumor cell injection and on days 3, 6, 8, and 10, as indicated by the dotted lines on the graph. [Figure 16] Lymphocyte proliferation in response to treatment with immune cytokines. Fasting blood samples were collected in EDTA-treated tubes before treatment (0) and on days 2, 5, and 7 after treatment. Cell counts were measured by Bayer Advia 120. Results are expressed as fold changes in lymphocyte counts. [Figure 17]Analysis of standard hematological parameters in response to dosing with immunocytokines. Fasting blood samples were collected in EDTA-treated tubes before treatment and on day 7 after treatment. Analysis of hemoglobin, hematocrit, red blood cell count, and platelet count was performed using a Bayer Advia 120. Results are expressed as percent change in parameters on day 7 after dosing. [Figure 18] Cytokine levels in plasma of cynomolgus monkeys dosed with immune cytokine molecules. Plasma samples were obtained pre-treatment (PT) and day 3 post-dosing (D3) and analyzed by MSD for levels of a) TNF-α, b) IL-8, c) IL-6, d) IFNγ, e) G-CSF, and f) IL-2. Where bars are not included, cytokine levels were below the quantitation limit of the assay. IL4, IL-5, and IL-1β were not detected in any samples at any time point and are therefore not included in the graph. [Figure 19] Soluble CD25 levels in plasma of cynomolgus monkeys dosed with immunocytokine molecules. Plasma samples were obtained pre-treatment (PT) and on day 3 post-dose (D3) and analyzed using a commercially available ELISA kit. * indicates levels above the limit of quantification (20,000 pg / mL). [Figure 20] Flow cytometry analysis of PBMC subsets. Whole blood was stained for markers of a) T cells, and b) B cells, NK cells, neutrophils, and monocytes prior to red blood cell lysis and fixation. Data are expressed as fold change in cell counts at day 5 post-dose. Data for 1D05 LC D9-7 ICK are missing due to unavailable samples. [Figure 21]Pharmacokinetic (PK) analysis of immunocytokines. Serum was prepared from blood samples collected at various time points over 96 hours. In panels a) and b), serum was incubated on PD-L1-coated plates, and immunocytokines were detected with biotinylated anti-human Fc detection antibody and streptavidin-labeled europium. In panels c) and d), serum was incubated on PD-L1-coated plates, and immunocytokines were detected with biotinylated anti-human IL-2 antibody and streptavidin-labeled europium. Results are expressed as ng / mL. [Figure 22a] Induction of IFNγ production in a monocyte-T cell co-culture assay by anti-PD-L1 antibodies in human IgG1 format. Each data point represents the mean fold induction ± standard error from at least three independent experiments. [Figure 22b] Induction of IFNγ production in a monocyte-T cell co-culture assay by anti-PD-L1 antibodies in human IgG4(PE) format. Each data point represents the mean fold induction ± standard deviation from two independent experiments. [Figure 23(a)] Induction of IL-2 in a murine T cell hybridoma assay. Human PD-L1-transfected LK35.2 cells were loaded with ovalbumin peptide and co-cultured overnight with DO-11-10 T cell hybridoma cells in the presence of anti-PD-L1 antibody or control before supernatant collection and analysis of IL-2 release. Each data point represents the background-corrected mean IL-2 release ± standard deviation from three independent experiments. [Figure 23(b)] Induction of IL-2 in a murine T cell hybridoma assay. Human PD-L1-transfected LK35.2 cells were loaded with ovalbumin peptide and co-cultured overnight with DO-11-10 T cell hybridoma cells in the presence of ICOS / PD-L1 bispecific molecules or individual antibodies before supernatant collection and analysis of IL-2 release. Each data point represents the background-corrected mean IL-2 release ± standard deviation from three independent experiments. [Figure 24(a)]Induction of IFNγ in a DC-T cell MLR assay. Monocyte-derived dendritic cells (DCs) were activated with E. coli LPS and co-cultured with allogeneic CD3+ T cells at a 1:1 ratio. After 5 days of co-culture, IFNγ was measured by DELFIA assay. Data are from a single experiment. [Figure 24(b)] Induction of IL-2 in a DC-T cell MLR assay. Monocyte-derived dendritic cells (DCs) were activated with E. coli LPS and co-cultured with allogeneic CD3+ T cells at a 1:1 ratio. After 3 days of co-culture, IL-2 was measured by DELFIA assay. Data are from a single experiment. [Figure 25] Titration of FIT-Ig molecules, parental monospecific antibodies, and control antibodies in the PD-L1 / TIGIT AlphaScreen® binding assay using Method 1. Antibodies were incubated with PD-L1 and TIGIT proteins for 1 hour before addition of AlphaScreen® acceptor beads for 1 hour, followed by AlphaScreen® donor beads for an additional hour before fluorescence detection. A) Titration of FIT-Ig molecules; B) Titration of monospecific antibodies. Data shown are representative of only one experiment. [Figure 26] Titration of FIT-Ig molecules, parental monospecific antibodies, and control antibodies in the PD-L1 / TIGIT AlphaScreen® binding assay using Method 2. AlphaScreen® donor and acceptor beads were coated with PD-L1 and TIGIT proteins, respectively, for 1 hour, after which antibodies were added for 1 hour, followed by fluorescence detection. A) Titration of FIT-Ig molecules; B) Titration of monospecific antibodies. Data shown are representative of only one experiment. [Figure 27] Titration of FIT-Ig molecules and control antibodies in a PD-L1 / TIGIT cell recruitment assay by flow cytometry. CHO human PD-L1 and HEK human TIGIT were stained with CellTrace™ Far Red and CellTrace™ Violet, respectively, and co-cultured in the presence of antibodies before fluorescent detection and identification of double-positive populations. Data shown are representative of only one experiment. [Figure 28] Lymphocyte proliferation in response to treatment with immune cytokines. Fasting blood samples were collected in EDTA-treated tubes before treatment (0) and on days 2, 5, 7, 10, 14, and 23 after treatment. Cell counts were measured by Bayer Advia 120. Results are expressed as fold changes in lymphocyte counts. [Figure 29] Soluble CD25 levels in plasma of cynomolgus monkeys dosed with immunocytokine molecules. Plasma samples were obtained before treatment (0) and on days 3, 7, and 10 after dosing and analyzed using a commercially available ELISA kit. [Figure 30] Analysis of standard hematological parameters in response to dosing with immunocytokines. Fasting blood samples were collected in EDTA-treated tubes before treatment (0) and on days 2, 5, 7, 10, 14, and 23 after treatment. Analysis of A) hemoglobin, B) hematocrit, C) red blood cell count, and D) platelet count was performed using a Bayer Advia 120. Results are expressed as fold changes in parameters at each time point. [Figure 31] Cytokine levels in plasma of cynomolgus monkeys dosed with immune cytokine molecules. Plasma samples were obtained before treatment (0) and on days 1, 3, 7, 10, 14, and 23 after dosing and analyzed by MSD for levels of a) TNF-α, b) IL-8, c) IL-6, d) IFNγ, e) G-CSF, f) IL-2, g) IL-4, and h) IL-5. Where bars are not included, cytokine levels were below the limit of quantitation of the assay. IL-1β was not detected in any samples and is therefore not included in the graph. [Figure 32] Pharmacokinetic (PK) analysis of immunocytokines. Serum was prepared from blood samples collected at various time points over 96 hours. Serum was incubated on PD-L1-coated plates, and immunocytokines were detected with biotinylated anti-human Fc detection antibody and streptavidin-labeled europium. Results are expressed as % peak concentration. [Figure 33]ICK molecule-induced proliferation of specific T cell subsets. Whole blood was incubated with antibodies for staining, followed by red blood cell lysis, fixation, and analysis by flow cytometry. Results are expressed as fold changes in the absolute numbers of (a) CD4+ T cells and (b) CD8+ T cells at each time point. [Figure 34] Effector function of lead antibodies in reporter cell assays. PD-L1-expressing target cells (ES2) were co-cultured overnight with Jurkat cells engineered to express NFAT-inducible luciferase and FcγRIIIa in the presence of PD-L1 antibodies. Each data point represents the mean fold induction of relative light units ± standard deviation. Data are from one representative experiment of three independent experiments. [Figure 35] Binding of lead antibodies to cells expressing cynomolgus monkey PD-L1. Antibodies were titrated on CHO cells expressing cynomolgus monkey PD-L1 and bound antibodies were detected with anti-human IgG AlexaFluor 647. Data are from a single experiment. [Figure 36(a)] Neutralization of human PD-L1 CHO-S FACS by the PD-1 receptor. Neutralization profile of lead antibody compared to benchmark anti-PD-L1 antibody and isotype control. Data representative of two independent experiments [Figure 36(b)] Neutralization of human PD-L1 CHO-S FACS by the CD80 receptor. Neutralization profile of lead antibody compared to benchmark anti-PD-L1 antibody and isotype control. Data representative of two independent experiments. [Figure 37] Induction of IFNγ production in a monocyte-T cell co-culture assay by anti-PD-L1 antibodies in human IgG1 format. Each data point represents the mean fold induction of IFNγ ± standard error from at least three independent experiments. DETAILED DESCRIPTION OF THE INVENTION

[0058] 1.Definition Unless otherwise defined herein, scientific and technical terms shall have the meaning commonly understood by those skilled in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[0059] The singular terms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The abbreviation "eg" is derived from the Latin "exempli gratia" and is used herein to indicate a non-limiting example. Thus, the abbreviation "eg" is synonymous with the term "for example."

[0060] In the specification and claims, the term "about" is used to modify, for example, the amounts, concentrations, volumes, processing temperatures, processing times, yields, flow rates, pressures, and similar values ​​and ranges of components in compositions used in describing embodiments of the present disclosure. The term "about" refers to variations in quantity that may occur, for example, through typical measuring and handling procedures for making a compound, composition, concentrate, or formulation for use, through accidental errors in these procedures, differences in purity in the manufacture, source, or starting materials or components used to carry out the method, and similar straightforward considerations. The term "about" also encompasses amounts that vary with aging of a formulation having a particular initial concentration or mixture, and amounts that vary by mixing or processing a formulation having a particular initial concentration or mixture. When modified by the term "about," the appended claims include equivalents of these quantities.

[0061] As used herein, "administering" or "administration" refers to the act of injecting or otherwise physically delivering an exogenous substance (e.g., an anti-hpD-L1 antibody provided herein) to a patient by mucosal delivery, intradermal delivery, intravenous delivery, intramuscular delivery, and / or any other method described herein or known in the art. When a disease or its symptoms are being treated, administration of the substance typically occurs after the onset of the disease or its symptoms. When a disease or its symptoms are being prevented, administration of the substance typically occurs before the onset of the disease or its symptoms.

[0062] The terms "antibody," "immunoglobulin," or "Ig" may be used interchangeably herein and refer to an immunoglobulin molecule that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or a combination of the foregoing, via at least one antigen recognition site within the variable region of the immunoglobulin molecule. As used herein, the term "antibody" encompasses intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments (e.g., Fab, Fab', F(ab')2, and Fv fragments), single-chain Fv (scFv) variants, multispecific antibodies such as bispecific antibodies (including biconjugated antibodies), chimeric antibodies, humanized antibodies, human antibodies, fusion proteins containing an antigenic portion of an antibody, and any other modified immunoglobulin molecule containing an antigen recognition site, so long as it exhibits the desired biological activity. The term "antibody" can also refer to a Y-shaped glycoprotein with a molecular weight of approximately 150 kDa, consisting of four polypeptide chains (two light (L) chains and two heavy (H) chains). There are five mammalian Ig heavy chain isotypes, designated by the Greek letters alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ). The type of heavy chain defines the class of antibody, i.e., IgA, IgD, IgE, IgG, and IgM, respectively. The gamma and alpha classes are further divided into subclasses, e.g., IgG1, hIgG2, mIgG2A, mIgG2B, IgG3, IgG4, IgA1, and IgA2, based on differences in constant domain sequence and function. In mammals, there are two types of immunoglobulin light chains: lambda and kappa. The "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of the antibody heavy or light chain. The variable domains of the heavy and light chains are called "V" and "V" respectively. H " and "V L These domains are generally the most variable parts of an antibody (compared to other antibodies of the same class) and contain the antigen-binding sites.

[0063] The antibodies described herein may be oligoclonal, polyclonal, monoclonal (including full-length monoclonal), camelized, chimeric, CDR-grafted, multispecific, bispecific (including biconjugated), catalytic, chimeric, humanized, fully human, or anti-idiotypic antibodies, including antibodies that may be labeled in soluble or conjugated form, as well as fragments, variants, or derivatives thereof, either alone or in combination with other amino acid sequences provided by known techniques. Antibodies may be from any species. The antibodies described herein may be naked or conjugated to other molecules, such as toxins, radioisotopes, etc.

[0064] The terms "antigen-binding domain," "antigen-binding region," "antigen-binding fragment," and similar terms refer to the portion of an antibody (e.g., the complementarity-determining region (CDR)) that contains the amino acid residues that interact with an antigen and confer to the binder its specificity and affinity for the antigen. The antigen-binding region can be derived from any animal species, including, for example, rodents (e.g., rabbits, rats, or hamsters) and humans. Preferably, the antigen-binding region is of human origin.

[0065] Antigen-binding fragments described herein may include single-chain Fvs (scFvs), single-chain antibodies, domain antibodies, Fv fragments, Fab fragments, F(ab') fragments, F(ab')2 fragments, antibody fragments exhibiting desired biological activity, disulfide-stabilized variable regions (dsFvs), dimeric variable regions (diabodies), anti-idiotypic (anti-Id) antibodies (e.g., anti-Id antibodies against antibodies), intrabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from any of the above antibody fragments and epitope-binding fragments. In particular, antibodies and antibody fragments described herein may include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e., molecules containing an antigen-binding site. Digestion of antibodies with the enzyme papain yields two identical antigen-binding fragments, also known as "Fab" fragments, that lack antigen-binding activity but have the ability to crystallize. As used herein, "Fab" refers to an antibody fragment containing one constant domain and one variable domain from each of the heavy and light chains. The term "Fc region" herein defines the C-terminal region of an immunoglobulin heavy chain and includes native sequence Fc regions and variable Fc regions. "Fc fragment" refers to the carboxy-terminal portions of both H chains held together by disulfides. The effector functions of an antibody are determined by the sequences in the Fc region, and this region is also recognized by Fc receptors (FcRs) found on certain types of cells. Digestion of an antibody with the enzyme pepsin results in an F(ab')2 fragment in which the two arms of the antibody molecule remain linked and contain two antigen-binding sites. The F(ab')2 fragment has the ability to cross-link antigens.

[0066] As used herein, "Fv" refers to the minimum antibody fragment that retains both the antigen-recognition and antigen-binding sites. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent or covalent association. In this configuration, the three CDRs of each variable domain interact to form a V H -V LThe six CDRs define an antigen-binding site on the surface of the dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing only three CDRs specific for an antigen) has the ability to recognize and bind antigen, albeit with lower affinity than the entire binding site.

[0067] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible natural mutations and / or post-translational modifications (e.g., isomerization, amidation), which may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic determinant or epitope. In contrast, polyclonal antibody preparations typically contain different antibodies directed against different antigenic determinants (or epitopes). As used herein, the term "monoclonal antibody" encompasses both intact and full-length monoclonal antibodies, as well as antibody fragments (e.g., Fab, Fab', F(ab')2, Fv), single-chain (scFv) variants, fusion proteins containing antibody portions, and any other modified immunoglobulin molecule containing an antigen recognition site. Furthermore, "monoclonal antibody" refers to antibodies produced by any number of methods, including, but not limited to, hybridoma, phage selection, recombinant expression, and transgenic animals.

[0068] Monoclonal antibodies herein may include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and / or light chains are identical to or homologous to corresponding sequences in antibodies from a particular species belonging to a particular antibody class or subclass, while the remaining chain(s) are identical to or homologous to corresponding sequences in antibodies from another species belonging to a different antibody class or subclass, as well as fragments of such antibodies that exhibit the desired biological activity.

[0069] The term "humanized antibody" refers to a subset of chimeric antibodies in which a "hypervariable region" from a non-human immunoglobulin (donor antibody) replaces residues from a hypervariable region in a human immunoglobulin (recipient antibody). Generally, a humanized antibody will comprise substantially all of at least one, and typically two, variable regions, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin sequence and all or substantially all of the framework regions are those of a human immunoglobulin sequence, except that the framework regions may contain one or more substitutions that improve antibody performance, e.g., binding affinity, isomerization, immunogenicity, etc.

[0070] The term "bispecific antibody" refers to an antibody that contains specificity for two target molecules, and includes DVD-Ig (see DiGiammarino et al., "Design and generation of DVD-Ig™ molecules for dual-specific targeting," Meth. Mo. Biol., 2012, 889, 145-156), mAb 2 (See WO2008 / 003103, mAb 2type, the description of which is incorporated herein by reference), FIT-Ig (WO2015 / 103072, the description of the FIT-Ig backbone is incorporated herein by reference), mAb-dAb, Dock-Lock, Fab-arm exchange, SEEDbody, Triomab, LUZ-Y, Fcab, κλ-body, orthogonal Fab, scDiabody-Fc, diabody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intrabody, BiTE, diabody, DART, TandAb, scDiabody, scDiabody-CH3, Diabody-CH3, triple body, miniantibody, minibody, TriBi minibody, scFv-CH3 Formats include, but are not limited to, KIH, scFv-CH-CL-scFv, F(ab')2-scFv, scFv-KIH, Fab-scFv-Fc, tetravalent HCab, ImmTAC, knobs-in-holes, knobs-in-hole with a common light chain, knobs-in-hole with a common light chain and charge pair, charge pair, charge pair with a common light chain, DT-IgG, DutaMab, IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, and zybody. For a review of bispecific formats, see Spiess, C., et al., Mol. Immunol. (2015).In another embodiment, the bispecific molecule comprises another non-Ig format, such as a T-cell receptor binding domain, an immunoglobulin superfamily domain, a jawless variable lymphocyte receptor, a fibronectin domain (e.g., Adnectin™), an antibody constant domain (e.g., a CH3 domain, e.g., CH2 and / or CH3 of an Fcab™) (wherein the constant domain is not a functional CH1 domain), an scFv, (scFv)2, sc-diabody, scFab, centyrin and epitope binding domains derived from a scaffold selected from CTLA-4 (Evibody™), a lipocalin domain, protein A Protein A (e.g., Affibody™ or SpA), A domains (e.g., Avimer™ or Maxibody™), heat shock proteins (such as epitope binding domains from GroEI and GroES), transferrin domains (e.g., transbodies), ankyrin repeat proteins (e.g., DARPin™), peptide aptamers, C-type lectin domains (e.g., Tetranectin™), human gamma-crystallin or human ubiquitin (affilin), PDZ domains, scorpion toxins, and antibodies fused to Kunitz-type domains of human protease inhibitors.

[0071] In one embodiment, the bispecific antibody is a mAb 2 mAb 2 is a V from an intact antibody fused to a modified constant region H and V L domains, which have been engineered to form antigen-binding sites known as "Fcabs." Fcab / mAb 2 The technology behind the format is described in more detail in WO2008 / 003103 and in mAb 2 The format description is incorporated herein by reference.

[0072] In one embodiment, a "bispecific antibody" does not include the FIT-Ig format. In one embodiment, a "bispecific antibody" is a mAb2 In one embodiment, a "bispecific antibody" does not include the FIT-Ig format or the mAb 2 Does not include any of the formats.

[0073] In another embodiment, the bispecific antibody is a "dual binding antibody." As used herein, a "dual binding antibody" refers to an antibody in which both antigen-binding domains are V H / V L and bispecific antibodies formed by a pair, including FIT-Ig (see WO2015 / 103072, incorporated herein by reference), mAb-dAb, Dock-Lock, Fab-arm exchange, SEEDbody, Triomab, LUZ-Y, Fcab, κλ-body, orthogonal Fab, scDiabody-Fc, diabody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intrabody, BiTE, diabody, DART, TandAb, scDiabody, scDiabody-CH3, diabody-CH3, triple body, minibody, minibody, scFv-CH3. These include, but are not limited to, KIH, scFv-CH-CL-scFv, F(ab')2-scFv, scFv-KIH, Fab-scFv-Fc, tetravalent HCab, ImmTAC, knob-in-hole, knob-in-hole with a common light chain, knob-in-hole with a common light chain and charge pair, charge pair, charge pair with a common light chain, DT-IgG, DutaMab, IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, and scFv4-Ig.

[0074] The terms "hypervariable region," "CDR region," or "CDR" refer to the regions of an antibody variable domain that are hypervariable in sequence and / or form structurally defined loops. Generally, the antigen-binding site of an antibody is composed of six hypervariable regions (V HThree in (CDRH1, CDRH2, CDRH3) and V L These regions of the heavy and light chains of an antibody confer antigen-binding specificity to the antibody. CDRs can be defined according to the Kabat system (Kabat, EA et al., 1991, "Sequences of Proteins of Immunological Interest", 5 th (See, e.g., NIH Publication no. 91-3242, USDapartment of Health and Human Services). Other systems may also be used to define CDRs, such as the system devised by Chothia et al. (See, e.g., Chothia, C. & Lesk, AM, 1987, "Canonical structures for the hypervariable regions of immunoglobulins", J. Mol. Biol., 196, 901-917) and the IMGT system (See, e.g., Lefranc, MP, 1997, "Unique database numbering system for immunogenetic analysis", Immunol. Today, 18, 50). Antibodies typically contain three heavy chain CDRs and three light chain CDRs. The term CDR(s) is used herein to refer to one or several of these regions. Those skilled in the art can easily compare different nomenclature systems and determine whether a particular sequence can be defined as a CDR.

[0075] A "human antibody" is an antibody that possesses an amino acid sequence corresponding to that of an antibody produced by a human and / or that has been produced using any of the techniques for producing human antibodies, and excludes humanized antibodies that contain non-human antigen-binding residues. The term "specifically binds" refers to a measurable and reproducible interaction, such as binding, between a target and an antibody that determines the presence of the target in the presence of a homogeneous population of molecules, including biological molecules. For example, an antibody that specifically binds to a target (which may be an epitope) is an antibody that binds to this target with greater affinity, avidity, more readily, and / or for longer than it binds to other targets. In one embodiment, the extent of binding of the antibody to an unrelated target is less than about 10% of the binding of the antibody to the target, as measured, for example, by radioimmunoassay (RIA).

[0076] Antibodies or fragments thereof that specifically bind to the hPD-L1 antigen may be cross-reactive with related antigens. Preferably, antibodies or fragments thereof that specifically bind to the hPD-L1 antigen do not cross-react with other antigens (but may optionally cross-react with PD-L1 from different species, such as rhesus monkeys or mice). Antibodies or fragments thereof that specifically bind to the hPD-L1 antigen can be identified, for example, by immunoassays, BIAcore™, or other techniques known in the art. An antibody or fragment thereof specifically binds to the PD-L1 antigen when it binds to the hPD-L1 antigen with higher affinity than to any cross-reactive antigens, as determined using experimental techniques such as radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA). Typically, a specific or selective response is at least 2 times the background signal or noise, more typically more than 10 times (e.g., more than 15 times, more than 20 times, more than 50 times, or more than 100 times) background. For a discussion of antibody specificity, see, e.g., pages 332-336 of Paul, ed., 1989, Fundamental Immunology Second Edition, Raven Press, New York.

[0077] The term "aliphatic amino acid" means that the amino acid R group is nonpolar and hydrophobic. Hydrophobicity increases with the number of C atoms in the hydrocarbon chain. Glycine, alanine, valine, leucine, and isoleucine are aliphatic amino acids.

[0078] The term "aromatic amino acid" means that the amino acid R group contains an aromatic ring system. Phenylalanine, tyrosine, and tryptophan are aromatic amino acids.

[0079] The term "hydroxyl-containing amino acid" means that the amino acid R group contains a hydroxyl group and is hydrophilic. Serine, cysteine, threonine, and methionine are hydroxyl-containing amino acids.

[0080] The term "basic amino acid" means that the amino acid R group contains nitrogen and is basic at neutral pH. Histidine, lysine, and arginine are basic amino acids.

[0081] The term "cyclic amino acid" means that the amino acid R group has an aliphatic ring structure. Proline is the only cyclic aliphatic amino acid.

[0082] The term "acidic amino acid" means that the amino acid R group is polar and negatively charged at physiological pH. Aspartic acid and glutamic acid are acidic amino acids.

[0083] The term "amide amino acid" means that the amino acid R group contains an amide group. Asparagine and glutamine are amide amino acids.

[0084] As used herein, "approval number" and "marketing authorization number" refer to a number issued by a regulatory agency when that agency determines that a particular medical product and / or composition may be sold and / or released in the agency's area of ​​jurisdiction. As used herein, "regulatory agency" refers to, for example, one of the agencies responsible for evaluating the safety and effectiveness of medical products and / or compositions and controlling the release / sale of such products and / or compositions in a given area. The Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EPA) in Europe are just two examples of such regulatory agencies. Other non-limiting examples may include the SDA, MPA, MHPRA, IMA, ANMAT, Hong Kong Department of Health-Drug Office, CDSCO, Medsafe, and KFDA.

[0085] As used herein, the term "biomarker" refers to a gene that is differentially expressed in individuals with a disease of interest, e.g., a gene that is differentially expressed in individuals with cancer. In one embodiment, PD-L1 is a biomarker whose expression in a tumor can indicate whether a patient will respond to a particular type of treatment, specifically whether a patient will respond to a treatment that targets PD-L1, e.g., immunotherapy using an anti-PD-L1 antibody. In one embodiment, PD-L1 is a biomarker whose expression in a tumor can indicate whether a patient will respond to a particular type of treatment, specifically whether a patient will respond to a treatment that targets PD-1, e.g., immunotherapy using an anti-PD-1 antibody. In another embodiment, PD-L1 can be free or membrane-bound. In another embodiment, PD-L1 can be immobilized or non-immobilized.

[0086] As used herein, "buffer" refers to a chemical agent that can absorb a certain amount of acid or base without undergoing a strong shift in pH.

[0087] As used herein, the term "carrier" refers to a diluent, adjuvant (e.g., Freund's adjuvant (complete and incomplete)), excipient, or vehicle with which a therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like, including those of petroleum, animal, vegetable, or synthetic origin. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions.

[0088] The terms "chemotherapeutic agent" or "chemotherapy" typically refer to therapeutic agents whose primary purpose is to destroy cancer cells by interfering with their ability to grow or proliferate. Many different types of chemotherapy drugs exist, with over 50 approved chemotherapy drugs available. Chemotherapy drugs can be classified based on how they work. Alkylating agents kill cancer cells by directly attacking DNA, the genetic material of genes. Cyclophosphamide is an alkylating agent. Antimetabolites interfere with the production of DNA, suppressing cell growth and proliferation. An example of an antimetabolite is 5-fluorouracil (5-FU). Antitumor antibiotics are produced from natural sources, such as fungi in the soil. They interfere with important cellular functions, including the production of DNA and cellular proteins. Doxorubicin and bleomycin belong to this group of chemotherapy drugs. Plant alkaloids prevent cells from dividing normally. Vinblastine and vincristine are plant alkaloids obtained from the periwinkle plant. Steroid hormones slow the growth of some hormone-dependent cancers. For example, tamoxifen is used to treat breast cancer, which depends on the hormone estrogen for growth. DNA damage response (DDR) inhibitors, such as PARP inhibitors, block DNA repair mechanisms after single- or double-strand breaks.

[0089] Examples of chemotherapeutic agents include adriamycin, doxorubicin, 5-fluorouracil, cytosine arabinoside (Ara-C), cyclophosphamide, thiotepa, taxotere (docetaxel), busulfan, cytoxin, taxol, methotrexate, cisplatin, melphalan, vinblastine, bleomycin, etoposide, ifosfamide, mitomycin C, mitoxantrone, vincleistine, vinorelbine carboplatin, teniposide, daunomycin, carminomycin, aminopterin, dactinomycin, mitomycin, esperamicin (see U.S. Pat. No. 4,675,187), melphalan, and other related nitrogen mustards. Suitable toxins and chemotherapeutic agents are described in Remington's Pharmaceutical Sciences, 19th Ed. (Mack Publishing Co. 1995) and Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7 th Ed. (MacMillan Publishing Co. 1985). Another example of a chemotherapeutic agent is the class of toxins conjugated to antibodies, including, but not limited to, pyrrolobenzodiazepines, maytansanoids, calicheamicin, and the like. Other suitable toxins and / or chemotherapeutic agents will be known to those skilled in the art.

[0090] As used herein, the term "composition" is intended to encompass a product containing specified ingredients (e.g., an antibody of the invention), optionally in specified amounts, and any product that results directly or indirectly from a combination of specified ingredients, optionally in specified amounts.

[0091] As used herein, the terms "comprising" or "comprises" are used in reference to antibodies, fragments, uses, compositions, methods, and their respective component(s) that are essential to the method or composition, but allow for the inclusion of unspecified elements, whether essential or not.

[0092] The term "consisting of" refers to the antibodies, fragments, uses, compositions, methods, and their respective components described herein, excluding any element not recited in the description of that embodiment.

[0093] As used herein, the term "consisting essentially of" refers to elements required for a given embodiment. The term permits the presence of elements that do not materially affect the basic, novel, or functional characteristic(s) of that embodiment.

[0094] As used herein, in the context of a polypeptide, the term "derivative" refers to a polypeptide comprising the amino acid sequence of an hPD-L1 polypeptide, a fragment of an hPD-L1 polypeptide, or an antibody that specifically binds to an hPD-L1 polypeptide that has been altered by the introduction of amino acid substitutions, deletions, or additions. As used herein, the term "derivative" also refers to an hPD-L1 polypeptide, a fragment of an hPD-L1 polypeptide, or an antibody that specifically binds to an hPD-L1 polypeptide that has been chemically modified, for example, by the covalent attachment of any type of molecule to the polypeptide. For example, and without limitation, an hPD-L1 polypeptide, a fragment of an hPD-L1 polypeptide, or an hPD-L1 antibody may be chemically modified by, for example, glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, protein cleavage, attachment to a cellular ligand or other protein, etc. A derivative is modified in such a way that either the type or location of the attached molecule is different from that of the native or starting peptide or polypeptide. A derivative further includes deletion of one or more chemical groups that are naturally present on the peptide or polypeptide. Derivatives of hPD-L1 polypeptides, hPD-L1 polypeptide fragments, or hPD-L1 antibodies may be chemically modified using techniques known to those skilled in the art, including, but not limited to, specific chemical cleavage, acetylation, formulation, metabolic synthesis with tunicamycin, etc. Furthermore, derivatives of hPD-L1 polypeptides, hPD-L1 polypeptide fragments, or hPD-L1 antibodies may contain one or more non-classical amino acids. Polypeptide derivatives retain similar or identical functions as the hPD-L1 polypeptides, hPD-L1 polypeptide fragments, or hPD-L1 antibodies described herein.

[0095] As used herein, the term "effector function" is intended to refer to one or more of antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC)-mediated responses, Fc-mediated phagocytosis or antibody-dependent cellular phagocytosis (ADCP), and antibody recycling via the FcRn receptor.

[0096] An "effective amount" refers to an amount effective, at a dosage and for a period of time necessary, to achieve a desired effect, including a therapeutic or prophylactic effect. A "therapeutically effective amount" refers to the minimum concentration necessary to achieve a measurable improvement or prevention of a particular disorder. The therapeutically effective amount herein may vary depending on factors such as the stage of disease, age, sex, and weight of the patient, and the ability of the antibody to elicit a desired response in an individual. A therapeutically effective amount is also one in which the beneficial effects of treatment outweigh any toxic or adverse effects of the antibody. A "prophylactically effective amount" refers to an amount effective, at a dosage and for a period of time necessary, to achieve a desired prophylactic effect. In some embodiments, the effective amount of an antibody of the present invention is from about 0.1 mg / kg (mg of antibody per kg of subject body weight) to about 100 mg / kg. In certain embodiments, an effective amount of an antibody provided herein is about 0.1 mg / kg, about 0.5 mg / kg, about 1 mg / kg, 3 mg / kg, 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, about 50 mg / kg, about 60 mg / kg, about 70 mg / kg, about 80 mg / kg, about 90 mg / kg, or about 100 mg / kg (or a range therein). In some embodiments, "effective amount," as used herein, also refers to the amount of an antibody of the invention to achieve a specified result (e.g., inhibition of cellular hPD-L1 biological activity).

[0097] As used herein, the term "epitope" refers to a localized region on the surface of an antigen, such as an hPD-L1 polypeptide or hPD-L1 polypeptide fragment, that can bind to one or more antigen-binding regions of an antibody, has antigenic or immunogenic activity, and is capable of eliciting an immune response in an animal, preferably a mammal, and most preferably a human. An epitope with immunogenic activity is a portion of a polypeptide that elicits an antibody response in an animal. An epitope with antigenic activity is a portion of a polypeptide to which an antibody specifically binds, as determined by any method known in the art, such as the immunoassays described herein. An antigenic epitope need not necessarily be immunogenic. Epitopes usually consist of chemically active surface groupings of molecules, such as amino acids or sugar side chains, and have specific three-dimensional structural characteristics, as well as specific charge characteristics. The region of a polypeptide that is associated with an epitope may be contiguous amino acids of the polypeptide, or an epitope may be assembled from two or more non-contiguous regions of the polypeptide. An epitope may or may not be a three-dimensional surface feature of an antigen. In certain embodiments, an hPD-L1 epitope is a three-dimensional surface feature of an hPD-L1 polypeptide (e.g., in the trimeric form of an hPD-L1 polypeptide). In other embodiments, an hPD-L1 epitope is a linear feature of an hPD-L1 polypeptide (e.g., in the trimeric or monomeric form of an hPD-L1 polypeptide). The antibodies provided herein may specifically bind to an epitope of hPD-L1 in the monomeric (denatured) form, an epitope of hPD-L1 in the trimeric (native) form, or an epitope of hPD-L1 in both the monomeric (denatured) and trimeric (native) forms. In certain embodiments, the antibodies provided herein specifically bind to an epitope of hPD-L1 in the trimeric form, but do not specifically bind to hPD-L1 in the monomeric form.

[0098] As used herein, the term "excipient" generally refers to an inert substance used as a diluent, vehicle, preservative, binder, or stabilizer for a drug, and includes, but is not limited to, proteins (e.g., serum albumin, etc.), amino acids (e.g., aspartic acid, glutamic acid, lysine, arginine, glycine, histidine, etc.), fatty acids and phospholipids (e.g., alkylsulfonates, caprylates, etc.), surfactants (e.g., SDS, polysorbates, nonionic surfactants, etc.), sugars (e.g., sucrose, maltose, trehalose, etc.), and polyols (e.g., mannitol, sorbitol, etc.). See also Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, Pa., which is incorporated herein by reference in its entirety.

[0099] As used herein, the terms "fixed" or "fixation" refer to a chemical process by which biological tissue is preserved to prevent autolysis or decay. Generally, fixation involves exposing the tissue to a chemical compound, e.g., an aldehyde such as alcohol or formaldehyde, to halt ongoing biochemical reactions. In some instances, fixation can also increase the mechanical strength and stability of the treated tissue. The term "unfixed" refers to tissue that has not been subjected to a chemical process to prevent tissue decay. As used herein, "surface-expressed" means that the protein is embedded in or spans the cell membrane, or is associated with a protein that is embedded in or spans the cell membrane (i.e., a membrane-associated protein). In one embodiment, a surface-expressed protein contains one or more transmembrane domains. In another embodiment, the protein is indirectly associated with the outer or inner surface of the cell membrane through association with another transmembrane protein (i.e., the surface-expressed protein does not span the cell membrane itself). In general, surface-expressed proteins that are integrated into the cell membrane or expressed endogenously within the cell are more likely to fold in the correct conformation than recombinantly produced free forms of the same proteins.

[0100] As used herein, in the context of a peptide or polypeptide, the term "fragment" refers to a peptide or polypeptide that comprises less than the full-length amino acid sequence. Such fragments can result, for example, from truncation at the amino terminus, truncation at the carboxy terminus, and / or internal deletion of a residue(s) from the amino acid sequence. Fragments can result, for example, from alternative RNA splicing or from in vivo protease activity. In certain embodiments, a PD-L1 fragment comprises a polypeptide comprising an amino acid sequence of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino acid residues, at least 70 contiguous amino acid residues, at least 80 contiguous amino acid residues, at least 90 contiguous amino acid residues, at least 100 contiguous amino acid residues, at least 125 contiguous amino acid residues, at least 150 contiguous amino acid residues, at least 175 contiguous amino acid residues, at least 200 contiguous amino acid residues, or at least 250 contiguous amino acid residues of an hPD-L1 polypeptide or an antibody that specifically binds to an hPD-L1 polypeptide. In certain embodiments, a fragment of an hPD-L1 polypeptide or an antibody that specifically binds to an hPD-L1 antigen retains at least one, at least two, or at least three functions of the polypeptide or antibody.

[0101] The term "free" refers to a polypeptide, such as PD-L1, or fragments and variants thereof, combined with a buffer, and the polypeptide is not bound to a cell surface or cell membrane. Thus, the term "free" can refer to a polypeptide that is capable of surface expression (i.e., contains one or more transmembrane or membrane-binding domains) but that is not expressed on the surface of a cell in its current state or is not bound to a protein expressed on the surface of a cell. A free polypeptide can also refer to a free recombinant or native or unbound polypeptide. In the context of phage display, the free antigen can be selected in solution (referred to herein as "soluble selection") or adsorbed to a surface, for example, the surface of a 96-well plate (referred to herein as "biopanning selection").

[0102] As used herein, the term "fusion protein" refers to a polypeptide comprising the amino acid sequence of an antibody and the amino acid sequence of a heterologous polypeptide or protein (i.e., a polypeptide or protein that is not normally part of an antibody (e.g., a non-anti-hPD-L1 antigen antibody)). The term "fusion", when used in reference to hPD-L1 or an anti-hPD-L1 antibody, refers to the conjugation of a peptide or polypeptide, or fragment, variant, and / or derivative thereof, with a heterologous peptide or polypeptide. Preferably, the fusion protein retains the biological activity of hPD-L1 or an anti-hPD-L1 antibody. In certain embodiments, the fusion protein comprises the VH domain, VL domain, VH CDRs (one, two, or three VH CDRs), and / or VL CDRs (one, two, or three VL CDRs) of an hPD-L1 antibody, and the fusion protein specifically binds to an hPD-L1 epitope.

[0103] The term "heavy chain," when used in reference to antibodies, refers to five different types, designated alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ), based on the amino acid sequence of the heavy chain constant domain. These different types of heavy chains are well known and give rise to five classes of antibodies: IgA, IgD, IgE, IgG, and IgM, respectively, including four subclasses of IgG: IgG1, IgG2, IgG3, and IgG4. Preferably, the heavy chain is a human heavy chain. In the human population, multiple heavy chain constant region alleles exist for each immunoglobulin or immunoglobulin subclass. The nucleotide and amino acid sequences of these allelic variants are accessible in publicly available databases, such as IMGT, ENSEMBL Swiss-Prot, and Uniprot. Allelic variants can also be identified in various genome sequencing projects. In one embodiment, the antibodies and antibody fragments disclosed herein comprise a heavy chain encoded by an IgG1 constant region allele, including, but not limited to, human IGHG1*01 (SEQ ID NOs: 340, 341, and 537), IGHG1*02 (SEQ ID NOs: 340, 341, and 537), IGHG1*03 (SEQ ID NOs: 523 and 524), IGHG1*04 (SEQ ID NOs: 525 and 526), ​​and IGHG1*05 (SEQ ID NOs: 340, 341, and 537). In one embodiment, the antibodies and antibody fragments disclosed herein comprise proteins encoded by IgG2 constant region alleles, including, but not limited to, human IGHG2*01 (SEQ ID NOs: 527 and 528), IGHG2*02 (SEQ ID NOs: 529 and 530), IGHG2*03 (SEQ ID NOs: 527 and 528), IGHG2*04 (SEQ ID NOs: 531 and 532), IGHG2*05 (SEQ ID NOs: 527 and 528), and IGHG2*06 (SEQ ID NOs: 533 and 534).In one embodiment, the antibodies and antibody fragments disclosed herein comprise proteins encoded by IgG3 constant region alleles, including but not limited to, human IGHG3*01, IGHG3*02, IGHG3*03, IGHG3*04, IGHG3*05, IGHG3*06, IGHG3*07, IGHG3*08, IGHG3*09, IGHG3*10, IGHG3*11, IGHG3*12, IGHG3*13, IGHG3*14, IGHG3*15, IGHG3*16, IGHG3*17, IGHG3*18, and IGHG3*19. In one embodiment, the antibodies and antibody fragments disclosed herein comprise proteins encoded by IgG4 constant region alleles, including, but not limited to, human IGHG4*01 (SEQ ID NOs: 192 and 193), IGHG4*02 (SEQ ID NOs: 194 and 195), IGHG4*03 (SEQ ID NOs: 196 and 197), and IGHG4*04 (SEQ ID NOs: 192 & 193). In another example, the heavy chain is a truncated IgG isotype, e.g., a truncated IgG4. In certain embodiments, the antibodies of the present invention comprise a human gamma 4 constant region. In another embodiment, the heavy chain constant region does not bind to an Fc-gamma receptor and comprises, for example, a Leu235Glu mutation. In another embodiment, the heavy chain constant region comprises a Ser228Pro mutation to increase stability. In another embodiment, the heavy chain constant region is IgG4-PE (SEQ ID NO: 199. In another embodiment, the antibodies and antibody fragments disclosed herein comprise a heavy chain constant region encoded by a mouse IgG1 constant region allele, including but not limited to, mouse IGHG1*01 or IGHG1*02. In one embodiment, the antibodies and antibody fragments disclosed herein comprise a heavy chain constant region encoded by a mouse IgG2 constant region allele, including but not limited to, mouse IGHG2A*01, IGHG2A*02, IGHG2B*01, IGHG2B*02, IGHG2C*01, IGHG2C*02, or IGHG2C*03. In one embodiment, the antibody or antibody fragment disclosed herein comprises a protein encoded by a mouse IgG3 constant region allele, including but not limited to, mouse IGHG3*01.

[0104] As used herein, the term "host" refers to an animal, preferably a mammal, and most preferably a human.

[0105] As used herein, the term "host cell" refers to a particular subject cell transfected with a nucleic acid molecule, and to the progeny or potential progeny of such a cell. The progeny of such a cell may not be identical to the parent cell transfected with the nucleic acid molecule due to mutations or environmental influences that may occur in subsequent generations, or due to integration of the nucleic acid molecule into the host cell genome.

[0106] As used herein, the term "IL-2 cytokine" refers to a cytokine-like molecule that has activity similar to wild-type IL-2. It may have activity at the high (αβγ) affinity IL-2 receptor and / or the intermediate affinity (αβ) IL-2 receptor. The cytokine may be a mutant IL-2 cytokine having one or more amino acid deletions, substitutions, or additions. Mutant cytokines are described in more detail herein below.

[0107] As used herein, "immunomodulatory agent" and variations thereof, including but not limited to immunomodulator, refer to an agent that modulates the host's immune system. In certain embodiments, an immunomodulatory agent is an immunosuppressant. In certain other embodiments, an immunomodulatory agent is an immunostimulatory agent. In accordance with the present invention, the immunomodulatory agent used in the combination therapies of the present invention does not include an anti-hPD-L1 antibody or antigen-binding fragment. Immunomodulatory agents include, but are not limited to, small molecules, peptides, polypeptides, proteins, fusion proteins, antibodies, inorganic molecules, mimetics, and organic molecules.

[0108] The term "in combination" in the context of the administration of other therapeutic agents refers to the use of two or more therapeutic agents. The use of the term "in combination" does not restrict the order in which therapeutic agents are administered to a subject with a disease. A first therapeutic agent can be administered before (e.g., 1 minute, 45 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks), simultaneously with, or after (e.g., 1 minute, 45 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks) the administration of a second therapeutic agent to a subject with, having, or susceptible to an hPD-L1-mediated disease. Any additional therapeutic agent may be administered in any order with the other additional therapeutic agents. In certain embodiments, an antibody of the invention may be administered in combination with one or more therapeutic agents (e.g., a therapeutic agent other than an antibody of the invention that is currently being administered to prevent, treat, manage, and / or ameliorate an hPD-L1-mediated disease). Non-limiting examples of therapeutic agents that may be administered in combination with an antibody of the invention include an analgesic, anesthetic, antibiotic, or immunomodulatory agent, or any other agent listed in the United States Pharmacopeia and / or Physician's Instructions.

[0109] As used herein, the term "immunocytokine" refers to an antibody format fused to a cytokine molecule. The antibody format can be any of those described herein, and the cytokine can be fused directly or via a linker or chemical conjugation to the N-terminus or C-terminus of the heavy or light chain of the antibody format.

[0110] As used herein, "injection device" refers to a device designed to perform an injection, which includes temporarily fluidly connecting the injection device to a human tissue, typically a non-tissue. The injection further includes administering a quantity of liquid medication into the tissue and disconnecting or removing the injection device from the tissue. In some embodiments, the injection device may be an intravenous or IV device, a type of injection device used when the target tissue is blood in the circulatory system, e.g., a venous blood vessel. A common, but non-limiting, example of an injection device is a needle and syringe.

[0111] As used herein, "instructions" refers to written, printed, or graphic material on the immediate container of an item, e.g., written material displayed on a vial containing a pharmaceutically active agent, or a display detailing the composition and use of a product of interest included in a kit containing the composition of interest. The instructions describe the method of treatment intended to be administered or performed.

[0112] An "isolated" or "purified" antibody or protein is one that has been identified, separated, and / or recovered from components of its production environment (e.g., natural or recombinant). For example, the antibody or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the antibody is derived, or, if chemically synthesized, substantially free of chemical precursors or other chemicals. The language "substantially free of cellular material" includes preparations of antibodies in which the antibody is separated from cellular components of the cells from which it was isolated or recombinantly produced. Thus, an antibody that is substantially free of cellular material contains less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous proteins (also referred to herein as "contaminating proteins"). If the antibody is recombinantly produced, the antibody is also preferably substantially free of culture medium; i.e., culture medium accounts for less than 20%, 10%, or 5% of the volume of the protein preparation. If the antibody is produced by chemical synthesis, the antibody is preferably substantially free of chemical precursors or other chemicals; i.e., the antibody is separated from chemical precursors or other chemicals involved in the synthesis of the protein. Accordingly, such preparations of antibodies have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the antibody of interest. In preferred embodiments, the antibodies of the invention are isolated or purified.

[0113] The term "Kabat numbering" and similar terms are recognized in the art and refer to a system for numbering amino acid residues that are more variable (i.e., hypervariable) than other amino acid residues in the heavy chain variable region of an antibody, or its antigen-binding portion (Kabat et al., (1971) Ann. NY Acad. Sci., 190:382-391 and Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NIH Publication No. 91-3242). For the heavy chain variable region, the hypervariable regions typically range from amino acid positions 31 to 35 for CDR1, amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3.

[0114] As used herein, "label" or "labeled" refers to the addition of a detectable moiety to a polypeptide, such as a radiolabel, a fluorescent label, an enzyme label, a chemiluminescent label, or a biotinyl group or gold. Radioisotopes or radionuclides include: 3 H, 14 C. 15 N, 35 S, 90 Y, 99 Tc, 115 In, 125 I, 131Fluorescent labels may include rhodamine, lanthanide fluorophores, or FITC; fluorescent labels may include horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase. Additional labels include, by way of example and not limitation, enzymes such as glucose-6-phosphate dehydratase ("G6PDH"), alpha-D-galactosidase, glucose oxidase, glucose amylase, carbonic anhydrase, acetylcholinesterase, lysozyme, malate dehydrogenase, and peroxidase; dyes (e.g., cyanine dyes, e.g., Cy5™, Cy5.5™, or Cy7™); additional fluorescent labels or fluorophores such as fluorescein and its derivatives, fluorescent dyes, GFP (GFP for "green fluorescent protein"), other fluorescent proteins (e.g., mCherry, mTomato), dansyl, umbelliferone, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, and fluorescamine; fluorophores such as lanthanide cryptates and chelates, e.g., europium (PerkinElmer and others), and the like. and Cisbio assays); chemiluminescent labels or chemifluorescent agents such as isoluminol, luminol, and dioxetanes; sensitizers; coenzymes; enzyme substrates; particles such as latex or carbon particles; metal sols; microcrystals; liposomes; cells, etc., which may be further labeled with dyes, catalysts, or other detectable groups; molecules such as biotin, digoxigenin, or 5-bromodeoxyuridine; or a toxin moiety such as a toxin moiety selected from the group consisting of Pseudomonas exotoxin (PE or a cytotoxic fragment or variant thereof), Diptheria toxin or a cytotoxic fragment or variant thereof, botulinum toxin A, B, C, D, E, or F, ricin or a cytotoxic fragment thereof, e.g., ricin A, abrin or a cytotoxic fragment thereof, saporin or a cytotoxic fragment thereof, pokeweed antiviral toxin or a cytotoxic fragment thereof, and bryodin 1 or a cytotoxic fragment thereof.

[0115] The term "light chain," when used in reference to an antibody, refers to an immunoglobulin light chain, of which there are two types in mammals: lambda (λ) and kappa (κ). Preferably, the light chain is a human light chain. Preferably, the light chain constant region is a human constant region. Multiple light chain constant region alleles exist in the human population. The nucleotide and amino acid sequences of these allelic variants are accessible in publicly available databases such as IMGT, ENSEMBL Swiss-Prot, and Uniprot. In one embodiment, the antibody and antibody fragment disclosed herein comprises proteins encoded by human κ constant region alleles, including, but not limited to, IGKC*01 (SEQ ID NOs: 206 and 207), IGKC*02 (SEQ ID NOs: 208 and 209), IGKC*03 (SEQ ID NOs: 210 and 211), IGKC*04 (SEQ ID NOs: 212 and 213), and IGKC*05 (SEQ ID NOs: 214 and 215). In one embodiment, the antibodies and antibody fragments disclosed herein are selected from the group consisting of IGLC1*01 (SEQ ID NOs: 216 and 217), IGLC1*02 (SEQ ID NOs: 218, 219, and 220), IGLC2*01 (SEQ ID NOs: 221, 222, and 538), IGLC2*02 (SEQ ID NOs: 224 and 225), IGLC2*03 (SEQ ID NOs: 224 and 225), IGLC3*01 (SEQ ID NOs: 226 and 227), IGLC3*02 (SEQ ID NOs: 228 and 229), IGLC3*03 (SEQ ID NOs: 230 and 231), IGLC3*04 (SEQ ID NOs: 232 and 233), IGLC3*05 (SEQ ID NOs: 234 and 235), IGLC3*06 (SEQ ID NOs: 236 and 237), IGLC3*07 (SEQ ID NOs: 238 and 239), IGLC3*08 (SEQ ID NOs: 239 and 240), IGLC3*09 (SEQ ID NOs: 241 and 242), IGLC3*10 (SEQ ID NOs: 243 and 244), IGLC3*11 (SEQ ID NOs: 245 and 246), IGLC3*12 (SEQ ID NOs: 247 and 248), IGLC3*13 (SEQ ID NOs: 249 and 250), IGLC3*14 (SEQ ID NOs: 251 and 252), IGLC3*15 (SEQ ID NOs: 253 and 254), 2 and 229), IGLC3*03 (SEQ ID NOs: 230 and 231), IGLC3*04 (SEQ ID NOs: 232 and 233), IGLC6*01 (SEQ ID NOs: 234 and 235), IGLC7*01 (SEQ ID NOs: 236 and 237), IGLC7*02 (SEQ ID NOs: 236 and 237), IGLC7*03 (SEQ ID NOs: 535 and 536). In another embodiment, the antibodies and antibody fragments disclosed herein comprise a light chain constant region encoded by a mouse kappa constant region allele, including but not limited to IGKC*01, IGKC*03, or IGKC*03.In another embodiment, the antibodies and antibody fragments disclosed herein comprise a light chain constant region encoded by a mouse lambda constant region allele, including but not limited to IGLC1*01, IGLC2*01, or IGLC3*01.

[0116] "Percent (%) amino acid sequence identity" and "homology" in the context of peptide, polypeptide, or antibody sequences are defined as the percentage of amino acid residues in a candidate sequence that are identical to a particular peptide or polypeptide sequence after aligning the sequences to achieve the maximum percent sequence identity and introducing gaps, if necessary, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be accomplished in a variety of ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEG ALIGN™ (DNASTAR) software. In one embodiment, the percent homology is about 70%. In one embodiment, the percent homology is about 75%. In one embodiment, the percent homology is about 80%. In one embodiment, the percent homology is about 85%. In one embodiment, the percent homology is about 90%. In one embodiment, the percent homology is about 92%. In one embodiment, the percent homology is about 95%. In one embodiment, the % homology is about 97%. In one embodiment, the % homology is about 98%. In one embodiment, the % homology is about 99%. In one embodiment, the % homology is 100%.

[0117] The terms "native" or "natural" when used in reference to biological materials, e.g., nucleic acid molecules, polypeptides, host cells, refer to those found in nature and that have not been manipulated by human beings.

[0118] As used herein, "packaging" refers to the manner in which components are grouped and / or contained in a unit suitable for distribution and / or use. Packaging can include, for example, boxes, bags, syringes, ampoules, vials, tubes, clamshell packaging, barriers, and / or containers for maintaining sterility, labeling, etc.

[0119] As used herein, the term "pharmaceutically acceptable" means approved by a federal or state regulatory agency or listed in the United States Pharmacopoeia, the European Pharmacopoeia, or other generally recognized pharmacopoeias, for use in animals, and more particularly in humans.

[0120] As used herein, the terms "polynucleotide," "nucleotide," "nucleic acid," "nucleic acid molecule," and other similar terms are used interchangeably and include DNA, RNA, mRNA, etc.

[0121] As used herein, the terms "prevent," "preventing," and "prevention" refer to the complete or partial inhibition of the onset, recurrence, or spread of an hPD-L1-mediated disease and / or symptoms associated therewith resulting from the administration of a therapeutic agent or combination of therapeutic agents provided herein (e.g., a prophylactic or therapeutic combination such as an antibody of the invention).

[0122] The term "soluble" refers to polypeptides such as PD-L1 and variants or fragments thereof that lack one or more transmembrane or cytoplasmic domains found in native or membrane-bound forms; in one embodiment, a "soluble" form of PD-L1 lacks both the transmembrane and cytoplasmic domains.

[0123] The term "subject" or "patient" refers to any animal, including, but not limited to, mammals. As used herein, the term "mammal" refers to any vertebrate that either nurses its young and gives birth to live young (eutherian or placental mammals) or lays eggs (metatherian or non-placental mammals). Examples of mammalian species include, but are not limited to, humans and other primates (including non-human primates such as chimpanzees and other ape and monkey species); livestock animals such as cows, sheep, pigs, goats, and horses; domestic mammals such as dogs and cats; laboratory animals, including rodents such as mice, rats (including cotton rats), and guinea pigs; and birds, including poultry, wild birds, and game birds, such as chickens, turkeys and other pheasants, ducks, and geese.

[0124] As used herein, "substantially all" refers to at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or about 100%.

[0125] As used herein, the term "substantially free of surfactant" refers to a formulation of an antibody that specifically binds to the hPD-L1 antigen that contains less than 0.0005%, less than 0.0003%, or less than 0.0001% surfactant, and / or less than 0.0005%, less than 0.0003%, or less than 0.0001% surfactant.

[0126] As used herein, the term "substantially free of salts" refers to a preparation of an antibody that specifically binds to the hPD-L1 antigen that contains less than 0.0005%, less than 0.0003%, or less than 0.0001% inorganic salts.

[0127] As used herein, the term "surfactant" refers to organic substances with an amphiphilic structure, i.e., they are composed of groups with opposite solubility tendencies, typically an oil-soluble hydrocarbon chain and a water-soluble ionic group. Depending on the nature of the surface-active moiety, surfactants can be classified as anionic, cationic, and nonionic surfactants. Surfactants are often used as wetting agents, emulsifiers, solubilizers, and dispersants for the preparation of various pharmaceutical compositions and biological materials.

[0128] As used herein, the term "tag" refers to any type of moiety attached to a polypeptide and / or polynucleotide, for example, encoding an hPD-L1 or PD-L1 antibody, or an antigen-binding fragment thereof. For example, a polynucleotide encoding hPD-L1, an hPD-L1 antibody, or an antigen-binding fragment thereof may contain one or more additional tag-encoding nucleotide sequences that encode, for example, a detectable moiety or a moiety that assists in affinity purification. Upon translation, the tag and antibody may be in the form of a fusion protein. The term "detectable" or "detection" with respect to a tag refers to any tag that can be visualized, or whose presence can be otherwise determined and / or measured (e.g., by quantification). A non-limiting example of a detectable tag is a fluorescent tag.

[0129] As used herein, the term "therapeutic agent" refers to any agent that can be used in the treatment, management, or amelioration of an hPD-L1-mediated disease and / or symptoms associated therewith. In certain embodiments, the term "therapeutic agent" refers to an antibody of the present invention. In certain other embodiments, the term "therapeutic agent" refers to an agent other than an antibody of the present invention. Preferably, a therapeutic agent is an agent that is known to be useful for, has been used, or is currently being used for, the treatment, management, or amelioration of an hPD-L1-mediated disease and / or symptoms associated therewith. In certain embodiments, a therapeutic agent is a fully human anti-hPD-L1 antibody, for example, a fully human anti-hPD-L1 monoclonal antibody.

[0130] As used herein, the term "therapy" refers to any protocol, method, and / or agent that may be used in the prevention, management, treatment, and / or amelioration of an hPD-L1 mediated disease (e.g., cancer). In certain embodiments, the term "therapy(s)" refers to biologic, supportive, and / or other therapies known to those of skill in the art, such as medical professionals, that are useful in the prevention, management, treatment, and / or amelioration of an hPD-L1 mediated disease.

[0131] The terms "treat," "treatment," and "treating" refer to the reduction or amelioration of the progression, severity, and / or duration of an hPD-L1-mediated disease (e.g., cancer) brought about by the administration of one or more therapeutic agents (including, but not limited to, the administration of one or more prophylactic or therapeutic agents, such as an antibody of the invention). In certain embodiments, such terms refer to reducing or inhibiting the binding of hPD-L1 to PD-1, reducing or inhibiting the binding of hPD-L1 to CD80, and / or inhibiting or reducing one or more symptoms associated with an hPD-L1-mediated disease, such as cancer. In certain embodiments, such terms refer to reducing or inhibiting the binding of hPD-L1 to PD-1 and / or CD80, and / or inhibiting or reducing one or more symptoms associated with an hPD-L1-mediated disease, such as cancer. In one example, the cell is a human cell. In certain embodiments, the prophylactic agent is a fully human anti-hPD-L1 antibody, e.g., a fully human anti-hPD-L1 monoclonal antibody.

[0132] The term "variable region" or "variable domain" refers to portions of the light and heavy chains, typically the amino-terminal 120-130 amino acids in the heavy chain and approximately 100-110 amino acids in the light chain, which vary widely in sequence among antibodies and are used in the binding and specificity of each particular antibody to its particular antigen. Antibody variability is concentrated in regions called complementarity-determining regions (CDRs), while the more highly conserved regions in the variable domains are called framework regions (FRs). PD-L1 and the CDRs of the heavy chain are primarily responsible for the interaction of the antibody with the antigen. The numbering of amino acid positions used herein is based on Kabat et al. (1991) Sequences of proteins of immunological interest. (USDepartment of Health and Human Services, Washington, DC) 5 th (Kabat et al.), ed. In a preferred embodiment, the variable region is a human variable region.

[0133] Definitions of common terms in cell and molecular biology are given in The Merck Manual of Diagnosis and Therapy, 19 thEdition (Published by Merck Research Laboratories, 2006) (ISBN 0-911910-19-0), Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Biology (Published by Blackwell Science Ltd., 1994) (ISBN 0-632-02182-9), Benjamin Lewin, Genes X (Published by Jones & Bartlett Publishing, 2009) (ISBN-10:0763766321), Kendrew et al. (Eds.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference (Published by VCH Publishers, Inc., 1995) (ISBN 1-56081-569-8), and Current Protocols in Protein Sciences 2009, Wiley Intersciences, Coligan et al., eds.

[0134] Unless otherwise stated, the present invention is not limited to or incorporates the teachings of any of the following publications: Sambrook et al., Molecular Cloning: A Laboratory Manual (4 ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA (2012); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (1995); Methods in Enzymology: Guide to Molecular Cloning Techniques Vol. 152, S.L. Berger and A.R. Kimmel Eds., Academic Press Inc., San Diego, USA (1987); Current Protocols in Protein Science (CPPS) (John E. Coligan, et al., ed., John Wiley and Sons, Inc.); Current Protocols in Cell Biology (CPCB) (Juan S. Bonifacino et al. ed., John Wiley and Sons, Inc.); and Culture of Animal Cells: A Manual of Basic Technique by R. Ian Freshney, Publisher: Wiley-Liss; 5th edition (2005), Animal Cell Culture Methods (Methods in Cell Biology, Vol. 57, Jennie P. Mather and David Barnes editors, Academic Press, 1st edition, 1998), all of which are incorporated herein by reference in their entirety.

[0135] Other terms are defined herein in the description of various aspects of the invention.

[0136] 2.PD-L1 antibody Many tumor cells express surface molecules that are cancer-specific and can serve as diagnostic and / or therapeutic antibody targets. Examples of cell surface proteins expressed by tumor molecules that may be useful as biomarkers include members of the B7 family of proteins, major histocompatibility complex (MHC) molecules, cytokines, and growth factor receptors, such as epidermal growth factor receptor (EGFR). The B7 family is a group of proteins that are members of the immunoglobulin (Ig) superfamily of cell surface proteins that bind to receptors on lymphocytes to regulate immune responses. This family includes transmembrane or glycosylphosphatidylinositol (GPI)-linked proteins characterized by extracellular Ig-like domains (IgV and IgC domains related to the variable and constant domains of immunoglobulins). All members have a short cytoplasmic domain. There are seven known members of the B7 family: B7-1, B7-2, PD-L1 (B7-H1), PD-L2, B7-H2, B7-H3, and B7-H4.

[0137] The complete amino acid sequence of PD-L1 can be found in NCBI Reference Sequence: NP_054862.1 (SEQ ID NO: 1), which references numerous journal articles, including, for example, Dong, H., et al. (1999), "PD-L1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion," Nat. Med. 5(12), 1365-1369, the entire disclosure of which is incorporated herein by reference. The amino acid sequence of PD-L1 contains a 30-amino acid long cytoplasmic domain unique to PD-L1, which shows little homology to other molecules, including other B7 family members.

[0138] In one embodiment, the antibody is a polyclonal antibody. Methods for generating polyclonal antibodies are known and include, for example, inoculating a suitable mammal with an antigen to induce the animal's immune system to produce immunoglobulins (IgG) that specifically bind to the injected antigen. Examples of suitable mammals include mice, guinea pigs, hamsters, rats, rabbits, sheep, or goats. Polyclonal IgG is then typically purified from the mammal's serum. In one embodiment, the antibody is a polyclonal antibody that binds to a surface-expressed protein. In another embodiment, the antibody is a polyclonal antibody that specifically binds to a member of the B7 family of proteins. In a more specific embodiment, the antibody is a polyclonal antibody that specifically binds to PD-L1. In another embodiment, the antibody is a polyclonal antibody that specifically binds to surface-expressed PD-LI. In a more specific embodiment, the polyclonal antibody or antigen-binding fragment thereof specifically binds to human PD-L1. In another embodiment, the antibody is a polyclonal antibody that specifically binds to soluble PD-L1. The term "soluble" also refers to a protein such as PD-L1 that lacks one or more transmembrane or cytoplasmic domains. In one embodiment, a "soluble" form of PD-L1 lacks both the transmembrane and cytoplasmic domains. In one embodiment, the antibody is a polyclonal antibody that binds to "free" PD-L1 (i.e., PD-L1 that is not directly or indirectly associated with a cell membrane or surface).

[0139] In another embodiment, the antibody can be a monoclonal antibody. Methods for producing monoclonal antibodies are known and include, for example, fusing myeloma cells with cells derived from an animal immunized with the desired antigen. In other embodiments, monoclonal antibodies can be generated using recombinant DNA technology. In one embodiment, the antibody is a monoclonal antibody that specifically binds to a surface-expressed protein. In one embodiment, the antibody is a fully human monoclonal antibody. In another embodiment, the antibody is a monoclonal antibody that specifically binds to a member of the B7 family of proteins. In a more specific embodiment, the antibody is a monoclonal antibody that specifically binds to PD-L1. In another embodiment, the antibody is a monoclonal antibody that specifically binds to surface-expressed PD-L1. In a more particular embodiment, the monoclonal antibody or its antigen-binding fragment specifically binds to human PD-L1. In another embodiment, the antibody is a monoclonal antibody that specifically binds to soluble PD-L1. In one embodiment, the antibody is a monoclonal antibody that specifically binds to soluble PD-L1 lacking one or more cell membrane domains or cytoplasmic domains. In one embodiment, the antibody is a monoclonal antibody that specifically binds to soluble PD-L1 lacking both a cell membrane domain and a cytoplasmic domain. In one embodiment, the antibody is a monoclonal antibody that binds to "free" PD-L1 (i.e., PD-L1 not directly or indirectly associated with a cell membrane or surface).

[0140] In one example, the binding site(s) of the antibody or fragment are selected from a plurality (e.g., a library) of binding sites, e.g., the plurality of binding sites comprises or consists of a plurality of four-chain antibodies or fragments thereof, e.g., dAbs, Fabs, or scFvs. Suitable methods for generating multiple binding sites for screening include phage display (generating a phage display library of antibody binding sites), ribosome display (generating a ribosome display library of antibody binding sites), yeast display (generating a yeast display library of antibody binding sites), or immunization of a non-human vertebrate (e.g., a Yuezhi animal, such as a mouse or rat, e.g., Velocimouse™, Kymouse™, Xenomouse™, Aliva Mouse™, HuMab Mouse™, Omnimouse™, Omnirat™, or MeMo Mouse™) with hPD-L1 or an hPD-L1 epitope and isolating a repertoire of antibody-producing cells (e.g., a B cell, plasma cell, or plasmablast repertoire), and / or a repertoire of isolated antibodies, fragments, or binding sites.

[0141] PD-L1 binding capacity, specificity, and affinity (Kd, K off , and / or K on ) can be determined by any routine method in the art, for example, by surface plasmon resonance (SPR). As used herein, "Kd" or "K D The term "antibody-antigen interaction" is intended to refer to the equilibrium dissociation constant of a particular antibody-antigen interaction. Such binding measurements can be performed using a variety of binding assays known in the art, for example, by surface plasmon resonance (SPR), e.g., Biacore™, or using a ProteOn XPR36™ (Bio-Rad®), using a KinExA® (Sapidyne Instruments, Inc.), or using a ForteBio Octet (Pall ForteBio Corp.).

[0142] In one embodiment, surface plasmon resonance (SPR) is performed at 25° C. In another embodiment, SPR is performed at 37° C.

[0143] In one embodiment, SPR is performed at physiological pH, for example, at about pH 7 or pH 7.6 (eg, Hepes-buffered saline (also called HBS-EP) at pH 7.6).

[0144] In one embodiment, SPR is performed at physiological salt levels, for example, 150 mM NaCl.

[0145] In one embodiment, SPR is performed in the presence of detergent levels of 0.05% or less by volume, for example, 0.05% P20 (Polysorbate 20, e.g., Tween 20™) and 3 mM EDTA.

[0146] In one example, SPR is performed in a pH 7.6 buffer, 150 mM NaCl, 0.05% detergent (e.g., P20), and 3 mM EDTA at 25° C. or 37° C. The buffer may contain 10 mM Hepes. In one example, SPR is performed in HBS-EP at 25° C. or 37° C. HBS-EP is available from Teknova Inc. (California, catalog number H8022).

[0147] In one example, the affinity of the antibody or fragment can be determined by: 1. Attaching anti-mouse (or species-matched other relevant human, rat, or non-human vertebrate antibody constant region) IgG (e.g., Biacore™ BR-1008-38) to a biosensor chip (e.g., a GLM chip), such as by primary amine coupling; 2. Exposing anti-mouse IgG (or other matched species antibody) to the test IgG antibody to capture the test antibody on the chip; passing the test antigen over the capture surface of the chip at 1024 nM, 256 nM, 64 nM, 16 nM, 4 nM, along with 3.0 nM (i.e., buffer only); 4. Determine the binding affinity of the test antibody to the test antigen using surface plasmon resonance, for example, under the SPR conditions described above (e.g., in physiological buffer at 25°C). SPR can be performed using any SPR instrument, for example, by Biacore™ or using a ProteOn XPR36™ (Bio-Rad®).

[0148] Regeneration of the capture surface can be performed using 10 mM glycine at pH 1.7. This removes the captured antibody and allows the surface to be used for another interaction. Binding data can be fitted to a 1:1 intrinsic model using standard techniques, for example, using the intrinsic model in ProteOn XPR36™ analysis software.

[0149] The present inventors have identified several antibodies with specificity for hPD-L1 that have many potential utilities and advantages over existing antibodies. For example, the antibodies described herein may have one or more of the following properties: a. Specificity that blocks only one of the ligands of PD-L1 (e.g., blocking the CD80 / PD-L1 interaction but not the PD-1 / PD-L1 interaction) b.Lack of immunogenicity / side effects c. Soluble d. Stability e. Ease of formulation f. Improved frequency and / or route of administration with improved half-life compared to existing anti-PDL1 antibodies g. Manufacturability (e.g., expression, ease of purification, isoforms)

[0150] 1D05 is a heavy chain variable region (V) of SEQ ID NO: 33, which comprises the CDRH1 amino acid sequence of SEQ ID NO: 27 (IMGT) or SEQ ID NO: 30 (Kabat), the CDRH2 amino acid sequence of SEQ ID NO: 28 (IMGT) or SEQ ID NO: 31 (Kabat), and the CDRH3 amino acid sequence of SEQ ID NO: 29 (IMGT) or SEQ ID NO: 32 (Kabat). H) amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 34. 1D05 contains a light chain variable region (V) of SEQ ID NO: 43, which contains a CDRL1 amino acid sequence of SEQ ID NO: 37 (IMGT) or SEQ ID NO: 40 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 38 (IMGT) or SEQ ID NO: 41 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 39 (IMGT) or SEQ ID NO: 42 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 44. H The domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 35 (heavy chain nucleic acid sequence SEQ ID NO: 36). The full-length light chain amino acid sequence is SEQ ID NO: 45 (light chain nucleic acid sequence SEQ ID NO: 46).

[0151] 84G09 is a heavy chain variable (V) nucleotide sequence of SEQ ID NO: 13, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 7 (IMGT) or SEQ ID NO: 10 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 8 (IMGT) or SEQ ID NO: 11 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 9 (IMGT) or SEQ ID NO: 12 (Kabat). H ) region amino acid sequence. HThe heavy chain nucleic acid sequence of the domain is SEQ ID NO: 14. 84G09 contains a light chain variable region (V) of SEQ ID NO: 23, which contains a CDRL1 amino acid sequence of SEQ ID NO: 17 (IMGT) or SEQ ID NO: 20 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 18 (IMGT) or SEQ ID NO: 21 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 19 (IMGT) or SEQ ID NO: 22 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 24. H The domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 15 (heavy chain nucleic acid sequence SEQ ID NO: 16). The full-length light chain amino acid sequence is SEQ ID NO: 25 (light chain nucleic acid sequence SEQ ID NO: 26).

[0152] 1D05 HC variant 1 comprises a heavy chain variable (V) variant of SEQ ID NO: 47, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 27 (IMGT) or SEQ ID NO: 30 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 28 (IMGT) or SEQ ID NO: 31 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 29 (IMGT) or SEQ ID NO: 32 (Kabat). H ) region amino acid sequence of SEQ ID NO: 43. 1D05 HC variant 1 has a light chain variable region (V) of SEQ ID NO: 43, which contains a CDRL1 amino acid sequence of SEQ ID NO: 37 (IMGT) or SEQ ID NO: 40 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 38 (IMGT) or SEQ ID NO: 41 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 39 (IMGT) or SEQ ID NO: 42 (Kabat).L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 44. H The domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length light chain amino acid sequence is SEQ ID NO: 45 (light chain nucleic acid sequence SEQ ID NO: 46).

[0153] 1D05 HC variant 2 comprises a heavy chain variable (V) variant of SEQ ID NO: 48, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 27 (IMGT) or SEQ ID NO: 30 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 28 (IMGT) or SEQ ID NO: 31 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 29 (IMGT) or SEQ ID NO: 32 (Kabat). H ) region amino acid sequence of SEQ ID NO: 43. 1D05 HC Variant 2 has a light chain variable region (V) of SEQ ID NO: 43, which contains a CDRL1 amino acid sequence of SEQ ID NO: 37 (IMGT) or SEQ ID NO: 40 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 38 (IMGT) or SEQ ID NO: 41 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 39 (IMGT) or SEQ ID NO: 42 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 44. HThe domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length light chain amino acid sequence is SEQ ID NO: 45 (light chain nucleic acid sequence SEQ ID NO: 46).

[0154] 1D05 HC variant 3 comprises a heavy chain variable (V) variant of SEQ ID NO: 49, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 27 (IMGT) or SEQ ID NO: 30 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 28 (IMGT) or SEQ ID NO: 31 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 29 (IMGT) or SEQ ID NO: 32 (Kabat). H ) region amino acid sequence of SEQ ID NO: 43. 1D05 HC variant 3 has a light chain variable region (V) of SEQ ID NO: 43, which contains a CDRL1 amino acid sequence of SEQ ID NO: 37 (IMGT) or SEQ ID NO: 40 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 38 (IMGT) or SEQ ID NO: 41 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 39 (IMGT) or SEQ ID NO: 42 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 44. H The domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. LThe domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length light chain amino acid sequence is SEQ ID NO: 45 (light chain nucleic acid sequence SEQ ID NO: 46).

[0155] 1D05 HC variant 4 comprises a heavy chain variable (V) variant of SEQ ID NO: 342, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 27 (IMGT) or SEQ ID NO: 30 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 28 (IMGT) or SEQ ID NO: 31 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 29 (IMGT) or SEQ ID NO: 32 (Kabat). H ) region amino acid sequence of SEQ ID NO: 43. 1D05 HC variant 4 has a light chain variable region (V) of SEQ ID NO: 43, which contains a CDRL1 amino acid sequence of SEQ ID NO: 37 (IMGT) or SEQ ID NO: 40 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 38 (IMGT) or SEQ ID NO: 41 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 39 (IMGT) or SEQ ID NO: 42 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 44. H The domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length light chain amino acid sequence is SEQ ID NO: 45 (light chain nucleic acid sequence SEQ ID NO: 46).

[0156] 1D05 LC variant 1 comprises a heavy chain variable (V) variant of SEQ ID NO: 33, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 27 (IMGT) or SEQ ID NO: 30 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 28 (IMGT) or SEQ ID NO: 31 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 29 (IMGT) or SEQ ID NO: 32 (Kabat). H ) region amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 34. 1D05 LC variant 1 comprises a light chain variable region (V) of SEQ ID NO: 50, which contains a CDRL1 amino acid sequence of SEQ ID NO: 37 (IMGT) or SEQ ID NO: 40 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 39 (IMGT) or SEQ ID NO: 42 (Kabat). L The CDRL2 sequence of 1D05 LC variant 1 has the amino acid sequence V of SEQ ID NO: 50. L As defined by the Kabat or IMGT system from the sequence. H The domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 35 (heavy chain nucleic acid sequence SEQ ID NO: 36).

[0157] 1D05 LC variant 2 comprises a heavy chain variable (V) of SEQ ID NO: 33, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 27 (IMGT) or SEQ ID NO: 30 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 28 (IMGT) or SEQ ID NO: 31 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 29 (IMGT) or SEQ ID NO: 32 (Kabat). H) region amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 34. 1D05 LC variant 2 comprises a light chain variable region (V) of SEQ ID NO: 51, which comprises a CDRL1 amino acid sequence of SEQ ID NO: 37 (IMGT) or SEQ ID NO: 40 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 38 (IMGT) or SEQ ID NO: 41 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 39 (IMGT) or SEQ ID NO: 42 (Kabat). L ) amino acid sequence. H The domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 35 (heavy chain nucleic acid sequence SEQ ID NO: 36).

[0158] 1D05 LC variant 3 comprises a heavy chain variable (V) nucleotide sequence of SEQ ID NO: 33, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 27 (IMGT) or SEQ ID NO: 30 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 28 (IMGT) or SEQ ID NO: 31 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 29 (IMGT) or SEQ ID NO: 32 (Kabat). H ) region amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 34. 1D05 LC variant 3 comprises a light chain variable region (V) of SEQ ID NO: 298, which contains a CDRL1 amino acid sequence of SEQ ID NO: 37 (IMGT) or SEQ ID NO: 40 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 39 (IMGT) or SEQ ID NO: 42 (Kabat). LThe CDRL2 sequence of 1D05 LC variant 3 has the amino acid sequence V L As defined by the Kabat or IMGT system from the sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 44. H The domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 35 (heavy chain nucleic acid sequence SEQ ID NO: 36). The full-length light chain amino acid sequence is SEQ ID NO: 45 (light chain nucleic acid sequence SEQ ID NO: 46).

[0159] 411B08 is a heavy chain variable (V) nucleotide sequence of SEQ ID NO: 58, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 52 (IMGT) or SEQ ID NO: 55 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 53 (IMGT) or SEQ ID NO: 56 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 54 (IMGT) or SEQ ID NO: 57 (Kabat). H ) region amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 59. 411B08 contains a light chain variable region (V) of SEQ ID NO: 68, which contains a CDRL1 amino acid sequence of SEQ ID NO: 62 (IMGT) or SEQ ID NO: 65 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 63 (IMGT) or SEQ ID NO: 66 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 64 (IMGT) or SEQ ID NO: 67 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 69. HThe domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 60 (heavy chain nucleic acid sequence SEQ ID NO: 61). The full-length light chain amino acid sequence is SEQ ID NO: 70 (light chain nucleic acid sequence SEQ ID NO: 71).

[0160] 411C04 is a heavy chain variable (V) nucleotide sequence of SEQ ID NO: 78, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 72 (IMGT) or SEQ ID NO: 75 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 73 (IMGT) or SEQ ID NO: 76 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 74 (IMGT) or SEQ ID NO: 77 (Kabat). H ) region amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 79. 411C04 contains a light chain variable region (V) of SEQ ID NO: 88, which contains a CDRL1 amino acid sequence of SEQ ID NO: 82 (IMGT) or SEQ ID NO: 85 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 83 (IMGT) or SEQ ID NO: 86 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 84 (IMGT) or SEQ ID NO: 87 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 89. HThe domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 80 (heavy chain nucleic acid sequence SEQ ID NO: 81). The full-length light chain amino acid sequence is SEQ ID NO: 90 (light chain nucleic acid sequence SEQ ID NO: 91).

[0161] 411D07 is a heavy chain variable (V) nucleotide sequence of SEQ ID NO: 98, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 92 (IMGT) or SEQ ID NO: 95 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 93 (IMGT) or SEQ ID NO: 96 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 94 (IMGT) or SEQ ID NO: 97 (Kabat). H ) region amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 99. 411D07 contains a light chain variable region (V) of SEQ ID NO: 108, which contains a CDRL1 amino acid sequence of SEQ ID NO: 102 (IMGT) or SEQ ID NO: 105 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 103 (IMGT) or SEQ ID NO: 106 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 104 (IMGT) or SEQ ID NO: 107 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 109. HThe domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 100 (heavy chain nucleic acid sequence SEQ ID NO: 101). The full-length light chain amino acid sequence is SEQ ID NO: 110 (light chain nucleic acid sequence SEQ ID NO: 111).

[0162] 385F01 comprises a heavy chain variable (V) sequence of SEQ ID NO: 118, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 112 (IMGT) or SEQ ID NO: 115 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 113 (IMGT) or SEQ ID NO: 116 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 114 (IMGT) or SEQ ID NO: 117 (Kabat). H ) region amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 119. 385F01 contains a light chain variable region (V) of SEQ ID NO: 128, which contains a CDRL1 amino acid sequence of SEQ ID NO: 122 (IMGT) or SEQ ID NO: 125 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 123 (IMGT) or SEQ ID NO: 126 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 124 (IMGT) or SEQ ID NO: 127 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 129. HThe domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 120 (heavy chain nucleic acid sequence SEQ ID NO: 121). The full-length light chain amino acid sequence is SEQ ID NO: 130 (light chain nucleic acid sequence SEQ ID NO: 131).

[0163] 386H03 is a heavy chain variable (V) nucleotide sequence of SEQ ID NO: 158, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 152 (IMGT) or SEQ ID NO: 155 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 153 (IMGT) or SEQ ID NO: 156 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 154 (IMGT) or SEQ ID NO: 157 (Kabat). H ) region amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 159. 386H03 contains a light chain variable region (V) of SEQ ID NO: 168, which contains a CDRL1 amino acid sequence of SEQ ID NO: 162 (IMGT) or SEQ ID NO: 165 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 163 (IMGT) or SEQ ID NO: 166 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 164 (IMGT) or SEQ ID NO: 167 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 169. HThe domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 160 (heavy chain nucleic acid sequence SEQ ID NO: 161). The full-length light chain amino acid sequence is SEQ ID NO: 170 (light chain nucleic acid sequence SEQ ID NO: 171).

[0164] 389A03 is a heavy chain variable (V) nucleotide sequence of SEQ ID NO: 178, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 172 (IMGT) or SEQ ID NO: 175 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 173 (IMGT) or SEQ ID NO: 176 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 174 (IMGT) or SEQ ID NO: 177 (Kabat). H ) region amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 179. 389A03 contains a light chain variable region (V) of SEQ ID NO: 188, which contains a CDRL1 amino acid sequence of SEQ ID NO: 182 (IMGT) or SEQ ID NO: 185 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 183 (IMGT) or SEQ ID NO: 186 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 184 (IMGT) or SEQ ID NO: 187 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 189. HThe domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 180 (heavy chain nucleic acid sequence SEQ ID NO: 181). The full-length light chain amino acid sequence is SEQ ID NO: 190 (light chain nucleic acid sequence SEQ ID NO: 191).

[0165] 413D08 is a heavy chain variable (V) nucleotide sequence of SEQ ID NO: 138, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 132 (IMGT) or SEQ ID NO: 135 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 133 (IMGT) or SEQ ID NO: 136 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 134 (IMGT) or SEQ ID NO: 137 (Kabat). H ) region amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 139. 413D08 contains a light chain variable region (V) of SEQ ID NO: 148, which contains a CDRL1 amino acid sequence of SEQ ID NO: 142 (IMGT) or SEQ ID NO: 145 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 143 (IMGT) or SEQ ID NO: 146 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 144 (IMGT) or SEQ ID NO: 147 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 149. HThe domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 140 (heavy chain nucleic acid sequence SEQ ID NO: 141). The full-length light chain amino acid sequence is SEQ ID NO: 150 (light chain nucleic acid sequence SEQ ID NO: 151).

[0166] 413G05 is a heavy chain variable (V) nucleotide sequence of SEQ ID NO: 244, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 238 (IMGT) or SEQ ID NO: 241 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 239 (IMGT) or SEQ ID NO: 242 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 240 (IMGT) or SEQ ID NO: 243 (Kabat). H ) region amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 245. 413G05 contains a light chain variable region (V) of SEQ ID NO: 254, which contains a CDRL1 amino acid sequence of SEQ ID NO: 248 (IMGT) or SEQ ID NO: 251 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 249 (IMGT) or SEQ ID NO: 252 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 250 (IMGT) or SEQ ID NO: 253 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 255. HThe domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 246 (heavy chain nucleic acid sequence SEQ ID NO: 247). The full-length light chain amino acid sequence is SEQ ID NO: 256 (light chain nucleic acid sequence SEQ ID NO: 257).

[0167] 413F09 contains the heavy chain variable (V) sequence of SEQ ID NO: 264, which comprises the CDRH1 amino acid sequence of SEQ ID NO: 258 (IMGT) or SEQ ID NO: 261 (Kabat), the CDRH2 amino acid sequence of SEQ ID NO: 259 (IMGT) or SEQ ID NO: 262 (Kabat), and the CDRH3 amino acid sequence of SEQ ID NO: 260 (IMGT) or SEQ ID NO: 263 (Kabat). H ) region amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 265. 413F09 contains a light chain variable region (V) of SEQ ID NO: 274, which contains a CDRL1 amino acid sequence of SEQ ID NO: 268 (IMGT) or SEQ ID NO: 271 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 269 (IMGT) or SEQ ID NO: 272 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 270 (IMGT) or SEQ ID NO: 273 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 275. HThe domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 266 (heavy chain nucleic acid sequence SEQ ID NO: 267). The full-length light chain amino acid sequence is SEQ ID NO: 276 (light chain nucleic acid sequence SEQ ID NO: 277).

[0168] 414B06 is a heavy chain variable (V) nucleotide sequence of SEQ ID NO: 284, which comprises a CDRH1 amino acid sequence of SEQ ID NO: 278 (IMGT) or SEQ ID NO: 281 (Kabat), a CDRH2 amino acid sequence of SEQ ID NO: 279 (IMGT) or SEQ ID NO: 282 (Kabat), and a CDRH3 amino acid sequence of SEQ ID NO: 280 (IMGT) or SEQ ID NO: 283 (Kabat). H ) region amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 285. 414B06 contains the light chain variable region (V) of SEQ ID NO: 294, which comprises the CDRL1 amino acid sequence of SEQ ID NO: 288 (IMGT) or SEQ ID NO: 291 (Kabat), the CDRL2 amino acid sequence of SEQ ID NO: 289 (IMGT) or SEQ ID NO: 292 (Kabat), and the CDRL3 amino acid sequence of SEQ ID NO: 290 (IMGT) or SEQ ID NO: 293 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 295. HThe domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 286 (heavy chain nucleic acid sequence SEQ ID NO: 287). The full-length light chain amino acid sequence is SEQ ID NO: 296 (light chain nucleic acid sequence SEQ ID NO: 297).

[0169] 416E01 contains a heavy chain variable region (V) of SEQ ID NO: 349, which contains the CDRH1 amino acid sequence of SEQ ID NO: 343 (IMGT) or SEQ ID NO: 346 (Kabat), the CDRH2 amino acid sequence of SEQ ID NO: 344 (IMGT) or SEQ ID NO: 347 (Kabat), and the CDRH3 amino acid sequence of SEQ ID NO: 345 (IMGT) or SEQ ID NO: 348 (Kabat). H ) amino acid sequence. H The heavy chain nucleic acid sequence of the domain is SEQ ID NO: 350. 416E01 contains a light chain variable region (V) of SEQ ID NO: 359, which contains a CDRL1 amino acid sequence of SEQ ID NO: 353 (IMGT) or SEQ ID NO: 356 (Kabat), a CDRL2 amino acid sequence of SEQ ID NO: 354 (IMGT) or SEQ ID NO: 357 (Kabat), and a CDRL3 amino acid sequence of SEQ ID NO: 355 (IMGT) or SEQ ID NO: 358 (Kabat). L ) amino acid sequence. L The light chain nucleic acid sequence of domain V is SEQ ID NO: 360. HThe domain may be combined with any of the heavy chain constant region sequences described herein, for example, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532, or SEQ ID NO:534. L The domain may be combined with any of the light chain constant region sequences described herein, for example, SEQ ID NOs: 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536, and 538. The full-length heavy chain amino acid sequence is SEQ ID NO: 351 (heavy chain nucleic acid sequence SEQ ID NO: 352). The full-length light chain amino acid sequence is SEQ ID NO: 361 (light chain nucleic acid sequence SEQ ID NO: 362).

[0170] The antibodies of the present invention are described with respect to the following concepts, aspects, statements, configurations, and embodiments. Unless otherwise stated, all concepts, embodiments, statements, configurations, and aspects should be read as being combinable with any other concept, aspect, statement, configuration, or embodiment.

[0171] Concept 1. An antibody or fragment thereof that specifically binds to hPD-L1 as defined by SEQ ID NO: 1 and competes with antibody 1D05 for binding to hPD-L1, wherein the antibody or fragment comprises a V H X1, X2, and X3 are independently any amino acid, and X4 is either present or absent, and if present, can be any amino acid.

[0172] In these concepts, the antibody or fragment may or may not include a bispecific antibody. In one embodiment, in these concepts, the antibody or fragment includes a bispecific antibody. In one embodiment, the bispecific antibody does not include the FIT-Ig format. In one embodiment, the bispecific antibody is a mAb 2In one embodiment, the bispecific antibody does not include the FIT-Ig format or the mAb 2 In one embodiment, the antibodies or fragments in these concepts include bispecific antibodies, but do not include bispecific antibodies with a FIT-Ig format. In one embodiment, the antibodies or fragments in these concepts include bispecific antibodies, but do not include bispecific antibodies with a mAb format. 2 In one embodiment, the antibody or fragment in this context includes a bispecific antibody, but does not include a bispecific antibody having a FIT-Ig format or a mAb format. 2 In another embodiment, the antibody or fragment in this context does not include a bispecific antibody having a bispecific format.

[0173] Preferably, an antibody or fragment thereof that specifically binds to the hPD-L1 antigen does not cross-react with other antigens (but may, optionally, cross-react with PD-L1 from different species, e.g., rhesus monkeys, cynomolgus monkeys, or mice). Antibodies or fragments thereof that specifically bind to the hPD-L1 antigen can be identified, for example, by immunoassays, BIAcore™, or other techniques known in the art. An antibody or fragment thereof specifically binds to the hPD-L1 antigen when it binds to the hPD-L1 antigen with higher affinity than it does to any cross-reactive antigens, as determined using experimental techniques such as radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA). Typically, a specific or selective reaction is at least 2-fold the background signal or noise, more typically more than 10-fold the background. For a discussion of antibody specificity, see, e.g., pages 332-336 of Paul, ed., 1989, Fundamental Immunology Second Edition, Raven Press, New York.

[0174] In one embodiment, the antibody or fragment is a human antibody. In one embodiment, the antibody or fragment is a human antibody or fragment. In one embodiment, the antibody or fragment is a fully human antibody or fragment. In one embodiment, the antibody or fragment is a fully human monoclonal antibody or fragment.

[0175] Concept 1a: An antibody or fragment thereof that specifically binds to hPD-L1 as defined by SEQ ID NO: 1 and competes with antibody 411B08 for binding to hPD-L1, wherein the antibody or fragment comprises a V H Also provided are antibodies or fragments thereof comprising the domain X1, X2, X3, X4, and X5, independently any amino acid.

[0176] Concept 1b: An antibody or fragment thereof that specifically binds to hPD-L1 as defined by SEQ ID NO: 1 and competes with antibody 411B08 for binding to hPD-L1, wherein the antibody or fragment comprises a V H Also provided are antibodies or fragments thereof comprising the domain, wherein X1 is any amino acid.

[0177] As provided in the concepts or embodiments herein, the anti-PD-L1 antibody or immunocytokine may have a K of less than 50 nM, less than 40 nM, or less than 30 nM as determined by surface plasmon resonance. D In another embodiment, the anti-PD-L1 antibody or immunocytokine may bind to PD-L1, e.g., human PD-L1, having a K of less than 20 nM, less than 15 nM, or less than 10 nM as determined by surface plasmon resonance. D The anti-PD-L1 or immunocytokine may bind to PD-L1, e.g., human PD-L1, having a K of less than 8 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, or less than 1 nM as determined by surface plasmon resonance. D It can bind to PD-L1 having the formula K, e.g., human PD-L1. Dcan be 0.9 nM or less, 0.8 nM or less, 0.7 nM or less, 0.6 nM or less, 0.5 nM or less, 0.4 nM or less, 0.3 nM or less, 0.2 nM or less, or 0.1 nM or less.

[0178] In another embodiment, K D is in the range of 0.01 to 1 nM, or in the range of 0.05 to 2 nM, or in the range of 0.05 to 1 nM. D may be in relation to hPD-L1, cynoPD-L1, and / or mouse PD-L1.

[0179] In another embodiment, the anti-PD-L1 antibodies described herein have a K of about 0.5-10 μM, for example, about 1-8 μM or about 1-7 μM. ON In another embodiment, the K ON The rate is about 1-5 μM, e.g., about 1 μM, about 1.5 μM, about 2 μM, about 2.5 μM, or about 3 μM. ON The rate is about 3.5 μM, about 4 μM, about 4.5, about 5 μM, or about 5.5 μM.

[0180] In another embodiment, the anti-PD-L1 antibodies described herein have a K of about 0.01-100 mM, such as about 0.1-50 mM or about 0.5-50 mM. OFF In another embodiment, the K OFF In another embodiment, the K OFF The rate is about 0.6 mM, about 0.7 mM, about 0.8 mM, or about 0.9 mM.

[0181] In another embodiment, the anti-PD-L1 antibodies (and immunocytokines) described in the concepts and aspects herein provide improved transient expression levels relative to other anti-PD-L1 antibodies and immunocytokines. Thus, in one embodiment, the anti-PD-L1 antibodies (or immunocytokines) are expressed in HEK293 cells, e.g., HEK293T cells, at an expression level of about 100 μg / mL, or in the range of about 100-350 μg / mL. In another embodiment, the expression level is greater than about 350 μg / mL.

[0182] In another embodiment, the anti-PD-L1 antibody (or immunocytokine) is expressed in CHO cells, e.g., Expi-CHO cells, at an expression level of about 100 μg / mL, or in the range of about 100-350 μg / mL, hi another embodiment, the expression level is greater than about 350 μg / mL.

[0183] In another embodiment, the anti-PD-L1 antibody (or immunocytokine) is expressed in CHO cells, such as Expi-CHO cells or CHO-E7 EBNA cells, at an expression level of about 100 μg / mL, or in the range of about 100-350 μg / mL, hi another embodiment, the expression level is greater than about 350 μg / mL. The antibody described herein as 1D05 and formatted as a human IgG1 (SEQ ID NO: 340) in a 2 L volume in CHO-E7 EBNA cells has an expression level of approximately 115 μg / mL. The antibody described herein as 416E01 and formatted as a human IgG1 (SEQ ID NO: 340) in a 2 L volume in CHO-E7 EBNA cells has an expression level of approximately 160 μg / mL. The antibody described herein as 1414B06 and formatted as a human IgG1 (SEQ ID NO: 340) in a 2 L volume in CHO-E7 EBNA cells has an expression level of approximately 783 μg / mL. The antibody described herein as 413G05 and formatted as a human IgG1 (SEQ ID NO: 340) in a 2 L volume in CHO-E7 EBNA cells has an expression level of approximately 383 μg / mL.

[0184] In any of these expression systems, expression is carried out in a volume of about 0.5 mL to 3 mL, for example about 0.5 mL to 2 mL. In any of these expression systems, the anti-PD-L1 antibody (or immunocytokine) may be expressed from a pTT5 vector. In any of these expression systems, the anti-PD-L1 antibody (or immunocytokine) may be expressed in conjunction with a lipid transfection reagent, and optionally in CHO cells, such as Expi-CHO cells. In any of these expression systems, the anti-PD-L1 antibody (or immunocytokine) may be expressed in conjunction with a PEI transfection reagent, and optionally in CHO cells, such as CHO-E7 EBNA cells. In any of these expression systems, the anti-PD-L1 antibody (or immunocytokine) may be expressed in conjunction with a helper plasmid (e.g., AKT helper plasmid), and optionally in CHO cells, such as CHO-E7 EBNA cells.

[0185] In any of these expression systems, the expression level is about 100 μg / mL to about 1500 μg / mL, for example, about 100 μg / mL to about 1000 μg / mL, or about 200 μg / mL to about 1000 μg / mL, or about 350 μg / mL to about 1000 μg / mL. In any of these expression systems, the lower limit of expression can be about 100 μg / mL, about 200 μg / mL, about 300 μg / mL, or about 400 μg / mL. In another embodiment, the lower limit of expression can be about 500 μg / mL, about 600 μg / mL, about 700 μg / mL, or about 800 μg / mL. In any of these expression systems, the upper limit of expression can be about 2000 μg / mL, about 1800 μg / mL, about 1600 μg / mL, or about 1500 μg / mL. In another embodiment, the upper limit of expression can be about 1250 μg / mL, about 1000 μg / mL, about 900 μg / mL, or about 800 μg / mL.

[0186] In another embodiment, the expression system is a Lonza expression system, such as the Lonza X-Ceed®. In the Lonza expression system, expression can be carried out in a volume of about 30 mL to 2 L, such as 50 mL to 1 L or 1 L to 2 L. In the Lonza expression system, the anti-PD-L1 antibody (or immunocytokine) can be expressed in conjunction with electroporation, and optionally without any helper plasmid. In the Lonza expression system, the anti-PD-L1 antibody (or immunocytokine) can be expressed at levels of about 1 g / L, or about 900 mg / L, or about 800 mg / L, or about 700 mg / L. In another embodiment, in the Lonza expression system, the anti-PD-L1 antibody (or immunocytokine) can be expressed at levels of about 600 mg / L, or about 500 mg / L, or about 400 mg / L. In the Lonza expression system, the anti-PD-L1 antibody (or immunocytokine) may be expressed at a level of about 400 mg / L to about 2 g / L, for example, about 500 mg / L to about 1.5 g / L, or about 500 mg / L to about 1 g / L. In another embodiment, the expression level is greater than 1 g / L. In another embodiment, the anti-PD-L1 antibodies described in the present concepts provide an improved half-life over other anti-PD-L1 antibodies, as further described herein in Aspect 1 below.

[0187] Concept 2. The antibody or fragment according to Concept 1, wherein X1 is a hydroxyl-containing amino acid, optionally T.

[0188] In one embodiment, the hydroxyl-containing amino acid is serine. In one embodiment, the hydroxyl-containing amino acid is cysteine. In one embodiment, the hydroxyl-containing amino acid is threonine. In one embodiment, the hydroxyl-containing amino acid is methionine. In one embodiment, the hydroxyl-containing amino acid is serine or cysteine. In one embodiment, the hydroxyl-containing amino acid is serine or threonine. In one embodiment, the hydroxyl-containing amino acid is serine or methionine. In one embodiment, the hydroxyl-containing amino acid is cysteine ​​or threonine. In one embodiment, the hydroxyl-containing amino acid is cysteine ​​or methionine. In one embodiment, the hydroxyl-containing amino acid is threonine or methionine.

[0189] In one embodiment, the hydroxyl-containing amino acid is selected from serine, cysteine, threonine, and methionine.

[0190] Concept 2a. The antibody or fragment according to Concept 1a, wherein X1 is an aliphatic amino acid or an amide amino acid.

[0191] In one embodiment, X1 is selected from asparagine (N) and valine (V). In one embodiment, X1 is valine. In one embodiment, X1 is asparagine.

[0192] Concept 2b. The antibody or fragment according to Concept 1b, wherein X1 is an aliphatic amino acid.

[0193] In one embodiment, X1 is selected from alanine (A) or valine (V). In one embodiment, X1 is valine. In one embodiment, X1 is alanine.

[0194] Concept 3. The antibody or fragment according to concept 1 or concept 2, wherein X2 is a basic amino acid, optionally K.

[0195] In one embodiment, the hydroxyl-containing amino acid is histidine. In one embodiment, the hydroxyl-containing amino acid is lysine. In one embodiment, the hydroxyl-containing amino acid is arginine. In one embodiment, the hydroxyl-containing amino acid is histidine or lysine. In one embodiment, the hydroxyl-containing amino acid is histidine or arginine. In one embodiment, the hydroxyl-containing amino acid is lysine or arginine.

[0196] In one embodiment, the hydroxyl-containing amino acid is selected from histidine, lysine, and arginine.

[0197] Concept 3a. The antibody or fragment according to Concept 1a or Concept 2a, wherein X2 is an aliphatic amino acid or an amide amino acid.

[0198] In one embodiment, X2 is selected from leucine (L), isoleucine (I), valine (V), asparagine (N), and glutamine (Q). In one embodiment, X2 is selected from leucine (L), isoleucine (I), and valine (V). In one embodiment, X2 is selected from asparagine (N) and glutamine (Q). In one embodiment, X2 is selected from leucine (L) and glutamine (Q). In one embodiment, X2 is leucine (L). In one embodiment, X2 is glutamine (Q).

[0199] Concept 4. The antibody or fragment of any one of Concepts 1-3, wherein X2 is a hydroxyl-containing amino acid, optionally S or T.

[0200] In one embodiment, the hydroxyl-containing amino acid is serine. In one embodiment, the hydroxyl-containing amino acid is cysteine. In one embodiment, the hydroxyl-containing amino acid is threonine. In one embodiment, the hydroxyl-containing amino acid is methionine. In one embodiment, the hydroxyl-containing amino acid is serine or cysteine. In one embodiment, the hydroxyl-containing amino acid is serine or threonine. In one embodiment, the hydroxyl-containing amino acid is serine or methionine. In one embodiment, the hydroxyl-containing amino acid is cysteine ​​or threonine. In one embodiment, the hydroxyl-containing amino acid is cysteine ​​or methionine. In one embodiment, the hydroxyl-containing amino acid is threonine or methionine.

[0201] In one embodiment, the hydroxyl-containing amino acid is selected from serine, cysteine, threonine, and methionine.

[0202] Concept 4a. The antibody or fragment of any one of Concepts 1a, 2a, or 3a, wherein X3 is an aromatic amino acid.

[0203] In one embodiment, X3 is selected from phenylalanine (F), tyrosine (Y), and tryptophan (W). In one embodiment, X3 is selected from tyrosine (Y) and tryptophan (W). In one embodiment, X3 is tyrosine (Y). In one embodiment, X3 is tryptophan (W).

[0204] Concept 5. The antibody or fragment of any one of Concepts 1-4, wherein X3 is an aromatic amino acid and optionally is W.

[0205] In one embodiment, the hydroxyl-containing amino acid is phenylalanine. In one embodiment, the hydroxyl-containing amino acid is tyrosine. In one embodiment, the hydroxyl-containing amino acid is tryptophan. In one embodiment, the hydroxyl-containing amino acid is phenylalanine or tyrosine. In one embodiment, the hydroxyl-containing amino acid is phenylalanine or tryptophan. In one embodiment, the hydroxyl-containing amino acid is tyrosine or tryptophan.

[0206] In one embodiment, the hydroxyl-containing amino acid is selected from phenylalanine, tyrosine, and tryptophan.

[0207] Concept 5a. The antibody or fragment of any one of Concepts 1a, 2a, 3a, or 4a, wherein X4 is an aromatic amino acid.

[0208] In one embodiment, X4 is selected from phenylalanine (F), tyrosine (Y), and tryptophan (W). In one embodiment, X4 is selected from tyrosine (Y) and phenylalanine (F). In one embodiment, X4 is tyrosine (Y). In one embodiment, X4 is phenylalanine (F).

[0209] Concept 6. The antibody or fragment of any one of Concepts 1 to 5, wherein X4 is absent.

[0210] Concept 6a. The antibody or fragment of Concept 1a, 2a, 3a, 4a, or 5a, wherein X5 is an aliphatic amino acid or a hydroxyl-containing amino acid.

[0211] In one embodiment, X5 is selected from leucine (L), isoleucine (I), valine (V), serine (S), cysteine ​​(C), and threonine (T). In one embodiment, X5 is selected from leucine (L), isoleucine (I), and valine (V). In one embodiment, X5 is selected from serine (S), cysteine ​​(C), and threonine (T). In one embodiment, X5 is selected from leucine (L) and serine (S). In one embodiment, X5 is serine (S). In one embodiment, X5 is leucine (L).

[0212] Concept 7. The antibody or fragment of any one of Concepts 1 to 5, wherein X4 is present.

[0213] Concept 8. The antibody or fragment of concept 7, wherein X4 is an aliphatic amino acid, optionally G.

[0214] In one embodiment, the hydroxyl-containing amino acid is selected from glycine, alanine, valine, leucine, and isoleucine.

[0215] In one embodiment, the hydroxyl-containing amino acid is selected from glycine and alanine. In one embodiment, the hydroxyl-containing amino acid is selected from glycine and valine. In one embodiment, the hydroxyl-containing amino acid is selected from glycine and leucine. In one embodiment, the hydroxyl-containing amino acid is selected from glycine and isoleucine. In one embodiment, the hydroxyl-containing amino acid is selected from alanine and valine. In one embodiment, the hydroxyl-containing amino acid is selected from alanine and leucine. In one embodiment, the hydroxyl-containing amino acid is selected from alanine and isoleucine. In one embodiment, the hydroxyl-containing amino acid is selected from valine and leucine. In one embodiment, the hydroxyl-containing amino acid is selected from valine and isoleucine. In one embodiment, the hydroxyl-containing amino acid is selected from leucine and isoleucine.

[0216] In one embodiment, the hydroxyl-containing amino acids are selected from three of each of glycine, alanine, valine, leucine, and isoleucine. In one embodiment, the hydroxyl-containing amino acids are selected from four of each of glycine, alanine, valine, leucine, and isoleucine.

[0217] Concept 9. A V antibody that specifically binds to hPD-L1 and competes with antibody 1D05 for binding to hPD-L1, and comprises a CDRH3 sequence of SEQ ID NO: 29 or 32, or a CDRH3 sequence of SEQ ID NO: 29 or 32 containing 6 or fewer amino acid substitutions. H An antibody or fragment thereof, which may optionally be an antibody or fragment thereof according to any one of concepts 1 to 8, comprising the domain.

[0218] Concept 9a: A V that specifically binds to hPD-L1 and competes with antibody 84G09 for binding to hPD-L1, and comprises a CDRH3 sequence of SEQ ID NO: 9 or 12, or a CDRH3 sequence of SEQ ID NO: 9 or 12 containing 6 or fewer amino acid substitutions. H An antibody or fragment thereof, optionally comprising a domain, which may be an antibody or fragment thereof according to any one of concepts 1 to 8.

[0219] Concept 9b: A V antibody that specifically binds to hPD-L1 and competes with antibody 411B08 for binding to hPD-L1, and comprises a CDRH3 sequence of SEQ ID NO: 54 or 57, or a CDRH3 sequence of SEQ ID NO: 54 or 57 containing 6 or fewer amino acid substitutions. H An antibody or fragment thereof, optionally comprising a domain, which may be an antibody or fragment thereof according to any one of concepts 1 to 8.

[0220] Concept 9c: A V that specifically binds to hPD-L1 and competes with antibody 411C04 for binding to hPD-L1, and comprises a CDRH3 sequence of SEQ ID NO: 74 or 77, or a CDRH3 sequence of SEQ ID NO: 74 or 77 containing 6 or fewer amino acid substitutions. H An antibody or fragment thereof, which may optionally be an antibody or fragment thereof according to any one of concepts 1 to 8, comprising the domain.

[0221] Concept 9d: A V antibody that specifically binds to hPD-L1 and competes with antibody 411D07 for binding to hPD-L1, and comprises a CDRH3 sequence of SEQ ID NO: 94 or 97, or a CDRH3 sequence of SEQ ID NO: 94 or 97 containing 3 or fewer amino acid substitutions. H An antibody or fragment thereof, which may optionally be an antibody or fragment thereof according to any one of concepts 1 to 8, comprising the domain.

[0222] Concept 9e: A V that specifically binds to hPD-L1 and competes with antibody 385F01 for binding to hPD-L1, and comprises a CDRH3 sequence of SEQ ID NO: 114 or 117, or a CDRH3 sequence of SEQ ID NO: 114 or 117 containing 6 or fewer amino acid substitutions. H An antibody or fragment thereof, which may optionally be an antibody or fragment thereof according to any one of concepts 1 to 8, comprising the domain.

[0223] Concept 9f: A V antibody that specifically binds to hPD-L1 and competes with antibody 386H03 for binding to hPD-L1, and comprises a CDRH3 sequence of SEQ ID NO: 144 or 147, or a CDRH3 sequence of SEQ ID NO: 144 or 147 containing 3 or fewer amino acid substitutions. H An antibody or fragment thereof, which may optionally be an antibody or fragment thereof according to any one of concepts 1 to 8, comprising the domain.

[0224] Concept 9g: A V antibody that specifically binds to hPD-L1 and competes with antibody 389A03 for binding to hPD-L1, and comprises a CDRH3 sequence of SEQ ID NO: 174 or 177, or a CDRH3 sequence of SEQ ID NO: 174 or 177 containing 6 or fewer amino acid substitutions. H An antibody or fragment thereof, which may optionally be an antibody or fragment thereof according to any one of concepts 1 to 8, comprising the domain.

[0225] Concept 9h: A V that specifically binds to hPD-L1 and competes with antibody 413D08 for binding to hPD-L1, and comprises a CDRH3 sequence of SEQ ID NO: 134 or 137, or a CDRH3 sequence of SEQ ID NO: 134 or 137 containing 5 or fewer amino acid substitutions. H An antibody or fragment thereof, which may optionally be an antibody or fragment thereof according to any one of concepts 1 to 8, comprising the domain.

[0226] Concept 9i: A V that specifically binds to hPD-L1 and competes with antibody 413G05 for binding to hPD-L1 and comprises a CDRH3 sequence of SEQ ID NO: 240 or 243, or a CDRH3 sequence of SEQ ID NO: 240 or 243 containing 6 or fewer amino acid substitutions. H An antibody or fragment thereof, which may optionally be an antibody or fragment thereof according to any one of concepts 1 to 8, comprising the domain.

[0227] Concept 9j: A V that specifically binds to hPD-L1 and competes with antibody 413F09 for binding to hPD-L1, and comprises a CDRH3 sequence of SEQ ID NO: 260 or 263, or a CDRH3 sequence of SEQ ID NO: 260 or 263 containing 6 or fewer amino acid substitutions. H An antibody or fragment thereof, which may optionally be an antibody or fragment thereof according to any one of concepts 1 to 8, comprising the domain.

[0228] Concept 9k: A V that specifically binds to hPD-L1 and competes with antibody 414B06 for binding to hPD-L1, and comprises a CDRH3 sequence of SEQ ID NO: 280 or 283, or a CDRH3 sequence of SEQ ID NO: 280 or 283 containing 6 or fewer amino acid substitutions. H An antibody or fragment thereof, which may optionally be an antibody or fragment thereof according to any one of concepts 1 to 8, comprising the domain.

[0229] Concept 91: A V antibody that specifically binds to hPD-L1 and competes with antibody 416E01 for binding to hPD-L1, and comprises a CDRH3 sequence of SEQ ID NO: 345 or 348, or a CDRH3 sequence of SEQ ID NO: 345 or 348 containing 6 or fewer amino acid substitutions.H An antibody or fragment thereof, which may optionally be an antibody or fragment thereof according to any one of concepts 1 to 8, comprising the domain.

[0230] In all of concepts 9, 9a-l, 17, 17a-l, 18, 18a-l, 19, 19a-l, 22, 22a-l, 23, 23a-l, 24, and 24a-l, in one embodiment the CDRs comprise one amino acid substitution, which may be a conservative amino acid substitution. In all of concepts 9, 9a-l, 17, 17a-l, 18, 18a-l, 19, 19a-l, 22, 22a-l, 23, 23a-l, 24, and 24a-l, in one embodiment the CDRs comprise two amino acid substitutions, which may be conservative amino acid substitutions. In all of concepts 9, 9a-l, 17, 17a-l, 18, 18a-l, 19, 19a-l, 22, 22a, 22b, 22d, 22f, 22g, 24, and 24a-l, in one embodiment the CDRs comprise three amino acid substitutions, which may be conservative amino acid substitutions. In all of concepts 9, 9a-c, 9e, 9g-l, 17, 17a-c, 17e, 17g-l, 19, 19a, 22, 22d, 22f, 22g, 24, and 24a-l, in one embodiment the CDRs comprise four amino acid substitutions, which may be conservative amino acid substitutions. In all of concepts 9, 9a-c, 9e, 9g-l, 17, 17a-c, 17e, 17g-l, 22d, 22f, and 22g, in one embodiment the CDRs comprise five amino acid substitutions, which may be conservative amino acid substitutions. In all of concepts 9, 9a-c, 9e, 9g, 9i-l, 17, 17a-c, 17e, 17g, and 17i-l, in one embodiment the CDRs comprise six amino acid substitutions, which may be conservative amino acid substitutions.

[0231] Amino acid substitutions include modifications in which an amino acid is replaced with a different naturally occurring amino acid residue. Such substitutions can be classified as "conservative," in which an amino acid residue contained in a polypeptide is replaced with another naturally occurring amino acid having similar characteristics in terms of polarity, side chain functionality, or size. Such conservative substitutions are well known in the art. Substitutions encompassed by the present invention can also be "non-conservative," in which an amino acid residue present in a peptide is replaced with an amino acid having different properties, such as a naturally occurring amino acid from a different group (e.g., replacing a magnetic or hydrophobic amino acid with alanine), or alternatively, a naturally occurring amino acid is replaced with an unconventional amino acid.

[0232] In one embodiment, conservative amino acid substitutions are as described herein. For example, the substitutions can be F for Y, S or K for T, A for P, D or Q for E, D or G for N, K for R, N or A for G, S or K for T, N or E for D, L or V for I, Y for F, T or A for S, K for R, N or A for G, R for K, or S, K, or P for A. In another embodiment, conservative amino acid substitutions can be those in which Y is replaced by F, T is replaced by A or S, I is replaced by L or V, W is replaced by Y, M is replaced by L, N is replaced by D, G is replaced by A, T is replaced by A or S, D is replaced by N, I is replaced by L or V, F is replaced by Y or L, S is replaced by A or T, and A is replaced by S, G, T, or V.

[0233] Concept 10. V that specifically binds to hPD-L1 and contains a CDRH3 of 12–20 amino acids. H domain, human V H gene segment, a human D gene segment, and a human J H Derived from the recombination of gene segments, human J HAn antibody or fragment wherein the gene segment is IGHJ5 (e.g., IGHJ5*02).

[0234] In one embodiment, CDRH3 is 14-17 amino acids and is a human J H The gene segment is IGHJ5 (e.g., IGHJ5*02).

[0235] Concept 10a: V that specifically binds to hPD-L1 and contains a CDRH3 of 8 to 16 amino acids H domain, human V H gene segment, a human D gene segment, and a human J H Derived from the recombination of gene segments, human J H An antibody or fragment wherein the gene segment is selected from IGHJ4 (e.g., IGHJ4*02), IGHJ5 (e.g., IGHJ5*02), and IGHJ6 (e.g., IGHJ6*02).

[0236] In another embodiment, a human J H In another embodiment, the gene segment is IGHJ6 (e.g., IGHJ6*02). In another embodiment, the CDRH3 is 10 to 17 amino acids and is a human J H The gene segment is IGHJ6 (e.g., IGHJ6*02).

[0237] In another embodiment, a human J H In another embodiment, the gene segment is IGHJ4 (e.g., IGHJ4*02). In another embodiment, the CDRH3 is 7 to 17 amino acids and is a human J H The gene segment is IGHJ4 (e.g., IGHJ4*02).

[0238] Optionally, the antibody of Concept 10 or 10a may have any of the properties of Concepts 1-9, including binding affinity, K on and K off rates, expression level, half-life, and the like.

[0239] Concept 11. Human V HThe antibody or fragment of concept 10 or 10a, wherein the gene segment is IGHV3 (e.g., IGHV3-9, such as IGHV3-9*01).

[0240] Concept 11a Human V H Also provided is an antibody or fragment according to Concept 10 or 10a, wherein the gene segment is selected from IGHV3 (e.g., IGHV3-9, such as IGHV3-9*01, or IGHV3-7, such as IGHV3-7*01, or IGHV3-33, such as IGHV3-33*01, or IGHV3-11, such as IGHV3-11*01, or IGHV3-23, such as IGHV3-23*04) or IGHV4 (e.g., IGHV4-4, such as IGHV4-4*02, or IGHV4-39, such as IGHV4-39*01).

[0241] In one embodiment, human V H The gene segment is IGHV3 (e.g., IGHV3-7, such as IGHV3-7*01). H The gene segment is IGHV3 (e.g., IGHV3-33, such as IGHV3-33*01). H The gene segment is IGHV3 (e.g., IGHV3-11, such as IGHV3-11*01). H The gene segment is IGHV3 (e.g., IGHV3-23, such as IGHV3-23*04).

[0242] In one embodiment, human V H The gene segment is IGHV4 (e.g., IGHV4-4, such as, for example, IGHV4-4*02). H The gene segment is IGHV4 (e.g., IGHV4-39, such as IGHV4-39*01).

[0243] Concept 11b. Also provided is an antibody or fragment according to Concept 10, 10a, 11, or 11a, wherein the human D gene segment is selected from IGHD1 (e.g., IGHD1-20, such as IGHD1-20*01), IGHD3 (e.g., IGHD3-10, such as IGHD3-10*01), IGHD4 (e.g., IGHD4-11, such as IGHD4-11*01), IGHD5 (e.g., IGHD5-7, such as IGHD5-18*01), and IGHD6 (e.g., IGHD6-13, such as IGHD6-13*01).

[0244] In one embodiment, the human D gene segment is IGHD1 (e.g., IGHD1-20, such as IGHD1-20*01). In one embodiment, the human D gene segment is IGHD3 (e.g., IGHD3-10, such as IGHD3-10*01). In one embodiment, the human D gene segment is IGHD4 (e.g., IGHD4-11, such as IGHD4-11*01). In one embodiment, the human D gene segment is IGHD5 (e.g., IGHD5-18, such as IGHD5-19*01). In one embodiment, the human D gene segment is IGHD6 (e.g., IGHD6-13, such as IGHD6-13*01).

[0245] In concepts 10, 11, and 11a, V H , D H , and J. HThe gene segments are as described in the antibody combinations in Table 5 herein below. In one embodiment, the heavy chain of the antibody is derived from a combination of IGHV3 (e.g., IGHV3-7, such as IGHV3-7*01), IGHD4 (e.g., IGHD4-11, such as IGHD4-11*01), and IGHJ4 (e.g., IGHJ4*02). In one embodiment, the heavy chain of the antibody is derived from a combination of IGHV4 (e.g., IGHV4-4, such as IGHV4-4*02), IGHD3 (e.g., IGHD3-10, such as IGHD3-10*01), and IGHJ4 (e.g., IGHJ4*02). In one embodiment, the heavy chain of the antibody is derived from a combination of IGHV4 (e.g., IGHV4-39, such as IGHV4-39*01), IGHD6 (e.g., IGHD6-13, such as IGHD6-13*01), and IGHJ1 (e.g., IGHJ1*01). In one embodiment, the heavy chain of the antibody is derived from a combination of IGHV3 (e.g., IGHV3-33, such as IGHV3-33*01), IGHD5 (e.g., IGHD5-18, such as IGHD5-18*01), and IGHJ6 (e.g., IGHJ6*02). In one embodiment, the heavy chain of the antibody is derived from a combination of IGHV3 (e.g., IGHV3-11, such as IGHV3-11*01), IGHD1 (e.g., IGHD1-20, such as IGHD1-20*01), and IGHJ6 (e.g., IGHJ6*02). In one embodiment, the heavy chain of the antibody is derived from a combination of IGHV3 (e.g., IGHV3-23, such as IGHV3-23*04), IGHD5 (e.g., IGHD5-18, such as IGHD5-18*01), and IGHJ4 (e.g., IGHJ4*02). In one embodiment, the heavy chain of the antibody is derived from a combination of IGHV3 (e.g., IGHV3-7, such as IGHV3-7*01), IGHD5 (e.g., IGHD5-24, such as IGHD5-24*01), and IGHJ4 (e.g., IGHJ4*02). In one embodiment, the heavy chain of the antibody is derived from a combination of IGHV3 (e.g., IGHV3-23, such as IGHV3-23*04), IGHD6 (e.g., IGHD6-13, such as IGHD6-13*01), and IGHJ4 (e.g., IGHJ4*02).

[0246] Concept 12. The antibody or fragment is a Vκ gene derived from the recombination of a human Vκ gene segment and a Jκ gene segment. L The antibody or fragment of Concept 10, 10a, 11, 11a, or 11b, comprising the domain, and wherein the human Vκ gene segment is IGκV1D (e.g., IGκV1D-39, such as IGκV1D-39*01).

[0247] Concept 12a Also provided is an antibody or fragment according to any of Concepts 10, 10a, 11, 11a, or 11b, wherein the human Vκ gene segment is selected from IGκV1 (e.g., IGκV1-17, such as IGκV1-17*01, or IGκV1-9, such as IGκV1-9*d01, or IGκV1D-12, such as IGκV1D-12*02, or IGκV1D-39, such as IGκV1D-39*01) and IGκV4 (e.g., IGκV4-1, such as IGκV4-1*01).

[0248] In one embodiment, the human Vκ gene segment is IGκV1 (e.g., IGκV1-17, such as IGκV1-17*01). In one embodiment, the human Vκ gene segment is IGκV1 (e.g., IGκV1-9, such as IGκV1-9*d01). In one embodiment, the human Vκ gene segment is IGκV1 (e.g., IGκV1D-12, such as IGκV1D-12*02). In one embodiment, the human Vκ gene segment is IGκV1 (e.g., IGκV1D-39, such as IGκV1D-39*01).

[0249] In one embodiment, the human Vκ gene segment is IGκV1 IGκV4 (eg, IGκV4-1, such as IGκV4-1*01).

[0250] Concept 12b Also provided is an antibody or fragment according to Concept 10, 10a, 11, or 11a, wherein the human Jκ gene segment is selected from IGκJ1 (e.g., IGκJ1*01), IGκJ2 (e.g., IGκJ2*04), IGκJ3 (e.g., IGκJ3*01), IGκJ4 (e.g., IGκJ4*01), or IGκJ5 (e.g., IGκJ5*01).

[0251] In one embodiment, the human Jκ gene segment is IGκJ1 (e.g., IGκJ1*01). In one embodiment, the human Jκ gene segment is IGκJ2 (e.g., IGκJ2*04). In one embodiment, the human Jκ gene segment is IGκJ3 (e.g., IGκJ3*01). In one embodiment, the human Jκ gene segment is IGκJ4 (e.g., IGκJ4*01). In one embodiment, the human Jκ gene segment is IGκJ5 (e.g., IGκJ5*01).

[0252] In both Concepts 12 and 12a, the Vκ and Jκ gene segments are as set forth in the antibody combinations in Table 5 herein below. In one embodiment, the light chain of the antibody is derived from a combination of IGKV1D (e.g., IGKV1D-12, such as IGKV1D-12*02) and IGKJ3 (e.g., IGKJ3*01). In one embodiment, the light chain of the antibody is derived from a combination of IGKV4 (e.g., IGKV4-1, such as IGKV14-1*01) and IGKJ2 (e.g., IGKJ2*04). In one embodiment, the light chain of the antibody is derived from a combination of IGKV1 (e.g., IGKV1-17, such as IGKV1-17*01) and IGKJ1 (e.g., IGKJ1*01). In one embodiment, the light chain of the antibody is derived from a combination of IGKV1D (e.g., IGKV1D-12, such as IGKV1D-12*02) and IGKJ4 (e.g., IGKJ4*01). In one embodiment, the light chain of the antibody is derived from a combination of IGKV1 (e.g., IGKV1-9, such as IGKV1-9*d01) and IGKJ5 (e.g., IGKJ5*01). In one embodiment, the light chain of the antibody is derived from a combination of IGKV1D (e.g., IGKV1D-12, such as IGKV1D-12*02) and IGKJ5 (e.g., IGKJ5*01).

[0253] Concept 13. An antibody or fragment thereof that specifically binds to an epitope identical to the epitope specifically bound by antibody 1D05.

[0254] Concept 13a. An antibody or fragment thereof that specifically binds to an epitope identical to the epitope specifically bound by antibody 84G09.

[0255] Concept 13b. An antibody or fragment thereof that specifically binds to an epitope identical to the epitope specifically bound by antibody 411B08.

[0256] Concept 13c. An antibody or fragment thereof that specifically binds to an epitope identical to the epitope specifically bound by antibody 411C04.

[0257] Concept 13d. An antibody or fragment thereof that specifically binds to an epitope identical to the epitope specifically bound by antibody 411D07.

[0258] Concept 13e. An antibody or fragment thereof that specifically binds to an epitope that is identical to the epitope specifically bound by antibody 385F01.

[0259] Concept 13f. An antibody or fragment thereof that specifically binds to the same epitope as the antibody 386H03 specifically binds.

[0260] Concept 13g. An antibody or fragment thereof that specifically binds to an epitope identical to the epitope specifically bound by antibody 389A03.

[0261] Concept 13h. An antibody or fragment thereof that specifically binds to an epitope identical to the epitope specifically bound by antibody 413D08.

[0262] Concept 13i. An antibody or fragment thereof that specifically binds to the same epitope as the antibody 413G05 specifically binds.

[0263] Concept 13j. An antibody or fragment thereof that specifically binds to an epitope identical to the epitope specifically bound by antibody 413F09.

[0264] Concept 13k. An antibody or fragment thereof that specifically binds to an epitope identical to the epitope specifically bound by antibody 414B06.

[0265] Concept 13l. An antibody or fragment thereof that specifically binds to an epitope identical to the epitope specifically bound by antibody 416E01.

[0266] The antibodies described in these concepts have the sequences described herein above.

[0267] In one embodiment, an antibody is provided that specifically binds to an epitope that is substantially similar to the epitope bound by the antibody in Concepts 13, 13a-13l.

[0268] Contact amino acid residues involved in the interaction of an antibody with an antigen can be determined by various methods known in the art.

[0269] In one embodiment, serial substitution of amino acids in the antigen sequence (using standard molecular biology techniques to mutate the DNA of the antigen coding sequence), in this case substitution of hPD-L1 with alanine (also known as alanine scanning) or another unrelated amino acid, may provide residues that will reduce or eliminate the ability of the antibody to recognize the antigen of interest. Binding may be assessed using standard techniques, including but not limited to SPR, HTRF, and ELISA (described elsewhere herein). Other substitutions may be made to enhance disruption of binding, such as altering the side chain charge of antigen sequence amino acids (e.g., changing lysine to glutamic acid), exchanging polar and non-polar residues (e.g., changing serine to leucine), etc. Alanine scanning or other amino acid substitution methods can be performed using recombinant soluble antigen, or, if the target is a cell membrane target, directly on cells using transient or stable expression of the mutated version.

[0270] In one embodiment, protein crystallography can be used to determine the contact residues between an antibody and an antigen (i.e., to determine the epitope to which the antibody binds), and crystallography allows direct visualization of the contact residues involved in antibody-antigen interactions. In addition to standard X-ray crystallography, cryo-electron microscopy has been used to determine the contact residues between an antibody and an HIV capsid protein (see Lee, Jeong Hyun, et al. "Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike.", Nature Communications, 6, (2015)).

[0271] In one embodiment, if an antibody recognizes a linear epitope, short peptides can be generated based on the antigen sequence, and antibody binding to these peptides can be assessed using standard techniques, including, but not limited to, SPR, HTRF, and ELISA (described elsewhere herein). Further investigation of the epitope can be provided by performing an alanine scan on any peptides that show binding. Instead of linear peptides, conformational scans can be performed using Pepscan technology (http: / / www.pepscan.com / ), which uses chemical attachment of peptides to a backbone, and has been used to determine discontinuous epitopes on CD20-targeting antibodies (Niederfellner, Gerhard, et al., "Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I / II distinction of CD20 antibodies." Blood, 118.2, (2011), 358-367).

[0272] In one embodiment, limited protein digestion and mass spectrophotometric analysis can be used to identify the binding epitope. The antibody-antigen complex is digested with a protease, such as, but not limited to, trypsin. The digested complex peptides are compared by mass spectrophotometric analysis of the digested antibody alone and the antigen alone to determine whether a specific epitope is protected by complex formation. Competitive binding, a further step involving amino acid substitution, can be used to narrow down the individual amino acid residues involved in the interaction (see, for example, Suckau, Detlev, et al., "Molecular epitope identification by limited proteolysis of an immobilized antigen-antibody complex and mass spectrometric peptide mapping." Proceedings of the National Academy of Sciences, 87.24, (1990), 9848-9852).

[0273] Therefore, in one embodiment, contact residues of the epitope are identified using an unrelated amino acid scan (e.g., an alanine scan). In another embodiment, the unrelated amino acid scan (e.g., an alanine scan) is performed using a technique selected from SPR, HTRF, ELISA, X-ray crystallography, cryo-electron microscopy, and a combination of limited protein digestion and mass spectrometry. In one embodiment, the unrelated amino acid scan (e.g., an alanine scan) is performed using HTRF. In one embodiment, the unrelated amino acid scan (e.g., an alanine scan) is performed using ELISA.

[0274] When an alanine scan is performed using either ELISA or HTRF, an amino acid residue is identified as contributing to the epitope if there is at least a 25% reduction in signal. In one embodiment, the signal reduction is at least 30%. In one embodiment, the signal reduction is at least 35%. In one embodiment, the signal reduction is at least 40%. In one embodiment, the signal reduction is at least 45%. In one embodiment, the signal reduction is at least 50%. In one embodiment, the signal reduction is at least 55%. In one embodiment, the signal reduction is at least 60%. In one embodiment, the signal reduction is at least 70%. In one embodiment, the signal reduction is at least 75%. In one embodiment, the signal reduction is at least 80%. In one embodiment, the signal reduction is at least 85%. In one embodiment, the signal reduction is at least 90%.

[0275] When an alanine scan is performed using SPR, an amino acid residue is identified as contributing to the epitope if there is at least a 10-fold reduction in affinity. In one embodiment, the affinity reduction is at least 15-fold. In one embodiment, the affinity reduction is at least 20-fold. In one embodiment, the affinity reduction is at least 30-fold. In one embodiment, the affinity reduction is at least 40-fold. In one embodiment, the affinity reduction is at least 50-fold. In one embodiment, the affinity reduction is at least 100-fold.

[0276] Therefore, in one embodiment, the contact residues of the epitope are identified by X-ray crystallography.Therefore, in one embodiment, the contact residues of the epitope are identified by cryo-electron microscopy.Therefore, in one embodiment, the contact residues of the epitope are identified by limited protein digestion combined with mass spectrometry.

[0277] Concept 14. The antibody or fragment of Concept 13, wherein the epitope is identified by an independent amino acid scan or X-ray crystallography.

[0278] Concept 15. The antibody or fragment of Concept 14, wherein the contact residues of the epitope are defined by at least a 10-fold reduction in affinity in an unrelated amino acid scan, e.g., an alanine scan, as determined by SPR.

[0279] In one embodiment, the decrease in affinity is at least 15-fold. In one embodiment, the decrease in affinity is at least 20-fold. In one embodiment, the decrease in affinity is at least 30-fold. In one embodiment, the decrease in affinity is at least 40-fold. In one embodiment, the decrease in affinity is at least 50-fold. In one embodiment, the decrease in affinity is at least 100-fold.

[0280] SPR can be performed as described above.

[0281] Concept 16. An antibody or fragment thereof that competes with antibody 1D05 for binding to hPD-L1.

[0282] Competition may be determined by surface plasmon resonance (SPR), techniques that will be readily apparent to those of skill in the art. SPR may be performed using Biacore™, Proteon™, or another standard SPR technique. Such competition may be due, for example, to antibodies or fragments that bind to the same or overlapping epitopes of hPD-L1. In one embodiment, competition may be determined by ELISA, techniques that will be readily apparent to those of skill in the art. In one embodiment, competition may be determined by homogeneous time-resolved fluorescence (HTRF), techniques that will be readily apparent to those of skill in the art. In one embodiment, competition may be determined by fluorescence-activated cell sorting (FACS), techniques that will be readily apparent to those of skill in the art. In one embodiment, competition may be determined by ForteBio Octet® Biolayer Interferometry (BLI), techniques that will be readily apparent to those of skill in the art.

[0283] In one embodiment, the antibody or fragment competes with hPD-1 (or a fusion protein thereof) for binding to cell surface-expressed hPD-L1 (e.g., in a dose-dependent manner). In one embodiment, the antibody or fragment competes with hPD-1 (or a fusion protein thereof) for binding to soluble hPDL-1 (e.g., in a dose-dependent manner).

[0284] In one embodiment, the antibody or fragment partially or completely inhibits the binding of PD-1 and / or CD80 to cell-surface-expressed PD-L1, such as hPD-L1. In another embodiment, the antibody or fragment partially or completely inhibits the binding of hPD-1 and / or CD80 to soluble hPD-L1. In some embodiments, the antibody or fragment partially or completely increases the secretion of IFNγ, CD25, and IL-2 from cells with cell-surface-expressed PD-L1. In one embodiment, the antibody or fragment partially or completely inhibits the binding of CD80 to soluble hPD-L1, but does not exhibit any detectable inhibition of PD-1 binding to cell-surface-expressed PD-L1. In one embodiment, the antibody or fragment partially or completely inhibits the binding of CD80 to soluble hPD-L1, but does not exhibit any detectable inhibition of PD-1 binding to soluble PD-L1.

[0285] As used herein, "inhibit," "inhibition," "inhibiting," and the like refer to the ability of an antagonist (e.g., an antibody or fragment thereof) to bind to an epitope that partially or completely prevents the binding of a receptor (e.g., CD80 or PD-1) to a ligand (e.g., PD-L1). If the epitope bound by the antagonist completely blocks the binding site of the ligand, ligand binding is completely prevented (this can be physical blocking, in the case of overlapping epitopes, or steric blocking, if the antagonist is large enough to prevent ligand binding to its unique epitope), and the ligand is not removed from circulation. Thus, the concentration of circulating ligand may appear to be increased. If the epitope bound by the antagonist partially blocks the binding site of the ligand, the ligand may be able to bind, but only weakly (in the case of partial inhibition) or bind in an orientation different from the natural binding interaction. In this case, some of the ligand may be removed from circulation, but not as much as would be removed if the ligand-binding site were completely free and available for binding. Therefore, inhibition refers to the physical interaction between ligand and receptor.Inhibition can be measured by HTRF, which is described in more detail elsewhere in this specification and in Mathis (1995) Clinical Chemistry 41(9),1391-1397.Inhibition can also be measured by flow cytometry, where receptor is expressed on cells, or by ELISA, where receptor is adsorbed onto plate.

[0286] Concept 16a. An antibody or fragment thereof that competes with antibody 84G09 for binding to hPD-L1.

[0287] Concept 16b. An antibody or fragment thereof that competes with antibody 411B08 for binding to hPD-L1.

[0288] Concept 16c. An antibody or fragment thereof that competes with antibody 411C04 for binding to hPD-L1.

[0289] Concept 16d. An antibody or fragment thereof that competes with antibody 411D07 for binding to hPD-L1.

[0290] Concept 16e. An antibody or fragment thereof that competes with antibody 385F01 for binding to hPD-L1.

[0291] Concept 16f. An antibody or fragment thereof that competes with antibody 386H03 for binding to hPD-L1.

[0292] Concept 16g. An antibody or fragment thereof that competes with antibody 389A03 for binding to hPD-L1.

[0293] Concept 16h. An antibody or fragment thereof that competes with antibody 413D08 for binding to hPD-L1.

[0294] Concept 16i. An antibody or fragment thereof that competes with antibody 413G05 for binding to hPD-L1.

[0295] Concept 16j. An antibody or fragment thereof that competes with antibody 413F09 for binding to hPD-L1.

[0296] Concept 16k. An antibody or fragment thereof that competes with antibody 414B06 for binding to hPD-L1.

[0297] Concept 16l. An antibody or fragment thereof that competes with antibody 416E01 for binding to hPD-L1.

[0298] The antibody has the sequence described herein above.

[0299] Concept 17.V H 17. The antibody or fragment of any one of concepts 10 to 16, wherein the domain comprises a CDRH3 sequence of SEQ ID NO: 29 or 32, or a CDRH3 sequence of SEQ ID NO: 29 or 32 containing six or fewer amino acid substitutions.

[0300] Concept 17a:V HThe antibody or fragment thereof according to any one of Concepts 10 to 16 (provided that when subject to Concept 13, it is subject to Concept 13a, and when subject to Concept 16, it is subject to Concept 16a), wherein the domain comprises a CDRH3 sequence of SEQ ID NO: 9 or 12, or a CDRH3 sequence of SEQ ID NO: 9 or 12 containing six or fewer amino acid substitutions.

[0301] Concept 17b:V H The antibody or fragment thereof according to any one of Concepts 10 to 16 (provided that if dependent on Concept 13, then dependent on Concept 13b, and if dependent on Concept 16, then dependent on Concept 16b), wherein the domain comprises the CDRH3 sequence of SEQ ID NO: 54 or 57, or the CDRH3 sequence of SEQ ID NO: 54 or 57 containing six or fewer amino acid substitutions.

[0302] Concept 17c:V H The antibody or fragment thereof according to any one of Concepts 10 to 16 (provided that if subject to Concept 13, then subject to Concept 13c, and if subject to Concept 16, then subject to Concept 16c), wherein the domain comprises the CDRH3 sequence of SEQ ID NO: 74 or 77, or the CDRH3 sequence of SEQ ID NO: 74 or 77 containing six or fewer amino acid substitutions.

[0303] Concept 17d:V H The antibody or fragment thereof according to any one of Concepts 10 to 16 (provided that if dependent on Concept 13, then dependent on Concept 13d, and if dependent on Concept 16, then dependent on Concept 16d), wherein the domain comprises the CDRH3 sequence of SEQ ID NO: 94 or 97, or the CDRH3 sequence of SEQ ID NO: 94 or 97 containing no more than three amino acid substitutions.

[0304] Concept 17e:V H The antibody or fragment thereof according to any one of Concepts 10 to 16 (provided that if dependent on Concept 13, then dependent on Concept 13e, and if dependent on Concept 16, then dependent on Concept 16e), wherein the domain comprises the CDRH3 sequence of SEQ ID NO: 114 or 117, or the CDRH3 sequence of SEQ ID NO: 114 or 117 containing six or fewer amino acid substitutions.

[0305] Concept 17f:V H The antibody or fragment thereof according to any one of Concepts 10 to 16 (provided that if dependent on Concept 13, then dependent on Concept 13f, and if dependent on Concept 16, then dependent on Concept 16f), wherein the domain comprises the CDRH3 sequence of SEQ ID NO: 144 or 147, or the CDRH3 sequence of SEQ ID NO: 144 or 147 containing no more than three amino acid substitutions.

[0306] Concept 17g:V H The antibody or fragment thereof according to any one of Concepts 10 to 16 (provided that if subject to Concept 13, then subject to Concept 13g, and if subject to Concept 16, then subject to Concept 16g), wherein the domain comprises the CDRH3 sequence of SEQ ID NO: 174 or 177, or the CDRH3 sequence of SEQ ID NO: 174 or 177 containing six or fewer amino acid substitutions.

[0307] Concept 17h:V H The antibody or fragment thereof according to any one of Concepts 10 to 16 (provided that if dependent on Concept 13, it is dependent on Concept 13h, and if dependent on Concept 16, it is dependent on Concept 16h), wherein the domain comprises the CDRH3 sequence of SEQ ID NO: 134 or 137, or the CDRH3 sequence of SEQ ID NO: 134 or 137 containing five or fewer amino acid substitutions.

[0308] Concept 17i:V H The antibody or fragment thereof according to any one of Concepts 10 to 16 (provided that if dependent on Concept 13, then dependent on Concept 13i, and if dependent on Concept 16, then dependent on Concept 16i), wherein the domain comprises the CDRH3 sequence of SEQ ID NO: 240 or 243, or the CDRH3 sequence of SEQ ID NO: 240 or 243 containing six or fewer amino acid substitutions.

[0309] Concept 17j:V HThe antibody or fragment thereof according to any one of Concepts 10 to 16 (provided that if dependent on Concept 13, then dependent on Concept 13j, and if dependent on Concept 16, then dependent on Concept 16j), wherein the domain comprises a CDRH3 sequence of SEQ ID NO: 260 or 263, or a CDRH3 sequence of SEQ ID NO: 260 or 263 containing six or fewer amino acid substitutions.

[0310] Concept 17k:V H The antibody or fragment thereof according to any one of Concepts 10 to 16 (provided that if dependent on Concept 13, it is dependent on Concept 13k, and if dependent on Concept 16, it is dependent on Concept 16k), wherein the domain comprises the CDRH3 sequence of SEQ ID NO: 280 or 283, or the CDRH3 sequence of SEQ ID NO: 280 or 283 containing six or fewer amino acid substitutions.

[0311] Concept 17l:V H The antibody or fragment thereof according to any one of Concepts 10 to 16 (provided that if dependent on Concept 13, then dependent on Concept 131, and if dependent on Concept 16, then dependent on Concept 161), wherein the domain comprises the CDRH3 sequence of SEQ ID NO: 345 or 348, or the CDRH3 sequence of SEQ ID NO: 345 or 348 containing six or fewer amino acid substitutions.

[0312] Concept 18.V H 18. The antibody or fragment of any of concepts 1-17, wherein the domain comprises a CDRH1 sequence of SEQ ID NO: 27 or 30, or a CDRH1 sequence of SEQ ID NO: 27 or 30 containing 3, 2, or 1 amino acid substitutions.

[0313] Concept 18a:V H The antibody or fragment thereof according to any one of concepts 1 to 17 (provided that if dependent on concept 9, then dependent on concept 9a; if dependent on concept 13, then dependent on concept 13a; if dependent on concept 16, then dependent on concept 16a; and if dependent on concept 17, then dependent on concept 17a), wherein the domain comprises the CDRH1 sequence of SEQ ID NO: 7 or 10, or the CDRH1 sequence of SEQ ID NO: 7 or 10 containing 3, 2, or 1 amino acid substitution(s).

[0314] Concept 18b:V H The antibody or fragment thereof according to any one of concepts 1 to 17 (provided that if dependent on concept 9, then dependent on concept 9b; if dependent on concept 13, then dependent on concept 13b; if dependent on concept 16, then dependent on concept 16b; and if dependent on concept 17, then dependent on concept 17b), wherein the domain comprises the CDRH1 sequence of SEQ ID NO: 52 or 55, or the CDRH1 sequence of SEQ ID NO: 52 or 55 containing 3, 2, or 1 amino acid substitution(s).

[0315] Concept 18c:V H The antibody or fragment thereof according to any one of concepts 1 to 17 (provided that if dependent on concept 9, then dependent on concept 9c; if dependent on concept 13, then dependent on concept 13c; if dependent on concept 16, then dependent on concept 16c; and if dependent on concept 17, then dependent on concept 17c), wherein the domain comprises the CDRH1 sequence of SEQ ID NO: 72 or 75, or the CDRH1 sequence of SEQ ID NO: 72 or 75 containing 3, 2, or 1 amino acid substitution(s).

[0316] Concept 18d:V H The antibody or fragment thereof according to any one of concepts 1 to 17 (provided that if dependent on concept 9, then dependent on concept 9d; if dependent on concept 13, then dependent on concept 13d; if dependent on concept 16, then dependent on concept 16d; and if dependent on concept 17, then dependent on concept 17d), wherein the domain comprises the CDRH1 sequence of SEQ ID NO: 92 or 95, or the CDRH1 sequence of SEQ ID NO: 92 or 95 containing 3, 2, or 1 amino acid substitution(s).

[0317] Concept 18e:V HThe antibody or fragment thereof according to any one of concepts 1 to 17 (provided that if dependent on concept 9, then dependent on concept 9e; if dependent on concept 13, then dependent on concept 13e; if dependent on concept 16, then dependent on concept 16e; and if dependent on concept 17, then dependent on concept 17e), wherein the domain comprises the CDRH1 sequence of SEQ ID NO: 112 or 115, or the CDRH1 sequence of SEQ ID NO: 112 or 115 containing 3, 2, or 1 amino acid substitution(s).

[0318] Concept 18f:V H The antibody or fragment thereof according to any one of concepts 1 to 17 (provided that if dependent on concept 9, then dependent on concept 9f; if dependent on concept 13, then dependent on concept 13f; if dependent on concept 16, then dependent on concept 16f; and if dependent on concept 17, then dependent on concept 17f), wherein the domain comprises the CDRH1 sequence of SEQ ID NO: 142 or 145, or the CDRH1 sequence of SEQ ID NO: 142 or 145 containing 3, 2, or 1 amino acid substitution(s).

[0319] Concept 18g:V H The antibody or fragment thereof according to any one of concepts 1 to 17 (provided that if dependent on concept 9, then dependent on concept 9g; if dependent on concept 13, then dependent on concept 13g; if dependent on concept 16, then dependent on concept 16g; and if dependent on concept 17, then dependent on concept 17g), wherein the domain comprises the CDRH1 sequence of SEQ ID NO: 172 or 175, or the CDRH1 sequence of SEQ ID NO: 172 or 175 containing 3, 2, or 1 amino acid substitution(s).

[0320] Concept 18h:V H The antibody or fragment thereof according to any one of concepts 1 to 17 (provided that if dependent on concept 9, then dependent on concept 9h; if dependent on concept 13, then dependent on concept 13h; if dependent on concept 16, then dependent on concept 16h; and if dependent on concept 17, then dependent on concept 17h), wherein the domain comprises the CDRH1 sequence of SEQ ID NO: 132 or 135, or the CDRH1 sequence of SEQ ID NO: 132 or 135 containing 3, 2, or 1 amino acid substitution(s).

[0321] Concept 18i:V H The antibody or fragment thereof according to any one of concepts 1 to 17 (provided that if dependent on concept 9, then dependent on concept 9i; if dependent on concept 13, then dependent on concept 13i; if dependent on concept 16, then dependent on concept 16i; and if dependent on concept 17, then dependent on concept 17i), wherein the domain comprises the CDRH1 sequence of SEQ ID NO: 238 or 241, or the CDRH1 sequence of SEQ ID NO: 238 or 241 containing 3, 2, or 1 amino acid substitution(s).

[0322] Concept 18j:V H The antibody or fragment thereof of any one of concepts 1 to 17 (provided that if dependent on concept 9, then dependent on concept 9j; if dependent on concept 13, then dependent on concept 13j; if dependent on concept 16, then dependent on concept 16j; and if dependent on concept 17, then dependent on concept 17j), wherein the domain comprises the CDRH1 sequence of SEQ ID NO: 258 or 261, or the CDRH1 sequence of SEQ ID NO: 258 or 261 containing 3, 2, or 1 amino acid substitution(s).

[0323] Concept 18k:V H The antibody or fragment thereof according to any one of concepts 1 to 17 (provided that if dependent on concept 9, then dependent on concept 9k; if dependent on concept 13, then dependent on concept 13k; if dependent on concept 16, then dependent on concept 16k; and if dependent on concept 17, then dependent on concept 17k), wherein the domain comprises the CDRH1 sequence of SEQ ID NO: 278 or 281, or the CDRH1 sequence of SEQ ID NO: 278 or 281 containing 3, 2, or 1 amino acid substitution(s).

[0324] Concept 18l:V HThe antibody or fragment thereof according to any one of concepts 1 to 17 (provided that if dependent on concept 9, then dependent on concept 91; if dependent on concept 13, then dependent on concept 131; if dependent on concept 16, then dependent on concept 161; and if dependent on concept 17, then dependent on concept 171), wherein the domain comprises the CDRH1 sequence of SEQ ID NO: 343 or 346, or the CDRH1 sequence of SEQ ID NO: 343 or 346 comprising 3, 2, or 1 amino acid substitution(s).

[0325] Concept 19.V H 19. The antibody or fragment of any of concepts 1-18, wherein the domain comprises a CDRH2 sequence of SEQ ID NO: 28 or 31, or a CDRH2 sequence of SEQ ID NO: 28 or 31 containing no more than four amino acid substitutions.

[0326] Concept 19a:V H 19. The antibody or fragment thereof according to any one of concepts 1 to 18 (provided that if dependent on concept 9, then dependent on concept 9a; if dependent on concept 13, then dependent on concept 13a; if dependent on concept 16, then dependent on concept 16a; if dependent on concept 17, then dependent on concept 17a; and if dependent on concept 18, then dependent on concept 18a), wherein the domain comprises the CDRH2 sequence of SEQ ID NO: 8 or 11, or the CDRH2 sequence of SEQ ID NO: 8 or 11 containing no more than four amino acid substitutions.

[0327] Concept 19b:V H The antibody or fragment thereof according to any one of concepts 1 to 18 (provided that if dependent on concept 9, then dependent on concept 9b; if dependent on concept 13, then dependent on concept 13b; if dependent on concept 16, then dependent on concept 16b; if dependent on concept 17, then dependent on concept 17b; and if dependent on concept 18, then dependent on concept 18b), wherein the domain comprises the CDRH2 sequence of SEQ ID NO: 53 or 56, or the CDRH2 sequence of SEQ ID NO: 53 or 56 containing 3, 2, or 1 amino acid substitution(s).

[0328] Concept 19c:V HThe antibody or fragment thereof according to any one of concepts 1 to 18 (provided that if dependent on concept 9, then dependent on concept 9c; if dependent on concept 13, then dependent on concept 13c; if dependent on concept 16, then dependent on concept 16c; if dependent on concept 17, then dependent on concept 17c; and if dependent on concept 18, then dependent on concept 18c), wherein the domain comprises the CDRH2 sequence of SEQ ID NO: 73 or 76, or the CDRH2 sequence of SEQ ID NO: 73 or 76 containing 3, 2, or 1 amino acid substitution(s).

[0329] Concept 19d:V H The antibody or fragment thereof according to any one of concepts 1 to 18 (provided that if dependent on concept 9, then dependent on concept 9d; if dependent on concept 13, then dependent on concept 13d; if dependent on concept 16, then dependent on concept 16d; if dependent on concept 17, then dependent on concept 17d; and if dependent on concept 18, then dependent on concept 18d), wherein the domain comprises the CDRH2 sequence of SEQ ID NO: 93 or 96, or the CDRH2 sequence of SEQ ID NO: 93 or 96 containing 3, 2, or 1 amino acid substitution(s).

[0330] Concept 19e:V H The antibody or fragment thereof according to any one of concepts 1 to 18 (provided that if dependent on concept 9, then dependent on concept 9e; if dependent on concept 13, then dependent on concept 13e; if dependent on concept 16, then dependent on concept 16e; if dependent on concept 17, then dependent on concept 17e; and if dependent on concept 18, then dependent on concept 18e), wherein the domain comprises the CDRH2 sequence of SEQ ID NO: 113 or 116, or the CDRH2 sequence of SEQ ID NO: 113 or 116 containing 3, 2, or 1 amino acid substitution(s).

[0331] Concept 19f:V HThe antibody or fragment thereof according to any one of concepts 1 to 18 (provided that if dependent on concept 9, then dependent on concept 9f; if dependent on concept 13, then dependent on concept 13f; if dependent on concept 16, then dependent on concept 16f; if dependent on concept 17, then dependent on concept 17f; and if dependent on concept 18, then dependent on concept 18f), wherein the domain comprises the CDRH2 sequence of SEQ ID NO: 143 or 146, or the CDRH2 sequence of SEQ ID NO: 143 or 146 containing 3, 2, or 1 amino acid substitution(s).

[0332] Concept 19g:V H The antibody or fragment thereof according to any one of concepts 1 to 18 (provided that if dependent on concept 9, then dependent on concept 9g; if dependent on concept 13, then dependent on concept 13g; if dependent on concept 16, then dependent on concept 16g; if dependent on concept 17, then dependent on concept 17g; and if dependent on concept 18, then dependent on concept 18g), wherein the domain comprises the CDRH2 sequence of SEQ ID NO: 173 or 176, or the CDRH2 sequence of SEQ ID NO: 173 or 176 containing 3, 2, or 1 amino acid substitution(s).

[0333] Concept 19h:V H The antibody or fragment thereof according to any one of concepts 1 to 18 (provided that if dependent on concept 9, then dependent on concept 9h; if dependent on concept 13, then dependent on concept 13h; if dependent on concept 16, then dependent on concept 16h; if dependent on concept 17, then dependent on concept 17h; and if dependent on concept 18, then dependent on concept 18h), wherein the domain comprises the CDRH2 sequence of SEQ ID NO: 133 or 136, or the CDRH2 sequence of SEQ ID NO: 133 or 136 containing 3, 2, or 1 amino acid substitution(s).

[0334] Concept 19i:V HThe antibody or fragment thereof according to any one of concepts 1 to 18 (provided that if dependent on concept 9, then dependent on concept 9i; if dependent on concept 13, then dependent on concept 13i; if dependent on concept 16, then dependent on concept 16i; if dependent on concept 17, then dependent on concept 17i; and if dependent on concept 18, then dependent on concept 18i), wherein the domain comprises the CDRH2 sequence of SEQ ID NO: 239 or 242, or the CDRH2 sequence of SEQ ID NO: 239 or 242 containing 3, 2, or 1 amino acid substitution(s).

[0335] Concept 19j:V H The antibody or fragment thereof of any one of concepts 1-18 (provided that if dependent on concept 9, then dependent on concept 9j; if dependent on concept 13, then dependent on concept 13j; if dependent on concept 16, then dependent on concept 16j; if dependent on concept 17, then dependent on concept 17j; and if dependent on concept 18, then dependent on concept 18j), wherein the domain comprises the CDRH2 sequence of SEQ ID NO: 259 or 262, or the CDRH2 sequence of SEQ ID NO: 259 or 262 containing 3, 2, or 1 amino acid substitution(s).

[0336] Concept 19k:V H The antibody or fragment thereof according to any one of concepts 1 to 18 (provided that if dependent on concept 9, then dependent on concept 9k; if dependent on concept 13, then dependent on concept 13k; if dependent on concept 16, then dependent on concept 16k; if dependent on concept 17, then dependent on concept 17k; and if dependent on concept 18, then dependent on concept 18k), wherein the domain comprises the CDRH2 sequence of SEQ ID NO: 279 or 282, or the CDRH2 sequence of SEQ ID NO: 279 or 282 containing 3, 2, or 1 amino acid substitution(s).

[0337] Concept 19l:V HThe antibody or fragment thereof according to any one of concepts 1 to 18 (provided that if dependent on concept 9, then dependent on concept 91; if dependent on concept 13, then dependent on concept 131; if dependent on concept 16, then dependent on concept 161; if dependent on concept 17, then dependent on concept 171; and if dependent on concept 18, then dependent on concept 181), wherein the domain comprises the CDRH2 sequence of SEQ ID NO: 344 or 347, or the CDRH2 sequence of SEQ ID NO: 344 or 347 comprising 3, 2, or 1 amino acid substitution(s).

[0338] Concept 20.V H 20. The antibody or fragment of any of concepts 1-19, wherein the domain comprises the amino acid sequence of SEQ ID NO: 33, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 33.

[0339] Concept 20a:V H 19. The antibody or fragment thereof according to any one of Concepts 1 to 19 (provided that when subject to Concept 9, it is subject to Concept 9a; when subject to Concept 13, it is subject to Concept 13a; when subject to Concept 16, it is subject to Concept 16a; when subject to Concept 17, it is subject to Concept 17a; when subject to Concept 18, it is subject to Concept 18a; and when subject to Concept 19, it is subject to Concept 19a), wherein the domain comprises the amino acid sequence of SEQ ID NO: 13, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 13.

[0340] Concept 20b:V H19. The antibody or fragment thereof according to any one of Concepts 1 to 19 (provided that when subject to Concept 9, it is subject to Concept 9b; when subject to Concept 13, it is subject to Concept 13b; when subject to Concept 16, it is subject to Concept 16b; when subject to Concept 17, it is subject to Concept 17b; when subject to Concept 18, it is subject to Concept 18b; and when subject to Concept 19, it is subject to Concept 19b), wherein the domain comprises the amino acid sequence of SEQ ID NO: 58 or a heavy chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 58.

[0341] Concept 20c:V H 19. The antibody or fragment thereof of any one of Concepts 1-19 (provided that if subject to Concept 9, then subject to Concept 9c; if subject to Concept 13, then subject to Concept 13c; if subject to Concept 16, then subject to Concept 16c; if subject to Concept 17, then subject to Concept 17c; if subject to Concept 18, then subject to Concept 18c; and if subject to Concept 19, then subject to Concept 19c), wherein the domain comprises the amino acid sequence of SEQ ID NO: 78 or a heavy chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 78.

[0342] Concept 20d:V H 19. The antibody or fragment thereof of any one of concepts 1-19 (provided that when subject to concept 9, it is subject to concept 9d; when subject to concept 13, it is subject to concept 13d; when subject to concept 16, it is subject to concept 16d; when subject to concept 17, it is subject to concept 17d; when subject to concept 18, it is subject to concept 18d; and when subject to concept 19, it is subject to concept 19d), wherein the domain comprises the amino acid sequence of SEQ ID NO:98 or a heavy chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO:98.

[0343] Concept 20e:V H19. The antibody or fragment thereof of any one of Concepts 1-19 (provided that if subject to Concept 9, then subject to Concept 9e; if subject to Concept 13, then subject to Concept 13e; if subject to Concept 16, then subject to Concept 16e; if subject to Concept 17, then subject to Concept 17e; if subject to Concept 18, then subject to Concept 18e; and if subject to Concept 19, then subject to Concept 19e), wherein the domain comprises the amino acid sequence of SEQ ID NO: 118, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 118.

[0344] Concept 20f:V H 19. The antibody or fragment thereof of any one of Concepts 1-19 (provided that if subject to Concept 9, then subject to Concept 9f; if subject to Concept 13, then subject to Concept 13f; if subject to Concept 16, then subject to Concept 16f; if subject to Concept 17, then subject to Concept 17f; if subject to Concept 18, then subject to Concept 18f; and if subject to Concept 19, then subject to Concept 19f), wherein the domain comprises the amino acid sequence of SEQ ID NO: 158 or a heavy chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 158.

[0345] Concept 20g:V H 19. The antibody or fragment thereof of any one of Concepts 1-19 (provided that if subject to Concept 9, then subject to Concept 9g; if subject to Concept 13, then subject to Concept 13g; if subject to Concept 16, then subject to Concept 16g; if subject to Concept 17, then subject to Concept 17g; if subject to Concept 18, then subject to Concept 18g; and if subject to Concept 19, then subject to Concept 19g), wherein the domain comprises the amino acid sequence of SEQ ID NO: 178 or a heavy chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 178.

[0346] Concept 20h:V HThe antibody or fragment thereof of any one of Concepts 1 to 19 (provided that if subject to Concept 9, then subject to Concept 9h; if subject to Concept 13, then subject to Concept 13h; if subject to Concept 16, then subject to Concept 16h; if subject to Concept 17, then subject to Concept 17h; if subject to Concept 18, then subject to Concept 18h; and if subject to Concept 19, then subject to Concept 19h), wherein the domain comprises the amino acid sequence of SEQ ID NO: 138 or a heavy chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 138.

[0347] Concept 20i:V H The antibody or fragment thereof of any one of Concepts 1-19 (provided that if subject to Concept 9, then subject to Concept 9i; if subject to Concept 13, then subject to Concept 13i; if subject to Concept 16, then subject to Concept 16i; if subject to Concept 17, then subject to Concept 17i; if subject to Concept 18, then subject to Concept 18i; and if subject to Concept 19, then subject to Concept 19i), wherein the domain comprises the amino acid sequence of SEQ ID NO:244, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO:244.

[0348] Concept 20j:V H The antibody or fragment thereof of any one of Concepts 1-19 (provided that if subject to Concept 9, then subject to Concept 9j; if subject to Concept 13, then subject to Concept 13j; if subject to Concept 16, then subject to Concept 16j; if subject to Concept 17, then subject to Concept 17j; if subject to Concept 18, then subject to Concept 18j; and if subject to Concept 19, then subject to Concept 19j), wherein the domain comprises the amino acid sequence of SEQ ID NO:264 or a heavy chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO:264.

[0349] Concept 20k:V HThe antibody or fragment thereof of any one of Concepts 1 to 19 (provided that if dependent on Concept 9, then dependent on Concept 9k; if dependent on Concept 13, then dependent on Concept 13k; if dependent on Concept 16, then dependent on Concept 16k; if dependent on Concept 17, then dependent on Concept 17k; if dependent on Concept 18, then dependent on Concept 18k; and if dependent on Concept 19, then dependent on Concept 19k), wherein the domain comprises the amino acid sequence of SEQ ID NO:284 or a heavy chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO:284.

[0350] Concept 20l:V H The antibody or fragment thereof of any one of Concepts 1-19 (provided that if subject to Concept 9, then subject to Concept 91; if subject to Concept 13, then subject to Concept 131; if subject to Concept 16, then subject to Concept 161; if subject to Concept 17, then subject to Concept 171; if subject to Concept 18, then subject to Concept 181; and if subject to Concept 19, then subject to Concept 191), wherein the domain comprises the amino acid sequence of SEQ ID NO: 349, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 349.

[0351] In one embodiment, the amino acid sequence is at least 70% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 75% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 95% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 96% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 97% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 98% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 99% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 99.5% identical to the designated sequence.

[0352] Concept 21.V H 21. The antibody or fragment of any of concepts 1 to 20, comprising a first and a second copy of the domain.

[0353] Concept 22. A V comprising a CDRL1 sequence of SEQ ID NO: 37 or 40, or a CDRL1 sequence of SEQ ID NO: 37 or 40 containing no more than three amino acid substitutions. L 22. The antibody or fragment of any one of concepts 1 to 21, comprising a domain.

[0354] Concept 22a: V comprising the CDRL1 sequence of SEQ ID NO: 17 or 20, or the CDRL1 sequence of SEQ ID NO: 17 or 20 containing no more than three amino acid substitutions L The antibody or fragment thereof according to any one of Concepts 1 to 21 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9a; if it is subordinate to Concept 13, it is subordinate to Concept 13a; if it is subordinate to Concept 16, it is subordinate to Concept 16a; if it is subordinate to Concept 17, it is subordinate to Concept 17a; if it is subordinate to Concept 18, it is subordinate to Concept 18a; if it is subordinate to Concept 19, it is subordinate to Concept 19a; and if it is subordinate to Concept 20, it is subordinate to Concept 20a), comprising the domain.

[0355] Concept 22b: V comprising the CDRL1 sequence of SEQ ID NO: 62 or 65, or the CDRL1 sequence of SEQ ID NO: 62 or 65 containing no more than three amino acid substitutions L The antibody or fragment thereof according to any one of Concepts 1 to 21 (provided that if it is subject to Concept 9, it is subject to Concept 9b; if it is subject to Concept 13, it is subject to Concept 13b; if it is subject to Concept 16, it is subject to Concept 16b; if it is subject to Concept 17, it is subject to Concept 17b; if it is subject to Concept 18, it is subject to Concept 18b; if it is subject to Concept 19, it is subject to Concept 19b; and if it is subject to Concept 20, it is subject to Concept 20b), comprising the domain.

[0356] Concept 22c: V comprising the CDRL1 sequence of SEQ ID NO: 82 or 85, or the CDRL1 sequence of SEQ ID NO: 82 or 85 comprising two or one amino acid substitution(s). LThe antibody or fragment thereof according to any one of Concepts 1 to 21 (provided that if it is subject to Concept 9, it is subject to Concept 9c; if it is subject to Concept 13, it is subject to Concept 13c; if it is subject to Concept 16, it is subject to Concept 16c; if it is subject to Concept 17, it is subject to Concept 17c; if it is subject to Concept 18, it is subject to Concept 18c; if it is subject to Concept 19, it is subject to Concept 19c; and if it is subject to Concept 20, it is subject to Concept 20c), comprising the domain.

[0357] Concept 22d: V comprising the CDRL1 sequence of SEQ ID NO: 102 or 105, or the CDRL1 sequence of SEQ ID NO: 102 or 105 containing 5 or fewer amino acid substitutions L The antibody or fragment thereof according to any one of Concepts 1 to 21 (provided that if it is subject to Concept 9, it is subject to Concept 9d; if it is subject to Concept 13, it is subject to Concept 13d; if it is subject to Concept 16, it is subject to Concept 16d; if it is subject to Concept 17, it is subject to Concept 17d; if it is subject to Concept 18, it is subject to Concept 18d; if it is subject to Concept 19, it is subject to Concept 19d; and if it is subject to Concept 20, it is subject to Concept 20d), comprising the domain.

[0358] Concept 22e: A V comprising the CDRL1 sequence of SEQ ID NO: 122 or 125, or the CDRL1 sequence of SEQ ID NO: 122 or 125 containing two or one amino acid substitution(s). L The antibody or fragment thereof according to any one of Concepts 1 to 21 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9e; if it is subordinate to Concept 13, it is subordinate to Concept 13e; if it is subordinate to Concept 16, it is subordinate to Concept 16e; if it is subordinate to Concept 17, it is subordinate to Concept 17e; if it is subordinate to Concept 18, it is subordinate to Concept 18e; if it is subordinate to Concept 19, it is subordinate to Concept 19e; and if it is subordinate to Concept 20, it is subordinate to Concept 20e), comprising the domain.

[0359] Concept 22f: V comprising the CDRL1 sequence of SEQ ID NO: 162 or 165, or the CDRL1 sequence of SEQ ID NO: 162 or 165 containing 5 or fewer amino acid substitutions LThe antibody or fragment thereof according to any one of Concepts 1 to 21 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9f; if it is subordinate to Concept 13, it is subordinate to Concept 13f; if it is subordinate to Concept 16, it is subordinate to Concept 16f; if it is subordinate to Concept 17, it is subordinate to Concept 17f; if it is subordinate to Concept 18, it is subordinate to Concept 18f; if it is subordinate to Concept 19, it is subordinate to Concept 19f; and if it is subordinate to Concept 20, it is subordinate to Concept 20f), comprising the domain.

[0360] Concept 22g: A V comprising the CDRL1 sequence of SEQ ID NO: 182 or 185, or the CDRL1 sequence of SEQ ID NO: 182 or 185 containing 5 or fewer amino acid substitutions L The antibody or fragment thereof according to any one of Concepts 1 to 21 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9g; if it is subordinate to Concept 13, it is subordinate to Concept 13g; if it is subordinate to Concept 16, it is subordinate to Concept 16g; if it is subordinate to Concept 17, it is subordinate to Concept 17g; if it is subordinate to Concept 18, it is subordinate to Concept 18g; if it is subordinate to Concept 19, it is subordinate to Concept 19g; and if it is subordinate to Concept 20, it is subordinate to Concept 20g), comprising the domain.

[0361] Concept 22h: A V comprising the CDRL1 sequence of SEQ ID NO: 142 or 145, or the CDRL1 sequence of SEQ ID NO: 142 or 145 containing two or one amino acid substitution(s). L The antibody or fragment thereof according to any one of concepts 1 to 21 (provided that if it is subject to concept 9, it is subject to concept 9h; if it is subject to concept 13, it is subject to concept 13h; if it is subject to concept 16, it is subject to concept 16h; if it is subject to concept 17, it is subject to concept 17h; if it is subject to concept 18, it is subject to concept 18h; if it is subject to concept 19, it is subject to concept 19h; and if it is subject to concept 20, it is subject to concept 20h), comprising the domain.

[0362] Concept 22i: A V comprising the CDRL1 sequence of SEQ ID NO: 248 or 251, or the CDRL1 sequence of SEQ ID NO: 248 or 251 containing two or one amino acid substitution(s). LThe antibody or fragment thereof according to any one of Concepts 1 to 21 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9i; if it is subordinate to Concept 13, it is subordinate to Concept 13i; if it is subordinate to Concept 16, it is subordinate to Concept 16i; if it is subordinate to Concept 17, it is subordinate to Concept 17i; if it is subordinate to Concept 18, it is subordinate to Concept 18i; if it is subordinate to Concept 19, it is subordinate to Concept 19i; and if it is subordinate to Concept 20, it is subordinate to Concept 20i), comprising the domain.

[0363] Concept 22j: V comprising the CDRL1 sequence of SEQ ID NO: 268 or 271, or the CDRL1 sequence of SEQ ID NO: 268 or 271 containing two or one amino acid substitution(s). L The antibody or fragment thereof according to any one of Concepts 1 to 21 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9j; if it is subordinate to Concept 13, it is subordinate to Concept 13j; if it is subordinate to Concept 16, it is subordinate to Concept 16j; if it is subordinate to Concept 17, it is subordinate to Concept 17j; if it is subordinate to Concept 18, it is subordinate to Concept 18j; if it is subordinate to Concept 19, it is subordinate to Concept 19j; and if it is subordinate to Concept 20, it is subordinate to Concept 20j), comprising the domain.

[0364] Concept 22k: A V comprising the CDRL1 sequence of SEQ ID NO: 288 or 291, or the CDRL1 sequence of SEQ ID NO: 288 or 291 containing two or one amino acid substitution(s). L The antibody or fragment thereof according to any one of concepts 1 to 21 (provided that if it is subordinate to concept 9, it is subordinate to concept 9k; if it is subordinate to concept 13, it is subordinate to concept 13k; if it is subordinate to concept 16, it is subordinate to concept 16k; if it is subordinate to concept 17, it is subordinate to concept 17k; if it is subordinate to concept 18, it is subordinate to concept 18k; if it is subordinate to concept 19, it is subordinate to concept 19k; and if it is subordinate to concept 20, it is subordinate to concept 20k), comprising the domain.

[0365] Concept 221: A V comprising the CDRL1 sequence of SEQ ID NO: 353 or 356, or the CDRL1 sequence of SEQ ID NO: 353 or 356 containing two or one amino acid substitution(s). LThe antibody or fragment thereof according to any one of Concepts 1 to 21 (provided that if it is subject to Concept 9, it is subject to Concept 91; if it is subject to Concept 13, it is subject to Concept 131; if it is subject to Concept 16, it is subject to Concept 161; if it is subject to Concept 17, it is subject to Concept 171; if it is subject to Concept 18, it is subject to Concept 181; if it is subject to Concept 19, it is subject to Concept 191; and if it is subject to Concept 20, it is subject to Concept 201), comprising the domain.

[0366] Concept 23. A V comprising a CDRL2 sequence of SEQ ID NO: 38 or 41, or a CDRL2 sequence of SEQ ID NO: 38 or 41 containing two or one amino acid substitution(s), such as a CDRL2 sequence of SEQ ID NO: 50. L Domain or V L 23. The antibody or fragment of any of concepts 1 to 22, comprising a domain.

[0367] Concept 23a: A V comprising the CDRL2 sequence of SEQ ID NO: 18 or 21, or the CDRL2 sequence of SEQ ID NO: 18 or 21 containing two or one amino acid substitution(s). L Domain or V L The antibody or fragment thereof according to any one of Concepts 1 to 22 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9a; if it is subordinate to Concept 13, it is subordinate to Concept 13a; if it is subordinate to Concept 16, it is subordinate to Concept 16a; if it is subordinate to Concept 17, it is subordinate to Concept 17a; if it is subordinate to Concept 18, it is subordinate to Concept 18a; if it is subordinate to Concept 19, it is subordinate to Concept 19a; if it is subordinate to Concept 20, it is subordinate to Concept 20a; and if it is subordinate to Concept 22, it is subordinate to Concept 22a), comprising the domain.

[0368] Concept 23b: V comprising the CDRL2 sequence of SEQ ID NO: 63 or 66, or the CDRL2 sequence of SEQ ID NO: 63 or 66 containing one amino acid substitution L Domain or V LThe antibody or fragment thereof according to any one of Concepts 1 to 22 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9b; if it is subordinate to Concept 13, it is subordinate to Concept 13b; if it is subordinate to Concept 16, it is subordinate to Concept 16b; if it is subordinate to Concept 17, it is subordinate to Concept 17b; if it is subordinate to Concept 18, it is subordinate to Concept 18b; if it is subordinate to Concept 19, it is subordinate to Concept 19b; if it is subordinate to Concept 20, it is subordinate to Concept 20b; and if it is subordinate to Concept 22, it is subordinate to Concept 22b), comprising the domain.

[0369] Concept 23c: A V comprising the CDRL2 sequence of SEQ ID NO: 83 or 86, or the CDRL2 sequence of SEQ ID NO: 83 or 86 containing one amino acid substitution L Domain or V L The antibody or fragment thereof according to any one of concepts 1 to 22 (provided that if it is subject to concept 9, it is subject to concept 9c; if it is subject to concept 13, it is subject to concept 13c; if it is subject to concept 16, it is subject to concept 16c; if it is subject to concept 17, it is subject to concept 17c; if it is subject to concept 18, it is subject to concept 18c; if it is subject to concept 19, it is subject to concept 19c; if it is subject to concept 20, it is subject to concept 20c; and if it is subject to concept 22, it is subject to concept 22c), comprising the domain.

[0370] Concept 23d: A V comprising the CDRL2 sequence of SEQ ID NO: 103 or 106, or the CDRL2 sequence of SEQ ID NO: 103 or 106 containing one amino acid substitution L Domain or V L The antibody or fragment thereof according to any one of concepts 1 to 22 (provided that if it is subject to concept 9, it is subject to concept 9d; if it is subject to concept 13, it is subject to concept 13d; if it is subject to concept 16, it is subject to concept 16d; if it is subject to concept 17, it is subject to concept 17d; if it is subject to concept 18, it is subject to concept 18d; if it is subject to concept 19, it is subject to concept 19d; if it is subject to concept 20, it is subject to concept 20d; and if it is subject to concept 22, it is subject to concept 22d), comprising the domain.

[0371] Concept 23e: A V comprising the CDRL2 sequence of SEQ ID NO: 123 or 126, or the CDRL2 sequence of SEQ ID NO: 123 or 126 containing one amino acid substitution. L Domain or V L The antibody or fragment thereof according to any one of concepts 1 to 22 (provided that if it is subordinate to concept 9, it is subordinate to concept 9e; if it is subordinate to concept 13, it is subordinate to concept 13e; if it is subordinate to concept 16, it is subordinate to concept 16e; if it is subordinate to concept 17, it is subordinate to concept 17e; if it is subordinate to concept 18, it is subordinate to concept 18e; if it is subordinate to concept 19, it is subordinate to concept 19e; if it is subordinate to concept 20, it is subordinate to concept 20e; and if it is subordinate to concept 22, it is subordinate to concept 22e), comprising the domain.

[0372] Concept 23f: A V comprising the CDRL2 sequence of SEQ ID NO: 153 or 156, or the CDRL2 sequence of SEQ ID NO: 153 or 156 containing one amino acid substitution L Domain or V L The antibody or fragment thereof according to any one of concepts 1 to 22 (provided that if it is subordinate to concept 9, it is subordinate to concept 9f; if it is subordinate to concept 13, it is subordinate to concept 13f; if it is subordinate to concept 16, it is subordinate to concept 16f; if it is subordinate to concept 17, it is subordinate to concept 17f; if it is subordinate to concept 18, it is subordinate to concept 18f; if it is subordinate to concept 19, it is subordinate to concept 19f; if it is subordinate to concept 20, it is subordinate to concept 20f; and if it is subordinate to concept 22, it is subordinate to concept 22f), comprising the domain.

[0373] Concept 23g: A V comprising the CDRL2 sequence of SEQ ID NO: 183 or 186, or the CDRL2 sequence of SEQ ID NO: 183 or 186 containing one amino acid substitution L Domain or V LThe antibody or fragment thereof according to any one of Concepts 1 to 22 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9g; if it is subordinate to Concept 13, it is subordinate to Concept 13g; if it is subordinate to Concept 16, it is subordinate to Concept 16g; if it is subordinate to Concept 17, it is subordinate to Concept 17g; if it is subordinate to Concept 18, it is subordinate to Concept 18g; if it is subordinate to Concept 19, it is subordinate to Concept 19g; if it is subordinate to Concept 20, it is subordinate to Concept 20g; and if it is subordinate to Concept 22, it is subordinate to Concept 22g), comprising the domain.

[0374] Concept 23h: A V comprising the CDRL2 sequence of SEQ ID NO: 143 or 146, or the CDRL2 sequence of SEQ ID NO: 143 or 146 containing one amino acid substitution L Domain or V L The antibody or fragment thereof according to any one of concepts 1 to 22 (provided that if it is subject to concept 9, it is subject to concept 9h; if it is subject to concept 13, it is subject to concept 13h; if it is subject to concept 16, it is subject to concept 16h; if it is subject to concept 17, it is subject to concept 17h; if it is subject to concept 18, it is subject to concept 18h; if it is subject to concept 19, it is subject to concept 19h; if it is subject to concept 20, it is subject to concept 20h; and if it is subject to concept 22, it is subject to concept 22h), comprising the domain.

[0375] Concept 23i: A V comprising the CDRL2 sequence of SEQ ID NO: 249 or 252, or the CDRL2 sequence of SEQ ID NO: 249 or 252 containing one amino acid substitution L Domain or V L The antibody or fragment thereof according to any one of Concepts 1 to 22 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9i; if it is subordinate to Concept 13, it is subordinate to Concept 13i; if it is subordinate to Concept 16, it is subordinate to Concept 16i; if it is subordinate to Concept 17, it is subordinate to Concept 17i; if it is subordinate to Concept 18, it is subordinate to Concept 18i; if it is subordinate to Concept 19, it is subordinate to Concept 19i; if it is subordinate to Concept 20, it is subordinate to Concept 20i; and if it is subordinate to Concept 22, it is subordinate to Concept 22i), comprising the domain.

[0376] Concept 23j: A V comprising the CDRL2 sequence of SEQ ID NO: 269 or 272, or the CDRL2 sequence of SEQ ID NO: 269 or 272 containing one amino acid substitution L Domain or V L The antibody or fragment thereof according to any one of Concepts 1 to 22 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9j; if it is subordinate to Concept 13, it is subordinate to Concept 13j; if it is subordinate to Concept 16, it is subordinate to Concept 16j; if it is subordinate to Concept 17, it is subordinate to Concept 17j; if it is subordinate to Concept 18, it is subordinate to Concept 18j; if it is subordinate to Concept 19, it is subordinate to Concept 19j; if it is subordinate to Concept 20, it is subordinate to Concept 20j; and if it is subordinate to Concept 22, it is subordinate to Concept 22j), comprising the domain.

[0377] Concept 23k: A V comprising the CDRL2 sequence of SEQ ID NO: 289 or 292, or the CDRL2 sequence of SEQ ID NO: 289 or 292 containing one amino acid substitution L Domain or V L The antibody or fragment thereof according to any one of concepts 1 to 22 (provided that if it is subordinate to concept 9, it is subordinate to concept 9k; if it is subordinate to concept 13, it is subordinate to concept 13k; if it is subordinate to concept 16, it is subordinate to concept 16k; if it is subordinate to concept 17, it is subordinate to concept 17k; if it is subordinate to concept 18, it is subordinate to concept 18k; if it is subordinate to concept 19, it is subordinate to concept 19k; if it is subordinate to concept 20, it is subordinate to concept 20k; and if it is subordinate to concept 22, it is subordinate to concept 22k), comprising the domain.

[0378] Concept 231: A V comprising the CDRL2 sequence of SEQ ID NO: 354 or 357, or the CDRL2 sequence of SEQ ID NO: 354 or 357 containing one amino acid substitution L Domain or V LThe antibody or fragment thereof according to any one of concepts 1 to 22 (provided that if it is subject to concept 9, it is subject to concept 91; if it is subject to concept 13, it is subject to concept 131; if it is subject to concept 16, it is subject to concept 161; if it is subject to concept 17, it is subject to concept 171; if it is subject to concept 18, it is subject to concept 181; if it is subject to concept 19, it is subject to concept 191; if it is subject to concept 20, it is subject to concept 201; and if it is subject to concept 22, it is subject to concept 221), comprising the domain.

[0379] Concept 24. A V comprising a CDRL3 sequence of SEQ ID NO: 39 or 42, or a CDRL3 sequence of SEQ ID NO: 39 or 42 containing no more than four amino acid substitutions. L Domain or V L 24. The antibody or fragment of any of concepts 1 to 23, comprising a domain.

[0380] Concept 24a: V comprising a CDRL3 sequence of SEQ ID NO: 19 or 22, or a CDRL3 sequence of SEQ ID NO: 19 or 22 containing no more than four amino acid substitutions L Domain or V L The antibody or fragment thereof according to any one of concepts 1 to 23 (provided that if it is subordinate to concept 9, it is subordinate to concept 9a; if it is subordinate to concept 13, it is subordinate to concept 13a; if it is subordinate to concept 16, it is subordinate to concept 16a; if it is subordinate to concept 17, it is subordinate to concept 17a; if it is subordinate to concept 18, it is subordinate to concept 18a; if it is subordinate to concept 19, it is subordinate to concept 19a; if it is subordinate to concept 20, it is subordinate to concept 20a; if it is subordinate to concept 22, it is subordinate to concept 22a; and if it is subordinate to concept 23, it is subordinate to concept 23a), comprising the domain.

[0381] Concept 24b: V comprising a CDRL3 sequence of SEQ ID NO: 64 or 67, or a CDRL3 sequence of SEQ ID NO: 64 or 67 containing no more than four amino acid substitutions L Domain or V LThe antibody or fragment thereof according to any one of concepts 1 to 23 (provided that if it is subordinate to concept 9, it is subordinate to concept 9b; if it is subordinate to concept 13, it is subordinate to concept 13b; if it is subordinate to concept 16, it is subordinate to concept 16b; if it is subordinate to concept 17, it is subordinate to concept 17b; if it is subordinate to concept 18, it is subordinate to concept 18b; if it is subordinate to concept 19, it is subordinate to concept 19b; if it is subordinate to concept 20, it is subordinate to concept 20b; if it is subordinate to concept 22, it is subordinate to concept 22b; and if it is subordinate to concept 23, it is subordinate to concept 23b), comprising the domain.

[0382] Concept 24c: A V comprising a CDRL3 sequence of SEQ ID NO: 84 or 87, or a CDRL3 sequence of SEQ ID NO: 84 or 87 containing no more than four amino acid substitutions. L Domain or V L The antibody or fragment thereof according to any one of concepts 1 to 23 (provided that if it is subject to concept 9, it is subject to concept 9c; if it is subject to concept 13, it is subject to concept 13c; if it is subject to concept 16, it is subject to concept 16c; if it is subject to concept 17, it is subject to concept 17c; if it is subject to concept 18, it is subject to concept 18c; if it is subject to concept 19, it is subject to concept 19c; if it is subject to concept 20, it is subject to concept 20c; if it is subject to concept 22, it is subject to concept 22c; and if it is subject to concept 23, it is subject to concept 23c), comprising the domain.

[0383] Concept 24d: V comprising a CDRL3 sequence of SEQ ID NO: 104 or 107, or a CDRL3 sequence of SEQ ID NO: 104 or 107 containing no more than four amino acid substitutions. L Domain or V LThe antibody or fragment thereof according to any one of concepts 1 to 23 (provided that if it is subject to concept 9, it is subject to concept 9d; if it is subject to concept 13, it is subject to concept 13d; if it is subject to concept 16, it is subject to concept 16d; if it is subject to concept 17, it is subject to concept 17d; if it is subject to concept 18, it is subject to concept 18d; if it is subject to concept 19, it is subject to concept 19d; if it is subject to concept 20, it is subject to concept 20d; if it is subject to concept 22, it is subject to concept 22d; and if it is subject to concept 23, it is subject to concept 23d), comprising the domain.

[0384] Concept 24e: A V comprising a CDRL3 sequence of SEQ ID NO: 124 or 127, or a CDRL3 sequence of SEQ ID NO: 124 or 127 containing no more than four amino acid substitutions. L Domain or V L The antibody or fragment thereof according to any one of concepts 1 to 23 (provided that if it is subordinate to concept 9, it is subordinate to concept 9e; if it is subordinate to concept 13, it is subordinate to concept 13e; if it is subordinate to concept 16, it is subordinate to concept 16e; if it is subordinate to concept 17, it is subordinate to concept 17e; if it is subordinate to concept 18, it is subordinate to concept 18e; if it is subordinate to concept 19, it is subordinate to concept 19e; if it is subordinate to concept 20, it is subordinate to concept 20e; if it is subordinate to concept 22, it is subordinate to concept 22e; and if it is subordinate to concept 23, it is subordinate to concept 23e), comprising the domain.

[0385] Concept 24f: A V comprising a CDRL3 sequence of SEQ ID NO: 164 or 167, or a CDRL3 sequence of SEQ ID NO: 164 or 167 containing no more than four amino acid substitutions L Domain or V LThe antibody or fragment thereof according to any one of concepts 1 to 23 (provided that if it is subordinate to concept 9, it is subordinate to concept 9f; if it is subordinate to concept 13, it is subordinate to concept 13f; if it is subordinate to concept 16, it is subordinate to concept 16f; if it is subordinate to concept 17, it is subordinate to concept 17f; if it is subordinate to concept 18, it is subordinate to concept 18f; if it is subordinate to concept 19, it is subordinate to concept 19f; if it is subordinate to concept 20, it is subordinate to concept 20f; if it is subordinate to concept 22, it is subordinate to concept 22f; and if it is subordinate to concept 23, it is subordinate to concept 23f), comprising the domain.

[0386] Concept 24g: A V comprising the CDRL3 sequence of SEQ ID NO: 184 or 187, or the CDRL3 sequence of SEQ ID NO: 184 or 187 containing no more than four amino acid substitutions. L Domain or V L The antibody or fragment thereof according to any one of Concepts 1 to 23 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9g; if it is subordinate to Concept 13, it is subordinate to Concept 13g; if it is subordinate to Concept 16, it is subordinate to Concept 16g; if it is subordinate to Concept 17, it is subordinate to Concept 17g; if it is subordinate to Concept 18, it is subordinate to Concept 18g; if it is subordinate to Concept 19, it is subordinate to Concept 19g; if it is subordinate to Concept 20, it is subordinate to Concept 20g; if it is subordinate to Concept 22, it is subordinate to Concept 22g; and if it is subordinate to Concept 23, it is subordinate to Concept 23g), comprising the domain.

[0387] Concept 24h: A ​​V comprising the CDRL3 sequence of SEQ ID NO: 144 or 147, or the CDRL3 sequence of SEQ ID NO: 144 or 147 containing no more than four amino acid substitutions L Domain or V LThe antibody or fragment thereof according to any one of concepts 1 to 23 (provided that if it is subject to concept 9, it is subject to concept 9h; if it is subject to concept 13, it is subject to concept 13h; if it is subject to concept 16, it is subject to concept 16h; if it is subject to concept 17, it is subject to concept 17h; if it is subject to concept 18, it is subject to concept 18h; if it is subject to concept 19, it is subject to concept 19h; if it is subject to concept 20, it is subject to concept 20h; if it is subject to concept 22, it is subject to concept 22h; and if it is subject to concept 23, it is subject to concept 23h), comprising the domain.

[0388] Concept 24i: A V comprising a CDRL3 sequence of SEQ ID NO: 250 or 253, or a CDRL3 sequence of SEQ ID NO: 250 or 253 containing no more than four amino acid substitutions. L Domain or V L The antibody or fragment thereof according to any one of Concepts 1 to 23 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9i; if it is subordinate to Concept 13, it is subordinate to Concept 13i; if it is subordinate to Concept 16, it is subordinate to Concept 16i; if it is subordinate to Concept 17, it is subordinate to Concept 17i; if it is subordinate to Concept 18, it is subordinate to Concept 18i; if it is subordinate to Concept 19, it is subordinate to Concept 19i; if it is subordinate to Concept 20, it is subordinate to Concept 20i; if it is subordinate to Concept 22, it is subordinate to Concept 22i; and if it is subordinate to Concept 23, it is subordinate to Concept 23i), comprising the domain.

[0389] Concept 24j: A V comprising a CDRL3 sequence of SEQ ID NO: 270 or 273, or a CDRL3 sequence of SEQ ID NO: 270 or 273 containing no more than four amino acid substitutions. L Domain or V LThe antibody or fragment thereof according to any one of Concepts 1 to 23 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 9j; if it is subordinate to Concept 13, it is subordinate to Concept 13j; if it is subordinate to Concept 16, it is subordinate to Concept 16j; if it is subordinate to Concept 17, it is subordinate to Concept 17j; if it is subordinate to Concept 18, it is subordinate to Concept 18j; if it is subordinate to Concept 19, it is subordinate to Concept 19j; if it is subordinate to Concept 20, it is subordinate to Concept 20j; if it is subordinate to Concept 22, it is subordinate to Concept 22j; and if it is subordinate to Concept 23, it is subordinate to Concept 23j), comprising the domain.

[0390] Concept 24k: A V comprising the CDRL3 sequence of SEQ ID NO: 290 or 293, or the CDRL3 sequence of SEQ ID NO: 290 or 293 containing no more than four amino acid substitutions. L Domain or V L The antibody or fragment thereof according to any one of concepts 1 to 23 (provided that if it is subordinate to concept 9, it is subordinate to concept 9k; if it is subordinate to concept 13, it is subordinate to concept 13k; if it is subordinate to concept 16, it is subordinate to concept 16k; if it is subordinate to concept 17, it is subordinate to concept 17k; if it is subordinate to concept 18, it is subordinate to concept 18k; if it is subordinate to concept 19, it is subordinate to concept 19k; if it is subordinate to concept 20, it is subordinate to concept 20k; if it is subordinate to concept 22, it is subordinate to concept 22k; and if it is subordinate to concept 23, it is subordinate to concept 23k), comprising the domain.

[0391] Concept 241: A V comprising the CDRL3 sequence of SEQ ID NO: 355 or 358, or the CDRL3 sequence of SEQ ID NO: 355 or 358 containing no more than four amino acid substitutions. L Domain or V LThe antibody or fragment thereof according to any one of Concepts 1 to 23 (provided that if it is subordinate to Concept 9, it is subordinate to Concept 91; if it is subordinate to Concept 13, it is subordinate to Concept 131; if it is subordinate to Concept 16, it is subordinate to Concept 161; if it is subordinate to Concept 17, it is subordinate to Concept 171; if it is subordinate to Concept 18, it is subordinate to Concept 181; if it is subordinate to Concept 19, it is subordinate to Concept 191; if it is subordinate to Concept 20, it is subordinate to Concept 201; if it is subordinate to Concept 22, it is subordinate to Concept 221; and if it is subordinate to Concept 23, it is subordinate to Concept 231), comprising the domain.

[0392] Concept 25. A VL domain comprising the amino acid sequence of SEQ ID NO: 43, or a light chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 43 (e.g., a VL domain sequence in a light chain sequence of SEQ ID NO: 50, 51, or 298). L Domain or V L 25. The antibody or fragment of any of concepts 1 to 24, comprising a domain.

[0393] Concept 25a:V L 25. The antibody or fragment thereof according to any one of Concepts 1 to 24 (provided that when subject to Concept 9, it is subject to Concept 9a; when subject to Concept 13, it is subject to Concept 13a; when subject to Concept 16, it is subject to Concept 16a; when subject to Concept 17, it is subject to Concept 17a; when subject to Concept 18, it is subject to Concept 18a; when subject to Concept 19, it is subject to Concept 19a; when subject to Concept 20, it is subject to Concept 20a; when subject to Concept 22, it is subject to Concept 22a; when subject to Concept 23, it is subject to Concept 23a; and when subject to Concept 24, it is subject to Concept 24a), wherein the domain comprises the amino acid sequence of SEQ ID NO:23 or a light chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO:23.

[0394] Concept 25b:V L25. The antibody or fragment thereof according to any one of Concepts 1 to 24 (provided that when subject to Concept 9, it is subject to Concept 9b; when subject to Concept 13, it is subject to Concept 13b; when subject to Concept 16, it is subject to Concept 16b; when subject to Concept 17, it is subject to Concept 17b; when subject to Concept 18, it is subject to Concept 18b; when subject to Concept 19, it is subject to Concept 19b; when subject to Concept 20, it is subject to Concept 20b; when subject to Concept 22, it is subject to Concept 22a; when subject to Concept 23, it is subject to Concept 23b; and when subject to Concept 24, it is subject to Concept 24b), wherein the domain comprises the amino acid sequence of SEQ ID NO:68 or a light chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO:68.

[0395] Concept 25c:V L 25. The antibody or fragment thereof of any one of Concepts 1-24 (provided that when subject to Concept 9, it is subject to Concept 9c; when subject to Concept 13, it is subject to Concept 13c; when subject to Concept 16, it is subject to Concept 16c; when subject to Concept 17, it is subject to Concept 17c; when subject to Concept 18, it is subject to Concept 18c; when subject to Concept 19, it is subject to Concept 19c; when subject to Concept 20, it is subject to Concept 20c; when subject to Concept 22, it is subject to Concept 22c; when subject to Concept 23, it is subject to Concept 23c; and when subject to Concept 24, it is subject to Concept 24c), wherein the domain comprises the amino acid sequence of SEQ ID NO: 88 or a light chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 88.

[0396] Concept 25d:V L25. The antibody or fragment thereof of any one of Concepts 1-24 (provided that when subject to Concept 9, it is subject to Concept 9d; when subject to Concept 13, it is subject to Concept 13d; when subject to Concept 16, it is subject to Concept 16d; when subject to Concept 17, it is subject to Concept 17d; when subject to Concept 18, it is subject to Concept 18d; when subject to Concept 19, it is subject to Concept 19d; when subject to Concept 20, it is subject to Concept 20d; when subject to Concept 22, it is subject to Concept 22d; when subject to Concept 23, it is subject to Concept 23d; and when subject to Concept 24, it is subject to Concept 24d), wherein the domain comprises the amino acid sequence of SEQ ID NO: 108 or a light chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 108.

[0397] Concept 25e:V L 25. The antibody or fragment thereof of any one of Concepts 1-24 (provided that if subject to Concept 9, then subject to Concept 9e; if subject to Concept 13, then subject to Concept 13e; if subject to Concept 16, then subject to Concept 16e; if subject to Concept 17, then subject to Concept 17e; if subject to Concept 18, then subject to Concept 18e; if subject to Concept 19, then subject to Concept 19e; if subject to Concept 20, then subject to Concept 20e; if subject to Concept 22, then subject to Concept 22e; if subject to Concept 23, then subject to Concept 23e; and if subject to Concept 24, then subject to Concept 24e), wherein the domain comprises the amino acid sequence of SEQ ID NO: 128 or a light chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 128.

[0398] Concept 25f:V LThe antibody or fragment thereof according to any one of Concepts 1 to 24 (provided that when subject to Concept 9, it is subject to Concept 9f; when subject to Concept 13, it is subject to Concept 13f; when subject to Concept 16, it is subject to Concept 16f; when subject to Concept 17, it is subject to Concept 17f; when subject to Concept 18, it is subject to Concept 18f; when subject to Concept 19, it is subject to Concept 19f; when subject to Concept 20, it is subject to Concept 20f; when subject to Concept 22, it is subject to Concept 22f; when subject to Concept 23, it is subject to Concept 23f; and when subject to Concept 24, it is subject to Concept 24f), wherein the domain comprises the amino acid sequence of SEQ ID NO: 168 or a light chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 168.

[0399] Concept 25g:V L 25. The antibody or fragment thereof of any one of Concepts 1-24 (provided that if subject to Concept 9, then subject to Concept 9g; if subject to Concept 13, then subject to Concept 13g; if subject to Concept 16, then subject to Concept 16g; if subject to Concept 17, then subject to Concept 17g; if subject to Concept 18, then subject to Concept 18g; if subject to Concept 19, then subject to Concept 19g; if subject to Concept 20, then subject to Concept 20g; if subject to Concept 22, then subject to Concept 22g; if subject to Concept 23, then subject to Concept 23g; and if subject to Concept 24, then subject to Concept 24g), wherein the domain comprises the amino acid sequence of SEQ ID NO: 188 or a light chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 188.

[0400] Concept 25h:V LThe antibody or fragment thereof of any one of Concepts 1-24 (provided that if subject to Concept 9, then subject to Concept 9h; if subject to Concept 13, then subject to Concept 13h; if subject to Concept 16, then subject to Concept 16h; if subject to Concept 17, then subject to Concept 17h; if subject to Concept 18, then subject to Concept 18h; if subject to Concept 19, then subject to Concept 19h; if subject to Concept 20, then subject to Concept 20h; if subject to Concept 22, then subject to Concept 22h; if subject to Concept 23, then subject to Concept 23h; and if subject to Concept 24, then subject to Concept 24h), wherein the domain comprises the amino acid sequence of SEQ ID NO: 148 or a light chain variable domain amino acid sequence at least 80% (e.g., at least 90% or at least 90%) identical to SEQ ID NO: 148.

[0401] Concept 25i:V L The antibody or fragment thereof of any one of Concepts 1-24 (provided that if subject to Concept 9, then subject to Concept 9i; if subject to Concept 13, then subject to Concept 13i; if subject to Concept 16, then subject to Concept 16i; if subject to Concept 17, then subject to Concept 17i; if subject to Concept 18, then subject to Concept 18i; if subject to Concept 19, then subject to Concept 19i; if subject to Concept 20, then subject to Concept 20i; if subject to Concept 22, then subject to Concept 22i; if subject to Concept 23, then subject to Concept 23i; and if subject to Concept 24, then subject to Concept 24i), wherein the domain comprises the amino acid sequence of SEQ ID NO:254 or a light chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO:254.

[0402] Concept 25j:V LThe antibody or fragment thereof of any one of Concepts 1-24 (provided that when subject to Concept 9, it is subject to Concept 9j; when subject to Concept 13, it is subject to Concept 13j; when subject to Concept 16, it is subject to Concept 16j; when subject to Concept 17, it is subject to Concept 17j; when subject to Concept 18, it is subject to Concept 18j; when subject to Concept 19, it is subject to Concept 19j; when subject to Concept 20, it is subject to Concept 20j; when subject to Concept 22, it is subject to Concept 22j; when subject to Concept 23, it is subject to Concept 23j; and when subject to Concept 24, it is subject to Concept 24j), wherein the domain comprises the amino acid sequence of SEQ ID NO:274 or a light chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO:274.

[0403] Concept 25k:V L The antibody or fragment thereof of any one of Concepts 1-24 (provided that if subject to Concept 9, then subject to Concept 9k; if subject to Concept 13, then subject to Concept 13k; if subject to Concept 16, then subject to Concept 16k; if subject to Concept 17, then subject to Concept 17k; if subject to Concept 18, then subject to Concept 18k; if subject to Concept 19, then subject to Concept 19k; if subject to Concept 20, then subject to Concept 20k; if subject to Concept 22, then subject to Concept 22k; if subject to Concept 23, then subject to Concept 23k; and if subject to Concept 24, then subject to Concept 24k), wherein the domain comprises the amino acid sequence of SEQ ID NO:294 or a light chain variable domain amino acid sequence that is at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO:294.

[0404] Concept 25l:V LThe antibody or fragment thereof of any one of Concepts 1-24 (provided that if subject to Concept 9, then subject to Concept 91; if subject to Concept 13, then subject to Concept 131; if subject to Concept 16, then subject to Concept 161; if subject to Concept 17, then subject to Concept 171; if subject to Concept 18, then subject to Concept 181; if subject to Concept 19, then subject to Concept 191; if subject to Concept 20, then subject to Concept 201; if subject to Concept 22, then subject to Concept 221; if subject to Concept 23, then subject to Concept 231; and if subject to Concept 24, then subject to Concept 241), wherein the domain comprises the amino acid sequence of SEQ ID NO: 359, or a light chain variable domain amino acid sequence at least 80% (e.g., at least 85% or at least 90%) identical to SEQ ID NO: 359.

[0405] In one embodiment, the amino acid sequence is at least 70% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 75% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 95% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 96% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 97% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 98% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 99% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 99.5% identical to the designated sequence.

[0406] Concept 26.V L Domain or V L 22. The antibody or fragment of any one of concepts 12 to 21, comprising a first and a second copy of the domain.

[0407] Concept 27. The antibody or fragment of any of concepts 1-26, which specifically binds to cynomolgus PD-L1 as defined by SEQ ID NO:2.

[0408] In one embodiment, the antibody or fragment binds to cynomolgus PD-L1 with an affinity of less than 1 nM (e.g., 1 nM to 0.01 pM, or 1 nM to 0.1 pM, or 1 nM to 1 pM). In one embodiment, the antibody or fragment binds to cynomolgus PD-L1 with an affinity of less than 10 nM (e.g., 10 nM to 0.01 pM, or 10 nM to 0.1 pM, or 10 nM to 1 pM). In one embodiment, the antibody or fragment binds to cynomolgus PD-L1 with an affinity of less than 0.1 nM (e.g., 0.1 nM to 0.01 pM, or 0.1 nM to 0.1 pM, or 0.1 nM to 1 pM). In one embodiment, the antibody or fragment binds to cynomolgus PD-L1 with an affinity of less than 0.01 nM (e.g., 0.011 nM to 0.01 pM or 0.01 nM to 0.1 pM).

[0409] In one embodiment, the antibody or fragment binds to cynomolgus PD-L1 with an affinity that is within 2-fold of its affinity to hPD-L1. In one embodiment, the antibody or fragment binds to cynomolgus PD-L1 with an affinity that is within 4-fold of its affinity to hPD-L1. In one embodiment, the antibody or fragment binds to cynomolgus PD-L1 with an affinity that is within 5-fold of its affinity to hPD-L1. In one embodiment, the antibody or fragment binds to cynomolgus PD-L1 with an affinity that is within 6-fold of its affinity to hPD-L1. In one embodiment, the antibody or fragment binds to cynomolgus PD-L1 with an affinity that is within 8-fold of its affinity to hPD-L1. In one embodiment, the antibody or fragment binds to cynomolgus PD-L1 with an affinity that is within 10-fold of its affinity to hPD-L1.

[0410] In one embodiment, the antibody or fragment does not detectably bind to cynomolgus monkey PD-L1. In one embodiment, the antibody or fragment does not detectably bind to murine PD-L1.

[0411] In one embodiment, the antibody or fragment binds to mouse PD-L1 with an affinity of less than 1 nM (e.g., 1 nM to 0.01 pM, or 1 nM to 0.1 pM, or 1 nM to 1 pM). In one embodiment, the antibody or fragment binds to mouse PD-L1 with an affinity of less than 10 nM (e.g., 10 nM to 0.01 pM, or 10 nM to 0.1 pM, or 10 nM to 1 pM). In one embodiment, the antibody or fragment binds to mouse PD-L1 with an affinity of less than 0.1 nM (e.g., 0.1 nM to 0.01 pM, or 0.1 nM to 0.1 pM, or 0.1 nM to 1 pM). In one embodiment, the antibody or fragment binds to mouse PD-L1 with an affinity of less than 0.01 nM (e.g., 0.011 nM to 0.01 pM or 0.01 nM to 0.1 pM).

[0412] Concept 28. The antibody or fragment of concepts 1-27, wherein the antibody or fragment comprises a kappa light chain.

[0413] The kappa light chain constant region amino acid and nucleotide sequences can be found in SEQ ID NOs:206 and 215.

[0414] In one embodiment, the light chain can be a lambda light chain. The lambda light chain constant region amino acid and nucleotide sequences can be found in SEQ ID NOs: 216-237, and SEQ ID NOs: 535, 536, and 538.

[0415] Concept 29. The amino acid substitution is a conservative amino acid substitution, and optionally, the conservative substitution is: 1) Alanine (A), serine (S), threonine (T), 2) Aspartic acid (D), glutamic acid (E), 3) Asparagine (N), Glutamine (Q), 4) Arginine (R), Lysine (K), 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V), and 6) The antibody or fragment of any one of concepts 9-28, which may be from one of six groups selected from phenylalanine (F), tyrosine (Y), tryptophan (W), each group containing amino acids that are conservative substitutions for one another. Conservative substitutions may be as described above in Concept 9.

[0416] Concept 30. The antibody or fragment of any of Concepts 1-29, wherein the antibody or fragment comprises a constant region, e.g., a human constant region, e.g., an effector-null human constant region, e.g., an IgG4 constant region or an IgG1 constant region, optionally wherein the constant region is IgG4-PE (SEQ ID NO: 199), or a deleted IgG1 as defined in SEQ ID NO: 205.

[0417] In other embodiments, the antibody or fragment has any of the isotypes or constant regions defined herein above. In one embodiment, the constant region is wild-type human IgG1 (SEQ ID NO: 340). For example, the constant region may be an effector-enabled IgG1 constant region, optionally having ADCC and / or CDC activity. In one embodiment, the constant region has been engineered for enhanced ADCC and / or CDC and / or ADCP. In another embodiment, the constant region has been engineered for enhanced effector function.

[0418] The IgG4 constant region may be any of the IgG4 constant region amino acid sequences or may be encoded by any of the nucleic acid sequences of SEQ ID NOs: 192 to 203. The heavy chain constant region may be an IgG4 containing both the Leu235Glu mutation and the Ser228Pro mutation. This "IgG4-PE" heavy chain constant region (encoded by SEQ ID NOs: 198, 199, 200, and 201) is effector null.

[0419] An alternative effector-null human constant region is a deleted IgG1, that is an IgG1*01 allele (e.g., encoded by LAGA, SEQ ID NO: 204, SEQ ID NO: 205) comprising a L235A and / or a G237A mutation. In one embodiment, an antibody or antibody fragment disclosed herein comprises an IgG1 heavy chain constant region, the sequence containing an alanine at position 235 and / or 237 (EU index numbering).

[0420] The antibody-dependent cellular phagocytosis (ADCP) mechanism is discussed in Gul et al., "Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer," Cancer Res., 75(23), December 1, 2015.

[0421] Efficacy, Efficacy The potency of Fc-mediated effects can be enhanced by engineering the Fc domain through a variety of established techniques. Such methods increase affinity for certain Fc receptors, thereby creating a potentially diverse profile of enhanced activation. This can be achieved by modifying one or several amino acid residues (e.g., as described in Lazar et al., 2006, Proc. Natl. Acad. Sci. USA, Mar. 14;103(11):4005-10; the modifications disclosed therein are incorporated herein by reference). IgG1 constant regions containing specific mutations or altered glycosylation on Asn297 (e.g., N297Q, EU index numbering) have been shown to enhance binding to Fc receptors. In one embodiment, such mutations are at one or more residues selected from residues 239, 332, and 330 for the human IgG1 constant region (or equivalent positions in other IgG isotypes). In one embodiment, the antibody or fragment comprises a human IgG1 constant region with one or more mutations independently selected from N297Q, S239D, I332E, and A330L (EU index numbering).

[0422] In another embodiment, increased affinity for Fc receptors is achieved by altering the native glycosylation profile of the Fc domain, for example, by generating hypofucosylated or defucosylated variants (as described in Natsume et al., 2009, Drug Des. Devel. Ther., 3:7-16 or Zhou Q., Biotechnol. Bioeng., 2008, Feb 15, 99(3):652-65, the modifications described therein are incorporated herein by reference). Nonfucosylated antibodies have the tri-mannosyl core structure of the complex N-glycan of Fc that does not contain a fucose residue. These glycoengineered antibodies, lacking the core fucose residue from the Fc N-glycan, may exhibit stronger ADCC than their fucosylated counterparts due to enhanced FcγRIIIa binding ability. For example, to increase ADCC, residues in the hinge region can be modified to increase binding to Fc-γRIII (see, e.g., Shields et al., 2001, J. Biol. Chem., Mar 2;276(9):6591-604; the modifications described therein are incorporated herein by reference). Thus, in one embodiment, the antibody or fragment comprises a human IgG heavy chain constant region that is a mutant version of the wild-type human IgG heavy chain constant region, wherein the mutant human IgG heavy chain constant region binds to a human Fcγ receptor selected from the group consisting of FcyRIIB and FcyRIIA with a higher affinity than the wild-type human IgG heavy chain constant region binds to the human Fcγ receptor. In one embodiment, the antibody or fragment comprises a human IgG heavy chain constant region that is a mutant version of the wild-type human IgG heavy chain constant region, wherein the mutant human IgG heavy chain constant region binds to human FcγRIIB with a higher affinity than the wild-type human IgG heavy chain constant region binds to human FcγRIIB. In one embodiment, the variant human IgG heavy chain constant region is a variant human IgG1, variant human IgG2, or variant human IgG4 heavy chain constant region. In one embodiment, the variant human IgG heavy chain constant region comprises one or more amino acid mutations selected from G236D, P238D, S239D, S267E, L328F, and L328E (EU index numbering system).In another embodiment, the variant human IgG heavy chain constant region comprises a set of amino acid mutations selected from the group consisting of one or more substitutions selected from the group consisting of S267E and L328F; P238D and L328E; P238D, and E233D, G237D, H268D, P271G, and A330R; P238D, E233D, G237D, H268D, P271G, and A330R; G236D and S267E; S239D and S267E; V262E, S267E, and L328F; and V264E, S267E, and L328F (EU index numbering system). In another embodiment, the variant human IgG heavy chain constant region further comprises one or more amino acid mutations that reduce the affinity of the IgG for human FcγRIIIA, human FcγRIIA, or human FcγRI. In one embodiment, FcγRIIB is expressed on a cell selected from the group consisting of a macrophage, a monocyte, a B cell, a dendritic cell, an endothelial cell, and an activated T cell. In one embodiment, the variant human IgG heavy chain constant region comprises one or more of the following amino acid mutations: G236A, S239D, F243L, T256A, K290A, R292P, S298A, Y300L, V305I, A330L, I332E, E333A, K334A, A339T, and P396L (EU index numbering system). In one embodiment, the mutant human IgG heavy chain constant region comprises a set of amino acid mutations selected from the group consisting of S239D; T256A; K290A; S298A; I332E; E333A; K334A; A339T; S239D and I332E; S239D, A330L, and I332E; S298A, E333A, and K334A; G236A, S239D, and I332E; and F243L, R292P, Y300L, V305I, and P396L (EU index numbering system). In one embodiment, the mutant human IgG heavy chain constant region comprises a S239D, A330L, or I332E amino acid mutation (EU index numbering system). In one embodiment, the variant human IgG heavy chain constant region comprises S239D and I332E amino acid mutations (EU index numbering system).In one embodiment, the variant human IgG heavy chain constant region is a variant human IgG1 heavy chain constant region comprising S239D and I332E amino acid mutations (EU index numbering system). In one embodiment, the antibody or fragment comprises a non-fucosylated Fc region. In another embodiment, the antibody or fragment thereof is defucosylated. In another embodiment, the antibody or fragment lacks fucosylation.

[0423] In another embodiment, the antibodies and fragments disclosed herein may contain a triple mutation (M252Y / S254T / T256E) that enhances binding to FcRn. For a discussion of the mutations in Table 2 affecting FcRn binding, see Dall et al., Immunol 2002;169:5171-5180 (the mutations described therein are incorporated herein by reference).

[0424] Similarly, enhanced CDC can be achieved by amino acid changes that increase affinity for C1q, the first component of the classical complement activation cascade (see Idusogie et al., J. Immunol., 2001, 166:2571-2575; the modifications described are incorporated herein by reference). Another approach is to create a chimeric Fc domain made from human IgG1 and human IgG3 segments that takes advantage of the higher affinity of IgG3 for C1q (Natsume et al., 2008, Cancer Res., 68:3863-3872; the modifications are incorporated herein by reference). In another embodiment, the antibodies or antibody fragments disclosed herein can contain mutated amino acids at residues 329, 331, and / or 322 to alter C1q binding and / or reduce or eliminate CDC activity. In another embodiment, the antibody or antibody fragment disclosed herein may contain an Fc region having modifications at residues 231 and 239, whereby amino acids have been replaced to alter the ability of the antibody to repair complement. In one embodiment, the antibody or fragment has a constant region comprising one or more mutations selected from E345K, E430G, R344D, and D356R, particularly a double mutation comprising R344D and D356R (EU index numbering system).

[0425] An antibody may have a heavy chain constant region that binds to one or more types of Fc receptor but does not induce cellular effector function, i.e., does not mediate ADCC, CDC, or ADCP activity. Such a constant region may not be able to bind to the specific Fc receptor(s) responsible for inducing ADCC, CDC, or ADCP activity. An antibody may have a heavy chain constant region that does not bind to Fcγ receptors. Thus, in one embodiment, the constant region may contain a Leu235Glu mutation (EU index numbering system).

[0426] In another embodiment, the antibodies and fragments disclosed herein are modified to increase or decrease serum half-life. In one embodiment, one or more of the following mutations are introduced to increase the biological half-life of the antibody: T252L, T254S, or T256F. Biological half-life can also be increased by modifying the heavy chain constant region CH1 domain or CL region to contain salvage receptor binding epitopes taken from two loops of the CH2 domain of the Fc region of IgG, as described in U.S. Patent Nos. 5,869,046 and 6,121,022, the modifications described therein being incorporated herein by reference. In another embodiment, the Fc hinge region of the antibody or antigen-binding fragment of the present invention is mutated to decrease the biological half-life of the antibody or fragment. One or more amino acid mutations are introduced into the CH2-CH3 domain interface region of the Fc-hinge fragment so that the antibody or fragment has impaired Staphylococcus protein A (SpA) binding compared to the SpA binding of the native Fc-hinge domain. Other methods of increasing serum half-life are known to those of skill in the art. Thus, in one embodiment, the antibody or fragment is PEGylated. In another embodiment, the antibody or fragment is fused to an albumin-binding domain, e.g., an albumin-binding single-domain antibody (dAb). In another embodiment, the antibody or fragment is PASylated (i.e., genetic fusion of a polypeptide sequence composed of PAS (XL-Protein GmbH), which forms an uncharged random coil structure with a large hydrodynamic volume). In another embodiment, the antibody or fragment is XTENylated® / rPEGylated (i.e., genetic fusion of a non-exact repetitive peptide sequence (Amunix, Versartis) to a therapeutic peptide). In another embodiment, the antibody or fragment is ELPylated (i.e., genetically fused to an ELP repeat sequence (PhaseBio)). These various half-life-enhancing fusions are described in more detail in Strohl, BioDrugs (2015) 29:215-239, e.g., the fusions in Tables 2 and 6, which are incorporated herein by reference.

[0427] The antibody may have a modified constant region that increases stability. Thus, in one embodiment, the heavy chain constant region contains a Ser228Pro mutation. In another embodiment, the antibodies and fragments disclosed herein contain a heavy chain hinge region that has been modified to alter the number of cysteine ​​residues. This modification can be used to facilitate assembly of the light and heavy chains or to increase or decrease the stability of the antibody.

[0428] Concept 31. The antibody or fragment of Concept 30, wherein the constant region is a murine constant region.

[0429] In another embodiment, the constant region may be of any non-human mammalian origin, such as rat, mouse, hamster, guinea pig, dog, cat, horse, chicken, llama, dromedary, etc. In one embodiment, the constant region is a rat constant region. In another embodiment, the constant region is a llama constant region. The mouse constant region may be any of the isotypes or alleles described herein above.

[0430] Concept 32. The antibody or fragment of concept 30 or concept 31, wherein the constant region has CDC and / or ADCC activity.

[0431] Concept 33. a)V H domain comprises the amino acid sequence of SEQ ID NO: 33, L the domain comprises the amino acid sequence of SEQ ID NO: 43; b)V H domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 33, L the domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 43; c)V H Domain V of SEQ ID NO: 47 H Contains the amino acid sequence of the V domain L the domain comprises the amino acid sequence of SEQ ID NO: 43; d)V H Domain V of SEQ ID NO: 48 H Contains the amino acid sequence of the V domainL the domain comprises the amino acid sequence of SEQ ID NO: 43; e)V H Domain V of SEQ ID NO: 49 H Contains the amino acid sequence of the V domain L the domain comprises the amino acid sequence of SEQ ID NO: 43; f)V H Domain V of SEQ ID NO: 342 H Contains the amino acid sequence of the V domain L the domain comprises the amino acid sequence of SEQ ID NO: 43; g)V H domain comprises the amino acid sequence of SEQ ID NO: 33, L Domain V of SEQ ID NO: 50 L comprising the amino acid sequence of the domain, h)V H Domain V of SEQ ID NO: 47 H Contains the amino acid sequence of the V domain L Domain V of SEQ ID NO: 50 L comprising the amino acid sequence of the domain, i)V H Domain V of SEQ ID NO: 48 H Contains the amino acid sequence of the V domain L Domain V of SEQ ID NO: 50 L comprising the amino acid sequence of the domain, j)V H Domain V of SEQ ID NO: 49 H Contains the amino acid sequence of the V domain L Domain V of SEQ ID NO: 50 L comprising the amino acid sequence of the domain, k)V H Domain V of SEQ ID NO: 342 H Contains the amino acid sequence of the V domain L Domain V of SEQ ID NO: 50 L comprising the amino acid sequence of the domain, l)V H domain comprises the amino acid sequence of SEQ ID NO: 33, L Domain V of SEQ ID NO: 51 L comprising the amino acid sequence of the domain, m)V H Domain V of SEQ ID NO: 47H Contains the amino acid sequence of the V domain L Domain V of SEQ ID NO: 51 L comprising the amino acid sequence of the domain, n)V H Domain V of SEQ ID NO: 48 H Contains the amino acid sequence of the V domain L Domain V of SEQ ID NO: 51 L comprising the amino acid sequence of the domain, o)V H Domain V of SEQ ID NO: 49 H Contains the amino acid sequence of the V domain L Domain V of SEQ ID NO: 51 L comprising the amino acid sequence of the domain, p)V H Domain V of SEQ ID NO: 342 H Contains the amino acid sequence of the V domain L Domain V of SEQ ID NO: 51 L comprising the amino acid sequence of the domain, q)V H domain comprises the amino acid sequence of SEQ ID NO: 33, L Domain V of SEQ ID NO: 298 L comprising the amino acid sequence of the domain, r)V H Domain V of SEQ ID NO: 47 H Contains the amino acid sequence of the V domain L Domain V of SEQ ID NO: 298 L comprising the amino acid sequence of the domain, s)V H Domain V of SEQ ID NO: 48 H Contains the amino acid sequence of the V domain L Domain V of SEQ ID NO: 298 L comprising the amino acid sequence of the domain, t)V H Domain V of SEQ ID NO: 49 H Contains the amino acid sequence of the V domain L Domain V of SEQ ID NO: 298 L comprising the amino acid sequence of the domain, u)V H Domain V of SEQ ID NO: 342 HContains the amino acid sequence of the V domain L Domain V of SEQ ID NO: 298 L comprising the amino acid sequence of the domain, v)V H domain comprises the amino acid sequence of SEQ ID NO: 58, L the domain comprises the amino acid sequence of SEQ ID NO: 68; w)V H domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 58, L the domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 68, x)V H domain comprises the amino acid sequence of SEQ ID NO: 78, L the domain comprises the amino acid sequence of SEQ ID NO: 88; y)V H domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 78, L the domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 88; z)V H the domain comprises the amino acid sequence of SEQ ID NO: 98, L the domain comprises the amino acid sequence of SEQ ID NO: 108; aa)V H domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 98, L a domain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 108; bb)V H domain comprises the amino acid sequence of SEQ ID NO: 118, L the domain comprises the amino acid sequence of SEQ ID NO: 128; cc)V H domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 118, L a domain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 128; dd)V H domain comprises the amino acid sequence of SEQ ID NO: 158, L the domain comprises the amino acid sequence of SEQ ID NO: 168; ee)V Hdomain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 158, L a domain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 168; ff)V H domain comprises the amino acid sequence of SEQ ID NO: 178, L the domain comprises the amino acid sequence of SEQ ID NO: 188; gg)V H domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 178, L a domain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 188; hh)V H domain comprises the amino acid sequence of SEQ ID NO: 138, L the domain comprises the amino acid sequence of SEQ ID NO: 148; ii) V H domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 138, L a domain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 148; jj)V H domain comprises the amino acid sequence of SEQ ID NO: 244, L the domain comprises the amino acid sequence of SEQ ID NO: 254; kk)V H domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 244, L a domain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 254; ll)V H domain comprises the amino acid sequence of SEQ ID NO: 264, L the domain comprises the amino acid sequence of SEQ ID NO: 274; mm)V H domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 264, L a domain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 274; nn)V H domain comprises the amino acid sequence of SEQ ID NO: 284, L the domain comprises the amino acid sequence of SEQ ID NO: 294; oo)V H domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 284, L a domain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 294; pp)V H domain comprises the amino acid sequence of SEQ ID NO: 349, L the domain comprises the amino acid sequence of SEQ ID NO: 359; qq)V H domain comprises an amino acid sequence at least 85% identical to SEQ ID NO: 349, L 33. The antibody of any one of concepts 1 to 32, wherein the domain comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 359.

[0432] In one embodiment, the amino acid sequence is at least 70% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 75% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 95% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 96% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 97% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 98% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 99% identical to the designated sequence. In one embodiment, the amino acid sequence is at least 99.5% identical to the designated sequence.

[0433] Concept 34. An antibody comprises a heavy chain and a light chain; a) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 35 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 45; b) the heavy chain amino acid sequence comprises an amino acid sequence at least 85% identical to SEQ ID NO: 35 and the light chain amino acid sequence comprises an amino acid sequence at least 85% identical to SEQ ID NO: 45; c) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 47 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 45; d) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 48 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 45; e) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 49 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 45; f) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 342 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 45; g) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 35 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 50; h) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 47 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 50; i) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 48 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 50; j) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 49 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 50; k) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 342 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 50; l) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 35 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 51; m) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 47 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 51; n) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 48 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 51; o) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 49 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 51; p) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 342 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 51; q) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 35 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 298; r) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 47 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 298; s) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 48 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 298; t) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 49 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 298; u) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 342 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 298; v) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 60 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 70; w) the heavy chain amino acid sequence comprises an amino acid sequence at least 85% identical to SEQ ID NO: 60 and the light chain amino acid sequence comprises an amino acid sequence at least 85% identical to SEQ ID NO: 70; x) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 80 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 90; y) the heavy chain amino acid sequence comprises an amino acid sequence at least 85% identical to SEQ ID NO: 80 and the light chain amino acid sequence comprises an amino acid sequence at least 85% identical to SEQ ID NO: 90; z) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 100 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 110; aa) the heavy chain amino acid sequence comprises an amino acid sequence at least 85% identical to SEQ ID NO: 100 and the light chain amino acid sequence comprises an amino acid sequence at least 85% identical to SEQ ID NO: 110; bb) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 120 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 130; cc) the heavy chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 120 and the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 130; dd) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 160 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 170; ee) the heavy chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 160 and the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 170; ff) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 180 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 190; gg) the heavy chain amino acid sequence comprises an amino acid sequence at least 85% identical to SEQ ID NO: 180 and the light chain amino acid sequence comprises an amino acid sequence at least 85% identical to SEQ ID NO: 190; hh) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 140 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 150; ii) the heavy chain amino acid sequence comprises an amino acid sequence at least 85% identical to SEQ ID NO: 140 and the light chain amino acid sequence comprises an amino acid sequence at least 85% identical to SEQ ID NO: 150; jj) the heavy chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 246 and the light chain amino acid sequence comprises the amino acid sequence of SEQ ID NO: 256; kk) the heavy chain amino acid sequence comprises an amino acid sequence at least 85% identical to SEQ ID NO: 246 and the light chain amino acid sequence comprises an amino a...

Claims

1. 1. An antibody or antigen-binding fragment thereof that specifically binds to human programmed cell death ligand 1 (PD-L1), the antibody or antigen-binding fragment comprising: a heavy chain variable region comprising a CDRH1 amino acid sequence of SEQ ID NO:7 according to the IMGT naming system or SEQ ID NO:10 according to the Kabat naming system, a CDRH2 amino acid sequence of SEQ ID NO:8 according to the IMGT naming system or SEQ ID NO:11 according to the Kabat naming system, and a CDRH3 amino acid sequence of SEQ ID NO:9 according to the IMGT naming system or SEQ ID NO:12 according to the Kabat naming system; and a light chain variable region comprising the CDRL1 amino acid sequence of SEQ ID NO: 17 according to the IMGT naming system or SEQ ID NO: 20 according to the Kabat naming system, the CDRL2 amino acid sequence of SEQ ID NO: 18 according to the IMGT naming system or SEQ ID NO: 21 according to the Kabat naming system, and the CDRL3 amino acid sequence of SEQ ID NO: 19 according to the IMGT naming system or SEQ ID NO: 22 according to the Kabat naming system; 4. An antibody or antigen-binding fragment comprising:

2. a) the heavy chain variable region comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:13; or b) the light chain variable region comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:

23. or c) the heavy chain variable region comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:

13. the light chain variable region comprises an amino acid sequence at least 90% identical to SEQ ID NO:23; or d) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 13 and the light chain variable region comprises the sequence comprising an amino acid sequence which is at least 90% identical to SEQ ID NO:23, The antibody or antigen-binding fragment of claim 1.

3. 3. A pharmaceutical composition for treating or preventing an hPD-L1 mediated disease or pathological condition in a human, comprising the antibody or antigen-binding fragment of claim 1 or 2 and a pharma- ceutical acceptable excipient, diluent or carrier.

4. An antibody or antigen-binding fragment thereof that specifically binds to human programmed cell death ligand 1 (PD-L1) wherein the antibody or antigen-binding fragment has a variable heavy chain (V H ) domain and the light chain variable (V L ) domain, a) The above V H The V domain has the amino acid sequence of SEQ ID NO: 13, L Domain is sequence number 23 amino acid sequence, or b) The above V H The domain is a CDRH1 amino acid sequence of SEQ ID NO: 7 according to the IMGT naming system or SEQ ID NO: 10 according to the Kabat naming system, a CDRH2 amino acid sequence of SEQ ID NO: 8 according to the IMGT naming system or SEQ ID NO: 11 according to the Kabat naming system, and a CDRH3 amino acid sequence of SEQ ID NO: 12 according to the IMGT naming system. 9 or SEQ ID NO: 12 according to the Kabat naming system, and L The domain is SEQ ID NO: 17 according to the IMGT naming system or SEQ ID NO: the CDRL1 amino acid sequence of SEQ ID NO: 20 according to the IMGT naming system, the CDRL2 amino acid sequence of SEQ ID NO: 18 according to the Kabat naming system, and the CDRL3 amino acid sequence of SEQ ID NO: 19 according to the IMGT naming system. has the CDRL3 amino acid sequence of SEQ ID NO:22 according to the Kabat naming system, An antibody or antigen-binding fragment.

5. 1. An antibody or antigen-binding fragment thereof that specifically binds to human programmed cell death ligand 1 (PD-L1), wherein the antibody or antigen-binding fragment comprises a heavy chain and a light chain; a) the heavy chain has the amino acid sequence of SEQ ID NO: 15 and the light chain has the amino acid sequence of SEQ ID NO: 25 or b) said heavy chain is encoded by the nucleic acid sequence of SEQ ID NO: 16 and said light chain is encoded by the nucleic acid sequence of SEQ ID NO: 26 encoded by the nucleic acid sequence An antibody or antigen-binding fragment.

6. The antibody or antigen-binding fragment of claim 1 , further comprising a light chain constant region.

7. The antibody or antigen-binding fragment of claim 6, wherein the light chain constant region is a kappa light chain or a lambda light chain.

8. 7. The antibody or antigen-binding fragment of claim 6, wherein the light chain constant region has the amino acid sequence of any one of SEQ ID NO:207, SEQ ID NO:209, SEQ ID NO:211, SEQ ID NO:213, SEQ ID NO:215, SEQ ID NO:217, SEQ ID NO:219, SEQ ID NO:221, SEQ ID NO:223, SEQ ID NO:225, SEQ ID NO:227, SEQ ID NO:229, SEQ ID NO:231, SEQ ID NO:233, SEQ ID NO:235, SEQ ID NO:237, SEQ ID NO:536 and SEQ ID NO:

538.

9. The antibody or antigen-binding fragment of any one of claims 1, 2 and 4 to 8, further comprising a heavy chain constant region.

10. 10. The antibody or antigen-binding fragment of claim 9, wherein the heavy chain constant region has the amino acid sequence of any one of SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:340, SEQ ID NO:524, SEQ ID NO:526, SEQ ID NO:528, SEQ ID NO:530, SEQ ID NO:532 and SEQ ID NO:

534.

11. The antibody or antigen-binding fragment of claim 9 , wherein the heavy chain constant region is an effector-null heavy chain constant region.

12. The antibody or antigen-binding fragment of claim 11 , wherein the effector-null heavy chain constant region is an IgG4 constant region or an IgG1 constant region.

13. Any of claims 1, 2 and 4 to 12, which can inhibit PD-L1-mediated T cell suppression. The antibody or antigen-binding fragment of any one of claims 1 to 4.

14. Any one of claims 1, 2 and 4 to 13, wherein the human PD-L1 is of SEQ ID NO: 1 or 2.

1. The antibody or antigen-binding fragment of claim 1.

15. V of SEQ ID NO:13 H The amino acid sequence and V of SEQ ID NO:23 L The antibody or antigen-binding fragment of any one of claims 1, 2, and 4 to 14, which competes for binding to human PD-L1 with an antibody comprising an amino acid sequence thereof.

16. The antibody or antigen-binding fragment of any one of claims 1, 2, and 4 to 15, wherein the antibody or antigen-binding fragment is a human antibody or an antigen-binding fragment thereof, or a humanized antibody or an antigen-binding fragment thereof.

17. A pharmaceutical composition for treating or preventing an hPD-L1 mediated disease or pathological condition in a human, comprising an effective amount of the antibody or antigen-binding fragment of any one of claims 4 to 16 and a pharma- ceutical acceptable excipient, diluent or carrier.

18. A kit for treating or preventing an hPD-L1 mediated disease or pathological condition in a human comprising the antibody or antigen-binding fragment of any one of claims 1, 2 and 4 to 16, or the pharmaceutical composition of claim 3 or 17.

19. 20. The kit of claim 18, further comprising a label or instructions for use in treating or preventing an hPD-L1 mediated disease or pathological condition in a human.

20. 20. The kit of claim 19, wherein the label or instructions include a marketing authorization number.

21. 21. The kit of any one of claims 18 to 20, further comprising an immune checkpoint inhibitor, an immunostimulant, a chemokine receptor antagonist, a targeted kinase inhibitor, an angiogenesis inhibitor, a chemokine, a cytokine, a bispecific molecule, or a cell-based therapeutic.

22. The kit of any one of claims 18 to 21, wherein the anti-PD-L1 antibody or antigen-binding fragment is comprised in an IV device or an injection device.

23. A nucleic acid encoding the heavy and light chains of an antibody according to any one of claims 1, 2 and 4 to 16.

24. a) V H The domain is encoded by a nucleic acid sequence that is at least 90% identical to SEQ ID NO:

14. or b) V L The domain is encoded by a nucleic acid sequence that is at least 90% identical to SEQ ID NO:

24. or c) V H The domain is encoded by a nucleic acid sequence that is at least 90% identical to SEQ ID NO:

14. Re, V L the domain is encoded by a nucleic acid sequence that is at least 90% identical to SEQ ID NO:24; or d) V H The domain is encoded by the nucleic acid sequence of SEQ ID NO: 14, L Domain is sequence number Encoded by 20 nucleic acid sequences, 24. The nucleic acid of claim 23.

25. 25. An expression vector comprising the nucleic acid of claim 23 or 24.

26. A host cell comprising a nucleic acid according to claim 23 or 24, or an expression vector according to claim 25. Cell.

27. The antibody or antigen-binding fragment of any one of claims 1, 2 and 4 to 16, or the pharmaceutical composition of claim 3 or 17, for use in the treatment or prevention of an hPD-L1 mediated disease or pathological condition in a human.

Citation Information

Patent Citations

  • Human antibodies to PD-l1

    WO2015112805A1